



AUSTRALIAN NSP SURVEY

NATIONAL DATA REPORT 2008 - 2012

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees

Never Stand Still

Medicine

The Kirby Institute

Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt DrUITT. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston. Biala Community Alcohol and Drug Services, Townsville AIDS, QUIHN Brisbane, Gold Coast, Sunshine Coast. West Moreton Sexual Health Service, Ipswich. Cairns B Hospital, Kobi House, Toowoomba. SAVIVE, Norwood, Parks, Port Adelaide, Northern Metropolitan, Shopfront. Hindmarsh Centre. Nunkuwarrin Yunti Community Health Centre, Noarlunga Community Health Centre. Clarence Community Health Centre, Anglicare Hobart, Glenorchy. Salvation Army Launceston. Darwin Health Drug and Alcohol Services. Bendigo NSP. InnerSpace, Collingwood. Health Works, Footscray. North Richmond NSP Services. Health Information Exchange, St Kilda. Western Australia Substance Users Association (WASUA), Northbridge, South West Coast. WA AIDS Council Mobile NSP. Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt DrUITT. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston.



Kirby Institute

©The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
University of New South Wales
Sydney NSW 2052
Australia

Telephone: **02 9385 0900**
International prefix: **612**

Facsimile: **02 9385 0920**
Email: recept@kirby.unsw.edu.au

Suggested citation: Iversen, J. and Maher, L. Australian Needle and Syringe Program National Data Report 2008-2012. The Kirby Institute, University of New South Wales, 2013. ISBN: 1448-5915.

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT

2008 - 2012

Report prepared by Jenny Iversen and Lisa Maher

The Kirby Institute

for infection and immunity in society
University of New South Wales
Sydney NSW 2052
Australia

May 2013

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist in the development and conduct of the Australian NSP Survey, and particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project, and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

Special thanks also go to Mr Philip Cunningham, Senior Scientist and Operations Manager and Ms Beth Catlett, DBS Coordinator from the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research (AMR). Thanks are also due to Ms Rachel McCleave and Ms Brenda Currie from the Kirby Institute and to Mr Greg Smith and Ashwin Prekesh from Educational Assessment Australia, UNSW Global Pty Limited.

In 2012, the project received support and input from the following members of the Australian NSP Survey National Advisory Group: Ms Tammy Waters (ACT); Ms Rose Mason (NSW); Mr Shayne Kilford (NT); Mr Robert Kemp (Chair) and Mr Gregory Perry (QLD); Mr Stephen Lymb and Ms Jenny Grant (SA); Ms Francine Smith (TAS); Mr Roland Jauernig (VIC); Ms Jude Bevan (WA); Ms Fiona Poeder (Australian Injecting and Illicit Drug Users League); Mr John Ryan (ANEX); and Ms Jenny Iversen (Secretariat), Professor John Kaldor and Professor Lisa Maher (Kirby Institute).

Ethical approvals were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, The University of New South Wales.

TABLE OF CONTENTS

Summary

Key Points	i
Introduction	1
Injecting behaviour.....	2
Sexual behaviour	4
BBV testing, drug treatment and prison history	4
HIV antibody prevalence	5
HCV antibody prevalence	6

Tables

1. National	9
2. Australian Capital Territory	27
3. New South Wales	38
4. Northern Territory.....	56
5. Queensland	67
6. South Australia	85
7. Tasmania	100
8. Victoria	111
9. Western Australia	122

Appendix

Participating NSP services	133
Methodological notes	135
List of tables	136

SUMMARY: KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- In 2012, 52 NSP services participated in the ANSPS and 2,391 NSP attendees completed the survey. The response rate was 46%.

Demographic characteristics:

- Over the period 2008 to 2012, the median age of survey respondents increased from 36 years to 38 years and the median time since first injection increased from 15 to 17 years.
- Median age at first injection remained stable at 18 years between 2008 and 2012.
- Among new initiates (less than 3 years since first injection), more than half (55%) reported last injecting performance and image-enhancing drugs (PIEDs) in the 2012 survey. Among males who were new initiates to injecting, more than two thirds (68%) reported last injecting PIEDs.

HIV and HCV antibody prevalence:

- Between 2008 and 2012, HIV antibody prevalence remained low at 1.5% or less nationally and at 3% or less in all state and territories.
- Among men, HIV prevalence declined from 2.1% in 2008 to 1.2% in 2012, however, among women HIV prevalence increased from 0.4% in 2008 to 1.3% in 2012. As a result, HIV prevalence was higher among women than men in 2012, the first time this has occurred since commencement of the ANSPS in 1995.
- HCV antibody prevalence declined significantly over the period, from 62% in 2008 to 53% in 2012, with the decline evident among both men (63% to 52%) and women (61% to 54%).
- HCV antibody prevalence was highest among participants aged 35 years and over and among those who first initiated injecting drugs more than ten years prior to survey participation in all years 2008 to 2012.

Injecting behaviour:

- Over the period 2008 to 2012, the proportion of respondents reporting daily or more frequent injection in the month prior to the survey remained stable at between 47% and 50%.
- Around one third of respondents reported heroin as the last drug injected and just over one quarter of respondents reported methamphetamine as the last drug injected in all years 2008 to 2012.
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2008 to 2012, with prevalence stable at between 14% and 16%.
- While relatively small proportions of survey respondents reported last injecting PIEDs, prevalence increased from 1% in 2008 to 7% in 2012. Increased prevalence of PIEDs injection was evident in New South Wales (2% in 2008 to 12% in 2012) and Queensland (1% in 2008 to 11% in 2012) and was stable at 2% or less in all other jurisdictions.
- Over the period 2008 to 2012, the proportion of respondents reporting re-use of needles and syringes (including reuse of one's own syringes) declined from 28% to 21%.
- The proportion of respondents reporting receptive sharing of needles and syringes was stable, ranging from 12% to 14% over the period 2008 to 2012. The proportion of respondents reporting receptive sharing of drug preparation equipment declined from 33% to 25%.

Introduction

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibodies and sexual and injecting behavioural risk among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle and Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing. See methodological notes (page 135) for further details on the ANSPS design and implementation. This report presents national and state/territory data for the period 2008 to 2012.

In 2012, 52 NSP services participated in the ANSPS, and all services had participated in a previous year. Over the period 2008 to 2012, the number of ANSPS respondents ranged from 2,270 to 2,697 and the annual response rate ranged from 39% to 46% (Table 1.1.1). Of the 2,391 ANSPS respondents in 2012, the vast majority (95%) were recruited from the 48 NSP services that participated in the ANSPS in all years 2008 to 2012.

Demographic Characteristics

The male to female ratio was approximately 2:1 for all survey years with less than one percent of respondents identifying as transgender. The majority of participants identified as heterosexual, with 9% identifying as bisexual and 3% as homosexual in 2012.

The proportion of respondents from an Indigenous Australian background was stable at 11% to 12% over the period 2008 to 2012. The majority of respondents were born in Australia (84% to 87%), with the United Kingdom and Ireland (4%) and New Zealand (4%) the predominant countries of birth outside Australia in 2012. Most respondents also reported that their parents spoke English at home (range 93% to 95% over the period 2008-2012).


The proportion of participants reporting incarceration in the 12 months prior to survey completion was also stable over the same period, at 9% to 13%. Among those reporting recent incarceration, approximately one in three reported injecting in prison in all years 2008 to 2012 (Table 1.1.1).

The median age at survey completion increased from 36 years in 2008 to 38 years in 2012 and there was a concurrent decrease in the proportion of young injectors (aged <25 years) from 9% to 7% over the period 2008 to 2012 (χ^2 trend $p < 0.001$). The median time since first injection increased from 15 years in 2008 to 17 years in 2012, although the proportion of new injectors (injecting for less than 3 years) increased from 5% in 2008 to 7% in 2012 (χ^2 trend $p = 0.002$). The median age at first drug injection remained stable at 18 years for all years between 2008 and 2012 (Table 1.1.1).

Injecting behaviour

Heroin was the most commonly reported drug last injected nationally in all years 2008 to 2012. Reports of heroin injection were stable (χ^2 trend $p=0.744$) over the past five years, with approximately one third of respondents reporting having last injected this drug (Figure 1). In 2012, heroin was the most commonly injected drug in the Australian Capital Territory (39%), New South Wales (30%), South Australia (36%) and Victoria (65%). Methamphetamine was the second most commonly reported drug last injected nationally, and prevalence was also stable with around one quarter of respondents last injecting this drug between 2008 and 2012 (χ^2 trend $p=0.456$). In 2012, methamphetamine was the most commonly reported drug last injected in Queensland (26%) and Western Australia (32%) and the second most prevalent drug last injected in all other jurisdictions.

Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine and all other drugs, 2008–2012




The third most commonly reported class of drug last injected nationally was pharmaceutical opioids (including morphine and oxycodone) and prevalence was stable at 14% to 16% over the period 2008 to 2012 (χ^2 trend $p=0.204$, Figure 2). As in previous years, pharmaceutical opioids were the drug most commonly injected in the Northern Territory (70%) and Tasmania (40%) in 2012.

Methadone was reported as the last drug injected by less than ten percent of the ANSPS sample in all years 2008 to 2012, with a decline in prevalence observed over the period 2008 to 2012 (χ^2 trend $p=0.004$). Methadone was the second most commonly reported drug last injected in Tasmania (17%) in 2012. Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents and prevalence over the period 2008 to 2012 remained stable at between 4% and 5% and 1% and 2% respectively.

A minority of survey respondents (1% to 2%) reported cocaine as the last drug injected, with the majority of reports occurring in New South Wales in all survey years (Table 3.1.2). A significant increase in the prevalence of PIEDs as the last drug injected occurred over the period 2008 to 2012 (χ^2 trend $p < 0.001$, Figure 2), although this increase was confined to NSW (2% to 12%, $p < 0.001$) and QLD (1% to 11%, $p < 0.001$) (Table 3.1.2 and 5.1.2). Prevalence of PIEDs injection was 2% or less in 2012 in all other jurisdictions. In 2012, more than half (55%) of new initiates to injecting (less than 3 years since first injection) reported last injecting PIEDs. In New South Wales and Queensland, more than three quarters of males who were new initiates to injecting reported last injecting PIEDs (76% and 78% respectively).


Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone and performance and image enhancing drugs, 2008–2012



Around half of ANSPS respondents reported daily or more frequent injecting in all of the past five years (Table 1.1.1). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion was stable at between 42% and 45% over the past five years (χ^2 trend $p = 0.229$). In 2012, 15% of respondents reported being present when someone injected for the first time in the last 12 months.

The proportion of respondents reporting reuse of needles and syringes (including one's own) in the month preceding the survey declined from 28% in 2008 to 21% in 2012 (χ^2 trend $p < 0.001$, Figure 3). Over the same period, prevalence of receptive sharing of needles and syringes was stable (range 12% to 14%, χ^2 trend $p = 0.222$) and receptive sharing of ancillary equipment declined from 33% to 25%. As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2012 (Table 1.1.2).

Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of a needle and syringe and receptive sharing of ancillary equipment in the last month, 2008–2012



Sexual behaviour

In each of the past five years, around half of respondents reported sex with a regular sex partner in the month prior to survey completion (range 47% to 52%). Of these, a majority (69% to 71%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (14% to 15%) reported sex with other sex partners in the month preceding survey participation, although condom use was higher among this group, with a quarter to a third reporting that they did not use condoms. The proportion of respondents reporting commercial sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years, while use of condoms at last commercial sex was high at between 78% and 85% in all years between 2008 and 2012 (Table 1.1.3).

BBV testing, drug treatment and prison history

ANSPS respondents reported high rates of both HIV and HCV testing in all of the last five years. In 2012, half (50%) of respondents reported testing for HIV in the past twelve months, and a slightly greater proportion (55%) reported a HCV test during that time. In addition, around a third of respondents reported having a HIV or HCV test more than twelve months ago, with relatively few (13% or less) reporting never being tested for either HIV or HCV (Table 1.1.4).

Respondents also reported high rates of engagement with drug treatment services, with three quarters (76%) of 2012 respondents reporting current or previous drug treatment. The proportion of respondents reporting methadone maintenance treatment at the time of survey participation remained stable at between 29% and 31% over the last five years, while 10% of survey respondents reported current buprenorphine treatment and a further 10% reported current buprenorphine-naloxone treatment (Table 1.1.5).


Around one half of respondents reported a lifetime history of imprisonment (48% to 50%) over the period 2008 to 2012, while a minority (9% to 13%) reported incarceration in 12 months prior to survey completion. Among those reporting recent incarceration, around one third (31% to 34%) reported injecting in prison (Table 1.1.1).

HIV antibody prevalence

While HIV antibody prevalence remained low and stable nationally at 1.5% or less over the period 2008 to 2012 (χ^2 trend $p=0.517$), trends in HIV prevalence differed by jurisdiction and by gender (Table 1.2.1). There was a significant decline in the overall proportion of HIV antibody positive respondents in New South Wales, from 2.2% in 2008 to 1.2% in 2012 (χ^2 trend $p=0.047$, Figure 4). However, there was an increase in the proportion of females testing HIV antibody positive in three states, Queensland (0% in 2008 to 1.3% in 2012, χ^2 trend $p=0.037$); South Australia (from 0% in 2008 to 5.5% in 2012, χ^2 trend $p=0.008$); and Western Australia (from 0% in 2008 to 4.8% in 2012, χ^2 trend $p=0.028$).


No respondents in Tasmania or the Australian Capital Territory tested positive to HIV antibodies in any of the past five years.

Figure 4. HIV antibody prevalence (%) by jurisdiction, 2008–2012



Over the period 2008 to 2012, anti-HIV prevalence in men declined from 2.1% in 2008 to 1.2% in 2012 (χ^2 trend $p=0.037$). However, anti-HIV prevalence in women increased significantly from 0.4% in 2008 to 1.3% in 2012 (χ^2 trend $p=0.006$). As a result of these trends, HIV prevalence was higher among women than men in 2012, the first time this has occurred since the commencement of the ANSPS in 1995 (Figure 5). However, it is important to note that both the increase in HIV prevalence among women (<1%) and the overall number of women testing HIV antibody positive ($n=9$) were very small. In addition, most of these women were aged ≥ 35 years, none were new initiates to injecting and the majority were aware of their HIV positive serostatus.

Figure 5. HIV antibody prevalence (%) by gender, 2008–2012




In 2012, the median age of HIV antibody positive respondents was 46 years (range 25-64 years) and respondents first injected a median of 22 years prior to survey participation (range 2-39 years).

HCV antibody prevalence

HCV antibody prevalence nationally declined significantly from 62% in 2008 to 53% in 2012 (χ^2 trend $p < 0.001$, Table 1.3.1). Significant declines in HCV prevalence were also observed over the period 2008 to 2012 in New South Wales (71% to 50%, χ^2 trend $p < 0.001$), Queensland (56% to 47%, χ^2 trend $p = 0.047$) and Tasmania (80% to 47%, χ^2 trend $p < 0.001$). An increase in HCV antibody prevalence was observed in South Australia (from 29% in 2008 to 41% in 2012, χ^2 trend $p = 0.009$). HCV antibody prevalence was stable over the period 2008 to 2012 in all other jurisdictions (Figure 6).

Figure 6. HCV antibody prevalence (%) by jurisdiction, 2008–2012



HCV antibody prevalence was significantly higher among participants with longer injection histories and among older participants in all years 2008 to 2012 (Table 1.3.3 and 1.3.4). HCV antibody prevalence was also higher among participants reporting heroin or pharmaceutical opioids as the last drug injected compared to those reporting methamphetamine (Figure 7). HCV antibody prevalence was also consistently higher among respondents reporting imprisonment in the year prior to survey completion than among those not reporting recent imprisonment in any of the past five years (Figure 8).

Figure 7. HCV antibody prevalence (%) by drug last injected and gender, 2008–2012





Figure 8. HCV antibody prevalence (%) by imprisonment in the previous 12 months and gender, 2008–2012



National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	51	51	52	52	52
N° surveyed	N=2270	N=2697	N=2396	N=2395	N=2391
Response (%)	39%	45%	39%	41%	46%
Gender (%)					
Male	1456 (64)	1756 (65)	1611 (67)	1602 (67)	1623 (68)
Female	803 (35)	924 (34)	771 (32)	780 (33)	753 (31)
Transgender	6 (<1)	9 (<1)	8 (<1)	10 (<1)	11 (<1)
Not reported	5 (<1)	8 (<1)	6 (<1)	3 (<1)	4 (<1)
Sexual identity (%)					
Heterosexual	1843 (81)	2236 (83)	1987 (83)	1982 (83)	1949 (82)
Bisexual	219 (10)	236 (9)	195 (8)	208 (9)	210 (9)
Homosexual	115 (5)	89 (3)	88 (4)	96 (4)	82 (3)
Not reported	93 (4)	136 (5)	126 (5)	109 (5)	150 (6)
Age and duration of injection (years)					
<i>Median age</i>	36	36	37	37	38
<i>Age range</i>	16-70	15-66	15-73	16-65	16-71
<i>Age group (%)</i>					
<25 years	208 (9)	285 (11)	203 (8)	182 (8)	176 (7)
25+ years	2056 (91)	2411 (89)	2191 (91)	2205 (92)	2212 (93)
Not reported	6 (<1)	1 (<1)	2 (<1)	1 (<1)	3 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	10-60	10-58	10-63	10-56	10-70
<i>N° not reported</i>	46	67	51	62	67
<i>Median years IDU</i>	15	15	16	17	17
<i>Range</i>	<1-48	<1-46	<1-60	<1-41	<1-53
<i>Duration of drug injection (%)</i>					
<3 years	113 (5)	162 (6)	131 (5)	168 (7)	173 (7)
3+ years	2110 (93)	2468 (92)	2213 (92)	2162 (90)	2150 (90)
Not reported	47 (2)	67 (2)	52 (2)	65 (3)	68 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	1934 (85)	2296 (85)	2071 (86)	2065 (86)	2056 (86)
Yes	250 (11)	323 (12)	275 (11)	276 (12)	294 (12)
Not reported	86 (4)	78 (3)	50 (2)	54 (2)	41 (2)
Region/Country of birth					
Australia	1918 (84)	2333 (87)	2088 (87)	2046 (85)	2070 (87)
Other Oceania	83 (4)	85 (3)	76 (3)	80 (3)	86 (4)
Asia	32 (1)	25 (1)	29 (1)	31 (1)	26 (1)
UK & Ireland	125 (6)	120 (4)	94 (4)	111 (5)	105 (4)
Other	68 (3)	89 (3)	69 (3)	101 (4)	85 (4)
Not reported	44 (2)	45 (2)	40 (2)	26 (1)	19 (<1)
Main language spoke at home by parents					
English speaking	2128 (94)	2548 (94)	2275 (95)	2237 (93)	2252 (94)
Non-English speaking	109 (5)	113 (4)	90 (4)	134 (6)	129 (5)
Not reported	33 (1)	36 (1)	31 (1)	24 (1)	10 (<1)
Imprisonment last year (%)					
No	1812 (80)	2238 (83)	1762 (74)	2049 (86)	2037 (87)
Yes	287 (13)	339 (13)	226 (9)	238 (10)	261 (11)
Not reported	171 (8)	120 (4)	408 (17)	108 (5)	56 (2)
Injected in prison last year (%)	N=287	N=339	N=226	N=238	N=261
Yes	96 (33)	113 (33)	69 (31)	75 (32)	90 (34)
Frequency of injection last month (%)					
Not last month	230 (10)	270 (10)	259 (11)	250 (10)	235 (10)
Less than weekly	343 (15)	418 (15)	423 (18)	387 (16)	444 (19)
Weekly not daily	576 (25)	618 (23)	563 (24)	563 (24)	554 (23)
Daily or more	1099 (48)	1361 (50)	1119 (47)	1159 (48)	1130 (47)
Not reported	22 (1)	30 (1)	32 (1)	36 (2)	28 (1)

Table 1.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=2270	N=2697	N=2396	N=2395	N=2391
Cocaine	53 (2)	66 (2)	31 (1)	23 (1)	21 (1)
Heroin	781 (34)	917 (34)	808 (34)	802 (33)	799 (33)
Methadone	192 (8)	232 (9)	177 (7)	173 (7)	159 (7)
Methamphetamine	645 (28)	657 (24)	628 (26)	649 (27)	621 (26)
Performance/Image-enhancing drugs	35 (2)	43 (2)	57 (2)	109 (5)	162 (7)
Pharmaceutical opioids	345 (15)	426 (16)	382 (16)	358 (15)	341 (14)
Suboxone®	--	35 (1)	46 (2)	43 (2)	46 (2)
Subutex®/Buprenorphine	104 (5)	134 (5)	100 (4)	94 (4)	84 (4)
More than one	53 (2)	86 (3)	118 (5)	106 (4)	121 (5)
Other drug	21 (1)	34 (1)	37 (2)	33 (1)	22 (1)
Not reported	41 (2)	67 (2)	12 (<1)	5 (<1)	15 (1)
N° Injected last month	N=2018	N=2397	N=2109	N=2109	N=2128
Places injected last month (%)					
Any public	886 (44)	1079 (45)	887 (42)	882 (42)	836 (39)
All private	1104 (55)	1298 (54)	1069 (51)	1154 (55)	1222 (57)
Not reported	28 (1)	20 (1)	153 (7)	73 (3)	70 (3)
Use of sterile needles & syringes last month (%)					
All injections	1429 (71)	1783 (74)	1477 (70)	1569 (74)	1593 (75)
Most of the time	475 (24)	503 (21)	398 (19)	383 (18)	366 (17)
Half of the time	48 (2)	39 (2)	38 (2)	41 (2)	36 (2)
Some of the time	28 (1)	35 (1)	28 (1)	26 (1)	21 (1)
Not last month	13 (<1)	8 (<1)	8 (<1)	4 (<1)	15 (<1)
Not reported	25 (1)	29 (1)	160 (8)	86 (4)	97 (5)
Re-used someone else's used needle & syringe last month (%)					
None	1640 (81)	1963 (82)	1595 (76)	1663 (79)	1713 (81)
Once	108 (5)	124 (5)	87 (4)	104 (5)	148 (7)
Twice	101 (5)	93 (4)	70 (3)	80 (4)	60 (3)
3-5 times	70 (3)	86 (4)	58 (3)	74 (4)	61 (3)
>5 times	55 (3)	73 (3)	47 (2)	58 (3)	67 (3)
Not reported	44 (2)	58 (2)	252 (12)	130 (6)	79 (4)
Number of people needle & syringe was re-used after last month (%)					
None	1640 (81)	1963 (82)	1595 (76)	1663 (79)	1713 (81)
One	169 (8)	185 (8)	127 (6)	166 (8)	158 (7)
Two	19 (<1)	26 (1)	21 (1)	23 (1)	23 (1)
Three to five	17 (<1)	15 (<1)	25 (1)	14 (<1)	11 (<1)
More than five	7 (<1)	10 (<1)	19 (1)	14 (<1)	22 (1)
Don't know	71 (4)	58 (2)	41 (2)	64 (3)	48 (2)
Not reported	95 (5)	140 (6)	281 (13)	165 (8)	153 (7)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	136 (7)	151 (6)	177 (8)	196 (9)	113 (5)
Casual sex partner	12 (<1)	4 (<1)	16 (<1)	9 (<1)	8 (<1)
Close friend	84 (4)	86 (4)	105 (5)	125 (6)	96 (5)
Acquaintance	29 (1)	32 (1)	38 (2)	59 (3)	44 (2)
Other	21 (1)	29 (1)	38 (2)	48 (2)	21 (1)
Equipment used after someone else last month (%)*					
Spoon	436 (24)	541 (25)	446 (21)	481 (22)	450 (21)
Water	314 (17)	358 (16)	316 (15)	310 (15)	311 (15)
Filter	219 (12)	273 (12)	212 (10)	222 (11)	226 (11)
Drug mix	155 (8)	202 (9)	177 (8)	174 (8)	190 (9)
None	1181 (64)	1409 (64)	1319 (63)	1387 (66)	1421 (67)
Injected by someone after that person injected themselves or others last month (%)					
No	1673 (83)	1958 (82)	1639 (78)	1731 (82)	1745 (82)
Yes	281 (14)	387 (16)	242 (11)	283 (13)	284 (13)
Not reported	64 (3)	52 (2)	228 (11)	95 (5)	99 (5)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	1686 (79)
Yes	--	--	--	--	320 (15)
Not reported	--	--	--	--	122 (6)

* More than one option could be selected ** New question in 2012

Table 1.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=2270	N=2697	N=2396	N=2395	N=2391
Sex with a regular partner last month (%)					
No	1015 (45)	1215 (45)	1082 (45)	1105 (46)	1173 (49)
Yes	1190 (52)	1382 (51)	1210 (51)	1135 (47)	1152 (48)
Not reported	65 (3)	100 (4)	104 (4)	157 (7)	66 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=1190	N=1382	N=1210	N=1135	N=1152
Never	828 (70)	999 (72)	840 (69)	800 (71)	815 (71)
Sometimes	144 (12)	179 (13)	154 (13)	133 (12)	147 (13)
Every time	154 (13)	135 (10)	145 (12)	141 (12)	127 (11)
Not reported	64 (5)	69 (5)	71 (6)	59 (5)	63 (5)
Sex with other partner/s last month (%)					
No	1838 (81)	2186 (81)	1923 (80)	1966 (82)	1953 (82)
Yes	345 (15)	378 (14)	327 (14)	330 (14)	336 (14)
Not reported	87 (4)	133 (5)	146 (6)	99 (4)	102 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=345	N=378	N=327	N=330	N=336
Never	85 (25)	129 (34)	116 (35)	108 (33)	115 (34)
Sometimes	101 (29)	96 (25)	72 (22)	80 (24)	92 (27)
Every time	143 (41)	148 (39)	124 (38)	127 (38)	109 (32)
Not reported	16 (5)	5 (1)	15 (5)	15 (5)	20 (6)
Sex work last month (%)					
No	1991 (88)	2458 (91)	2092 (87)	2169 (91)	2195 (92)
Yes	139 (6)	130 (5)	128 (5)	114 (5)	119 (5)
Not reported	140 (6)	109 (4)	176 (7)	112 (5)	77 (3)
Condom used at last sex work last month (%)					
Yes	105 (83)	106 (84)	95 (78)	88 (85)	98 (84)

Table 1.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

	2008	2009	2010	2011	2012
N° surveyed	N=2270	N=2697	N=2396	N=2395	N=2391
Previous HIV test (%)					
Yes, last year	1124 (50)	1360 (50)	1141 (48)	1172 (49)	1157 (48)
> 1 year ago	818 (36)	922 (34)	819 (34)	849 (35)	840 (35)
Never tested	215 (9)	310 (11)	282 (12)	287 (12)	299 (13)
Not reported	113 (5)	105 (4)	154 (6)	87 (4)	95 (4)
Previous HCV test (%)					
Yes, last year	1257 (55)	1549 (57)	1280 (53)	1289 (54)	1305 (55)
> 1 year ago	769 (34)	855 (32)	750 (31)	794 (33)	781 (33)
Never tested	154 (7)	196 (7)	190 (8)	169 (7)	181 (8)
Not reported	90 (4)	97 (4)	176 (7)	143 (6)	124 (5)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=1203	N=1383	N=1274	N=1267	N=1269
Interferon/Interferon+Ribavirin	107 (9)	126 (9)	136 (11)	121 (10)	122 (10)
Other	21 (2)	17 (1)	17 (1)	18 (1)	14 (1)
No treatment	1039 (86)	1174 (85)	1072 (84)	1054 (83)	1078 (85)
Not reported	36 (3)	66 (5)	49 (4)	74 (6)	55 (4)
Current treatment for HCV					
	N=27	N=25	N=32	N=36	N=27
Interferon/Interferon+Ribavirin	18	21	26	28	18
Other	9	4	6	8	9

Table 1.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=2270	N=2697	N=2396	N=2395	N=2391
Any treatment/therapy for drug use (%)					
No	444 (20)	509 (19)	425 (18)	489 (20)	539 (23)
Yes	1785 (79)	2144 (80)	1910 (80)	1842 (77)	1826 (76)
Not reported	41 (2)	44 (2)	61 (3)	64 (3)	26 (1)
History of methadone maintenance treatment (%)					
Currently	696 (31)	823 (31)	725 (30)	693 (29)	712 (30)
Previously	587 (26)	645 (24)	600 (25)	586 (24)	622 (26)
Never	938 (41)	1167 (43)	946 (39)	1006 (42)	1041 (44)
Not reported	49 (2)	62 (2)	125 (5)	110 (5)	16 (1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	290 (13)	339 (13)	267 (11)	231 (10)	241 (10)
Previously	566 (25)	679 (25)	637 (27)	641 (27)	665 (28)
Never	1355 (60)	1621 (60)	1461 (61)	1426 (60)	1456 (61)
Not reported	49 (2)	58 (2)	31 (1)	97 (4)	29 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	142 (6)	211 (8)	200 (8)	224 (9)	245 (10)
Previously	270 (12)	411 (15)	413 (17)	438 (18)	469 (20)
Never	1787 (79)	2003 (74)	1737 (73)	1640 (68)	1639 (69)
Not reported	71 (3)	72 (3)	46 (2)	93 (4)	38 (2)

Table 1.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month by survey year

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=2018	N=2397	N=2109	N=2109	N=2128
Needle Syringe Program	1879 (83)	1569 (65)	2063 (86)	1917 (91)	1888 (89)
Chemist/Pharmacy	876 (36)	601 (25)	450 (19)	415 (20)	503 (24)
Personal sources	--	418 (17)	256 (11)	184 (9)	248 (12)
Dispensing/Vending Machine	--	222 (9)	181 (8)	205 (10)	255 (12)
Other sources	--	69 (3)	77 (3)	35 (2)	18 (1)

* More than one option could be selected

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	1396	29 (2.1)	764	3 (0.4)	2170	33 (1.5)
2009	1725	28 (1.6)	915	2 (0.2)	2657	31 (1.2)
2010	1579	21 (1.3)	759	2 (0.3)	2352	23 (1.0)
2011	1560	21 (1.4)	764	7 (0.9)	2337	29 (1.2)
2012	1546	18 (1.2)	718	9 (1.3)	2279	28 (1.2)
X ² trend p value		0.037		0.006		0.517

* Totals include people whose gender was not reported or reported as transgender

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Heterosexual	1228	3 (0.2)	537	1 (0.2)	1767	4 (0.2)
Bisexual	56	3 (5.4)	152	2 (1.3)	209	6 (2.9)
Homosexual	62	23 (37.1)	48	0 (0.0)	112	23 (20.6)
p value		<0.001		0.181		<0.001
2009						
Heterosexual	1510	7 (0.5)	682	2 (0.3)	2207	9 (0.4)
Bisexual	78	2 (2.5)	146	0 (0.0)	229	3 (1.3)
Homosexual	30	18 (37.5)	37	0 (0.0)	87	18 (20.7)
p value		<0.001		1.000		<0.001
2010						
Heterosexual	1390	4 (0.3)	558	2 (0.4)	1954	6 (0.3)
Bisexual	61	3 (4.9)	124	0 (0.0)	188	3 (1.6)
Homosexual	48	14 (29.2)	36	0 (0.0)	85	14 (16.5)
p value		<0.001		1.000		<0.001
2011						
Heterosexual	1393	6 (0.4)	547	5 (0.9)	1943	11 (0.6)
Bisexual	57	3 (5.3)	141	2 (1.4)	203	6 (3.0)
Homosexual	51	12 (23.5)	38	0 (0.0)	91	12 (13.2)
p value		<0.001		0.751		<0.001
2012						
Heterosexual	1350	4 (0.3)	506	8 (1.5)	1859	12 (0.7)
Bisexual	69	2 (2.9)	127	0 (0.0)	200	3 (1.5)
Homosexual	42	9 (21.4)	31	0 (0.0)	77	9 (11.7)
p value		<0.001		0.570		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
< 25 years	107	0 (0.0)	89	0 (0.0)	196	0 (0.0)
25 – 34	468	7 (1.5)	297	3 (1.0)	767	11 (1.4)
35+ years	816	22 (2.7)	377	0 (0.0)	1201	22 (1.8)
p value		0.102		0.094		0.147
2009						
< 25 years	156	1 (0.6)	117	0 (0.0)	275	1 (0.4)
25 – 34	575	7 (1.2)	346	0 (0.0)	925	7 (0.8)
35+ years	984	20 (1.6)	446	1 (0.2)	1441	22 (1.5)
p value		0.282		0.593		0.100
2010						
< 25 years	105	1 (1.0)	90	0 (0.0)	197	1 (0.5)
25 – 34	502	3 (0.6)	263	0 (0.0)	766	3 (0.4)
35+ years	970	16 (1.7)	405	2 (0.5)	1386	18 (1.3)
p value		0.226		0.629		0.089
2011						
< 25 years	118	1 (0.9)	56	2 (3.6)	176	3 (1.7)
25 – 34	457	1 (0.2)	287	1 (0.4)	748	2 (0.3)
35+ years	979	19 (1.9)	419	4 (1.0)	1404	24 (1.3)
p value		0.015		0.116		0.005
2012						
< 25 years	130	0 (0.0)	38	0 (0.0)	169	0 (0.0)
25 – 34	412	0 (0.0)	241	3 (1.2)	657	5 (0.8)
35+ years	1003	16 (1.6)	438	6 (1.4)	1451	23 (1.6)
p value		0.134		1.000		0.113

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
<3 years	67	5 (7.4)	43	0 (0.0)	110	5 (4.6)
3 to 10 years	308	4 (1.3)	202	0 (0.0)	511	4 (0.8)
11 + years	986	19 (1.9)	508	3 (0.6)	1502	23 (1.5)
p value		0.005		0.484		0.013
2009						
<3 years	90	2 (2.2)	67	0 (0.0)	158	2 (1.3)
3 to 10 years	317	5 (1.6)	237	0 (0.0)	558	5 (0.9)
11 + years	1279	21 (1.6)	585	1 (0.2)	1875	23 (1.2)
p value		0.909		0.771		0.807
2010						
<3 years	87	2 (2.3)	36	0 (0.0)	124	2 (1.6)
3 to 10 years	253	3 (1.2)	181	0 (0.0)	435	3 (0.7)
11 + years	1202	15 (1.3)	527	2 (0.4)	1740	17 (1.0)
p value		0.562		1.000		0.560
2011						
<3 years	114	2 (1.8)	48	0 (0.0)	163	2 (1.2)
3 to 10 years	251	4 (1.6)	152	2 (1.3)	404	6 (1.5)
11 + years	1148	15 (1.3)	549	5 (0.9)	1707	21 (1.2)
p value		0.731		0.780		0.845
2012						
<3 years	126	1 (0.8)	35	0 (0.0)	162	1 (0.6)
3 to 10 years	242	3 (1.2)	129	3 (2.3)	373	6 (1.6)
11 + years	1134	14 (1.2)	535	6 (1.1)	1680	21 (1.3)
p value		1.000		0.615		0.701

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Heroin	494	3 (0.6)	253	1 (0.4)	749	4 (0.5)
Methamphetamine	362	17 (4.7)	238	1 (0.4)	604	19 (3.2)
Other	514	8 (1.6)	261	1 (0.4)	779	9 (1.2)
p value		<0.001		0.995		<0.001
2009						
Heroin	591	5 (0.9)	311	1 (0.3)	907	6 (0.7)
Methamphetamine	402	15 (3.7)	243	1 (0.4)	649	16 (2.5)
Other	687	8 (1.2)	337	0 (0.0)	1032	9 (0.9)
p value		0.001		0.507		0.002
2010						
Heroin	522	6 (1.2)	272	2 (0.7)	797	8 (1.0)
Methamphetamine	396	10 (2.5)	210	0 (0.0)	612	10 (1.6)
Other	652	4 (0.6)	273	0 (0.0)	930	4 (0.4)
p value		0.028		0.207		0.052
2011						
Heroin	513	2 (0.4)	267	4 (1.5)	783	7 (0.9)
Methamphetamine	382	12 (3.1)	247	1 (0.4)	632	13 (2.1)
Other	662	7 (1.1)	248	2 (0.8)	917	9 (1.0)
p value		0.002		0.518		0.122
2012						
Heroin	507	2 (0.4)	262	6 (2.3)	773	9 (1.2)
Methamphetamine	355	8 (2.3)	216	2 (0.9)	577	10 (1.7)
Other	673	8 (1.2)	236	1 (0.4)	914	9 (1.0)
p value		0.045		0.167		0.467

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Less than daily	569	17 (3.0)	309	1 (0.3)	882	18 (2.0)
Daily or more	679	8 (1.2)	363	1 (0.3)	1047	10 (1.0)
Not last month	136	4 (2.9)	83	1 (1.2)	220	5 (2.3)
p value		0.065		0.462		0.100
2009						
Less than daily	645	12 (1.9)	371	2 (0.5)	1023	14 (1.4)
Daily or more	896	12 (1.3)	434	0 (0.0)	1339	13 (1.0)
Not last month	169	4 (2.4)	96	0 (0.0)	266	4 (1.5)
p value		0.535		0.239		0.591
2010						
Less than daily	696	9 (1.3)	351	2 (0.6)	1053	11 (1.0)
Daily or more	705	4 (0.6)	309	0 (0.0)	1018	4 (0.4)
Not last month	156	7 (4.5)	92	0 (0.0)	252	7 (2.8)
p value		0.002		0.616		0.004
2011						
Less than daily	619	11 (1.8)	306	3 (1.0)	929	15 (1.6)
Daily or more	752	5 (0.7)	369	4 (1.1)	1127	9 (0.8)
Not last month	161	4 (2.5)	83	0 (0.0)	246	4 (1.6)
p value		0.047		1.000		0.179
2012						
Less than daily	632	8 (1.3)	312	6 (1.9)	953	15 (1.6)
Daily or more	748	6 (0.8)	324	3 (0.9)	1076	9 (0.8)
Not last month	146	4 (2.7)	78	0 (0.0)	225	4 (1.8)
p value		0.111		0.483		0.209

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No receptive sharing	1024	23 (2.3)	544	2 (0.4)	1576	26 (1.7)
Receptive sharing	193	2 (1.0)	118	0 (0.0)	312	2 (0.6)
p value		0.408		1.000		0.300
2009						
No receptive sharing	1268	24 (1.9)	653	2 (0.3)	1936	27 (1.4)
Receptive sharing	238	0 (0.0)	133	0 (0.0)	372	0 (0.0)
p value		0.023		1.000		0.015
2010						
No receptive sharing	1066	14 (1.3)	499	1 (0.2)	1570	15 (1.0)
Receptive sharing	167	1 (0.6)	89	1 (1.1)	257	2 (0.8)
p value		0.708		0.028		1.000
2011						
No receptive sharing	1093	15 (1.4)	529	7 (1.3)	1627	22 (1.4)
Receptive sharing	198	1 (0.5)	105	0 (0.0)	306	1 (0.3)
p value		0.491		0.607		0.158
2012						
No receptive sharing	1117	12 (1.1)	506	9 (1.8)	1634	22 (1.4)
Receptive sharing	220	0 (0.0)	100	0 (0.0)	320	0 (0.0)
p value		0.234		0.368		0.037

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No imprisonment	1079	26 (2.4)	648	0 (0.0)	1735	27 (1.6)
Imprisonment	208	2 (1.0)	65	2 (3.1)	274	4 (1.5)
p value		0.296		0.008		1.000
2009						
No imprisonment	1402	27 (1.9)	794	2 (0.3)	2213	30 (1.4)
Imprisonment	245	1 (0.4)	88	0 (0.0)	333	1 (0.3)
p value		0.108		1.000		0.172
2010						
No imprisonment	1119	18 (1.6)	605	2 (0.3)	1737	20 (1.1)
Imprisonment	167	1 (0.6)	52	0 (0.0)	219	1 (0.5)
p value		0.497		1.000		0.502
2011						
No imprisonment	1303	21 (1.6)	683	6 (0.9)	1997	28 (1.4)
Imprisonment	176	0 (0.0)	56	1 (1.8)	233	1 (0.4)
p value		0.163		0.425		0.356
2012						
No imprisonment	1289	17 (1.3)	639	9 (1.4)	1942	27 (1.4)
Imprisonment	199	1 (0.5)	47	0 (0.0)	247	1 (0.4)
p value		0.496		1.000		0.360

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No condom use	547	4 (0.7)	380	0 (0.0)	930	4 (0.4)
Condom use	93	3 (3.2)	52	1 (1.9)	147	5 (3.4)
p value		0.067		0.120		0.004
2009						
No condom use	671	4 (0.6)	483	1 (0.2)	1162	5 (0.4)
Condom use	91	4 (4.4)	41	0 (0.0)	132	4 (3.0)
p value		0.009		1.000		0.009
2010						
No condom use	506	6 (1.2)	313	0 (0.0)	823	6 (0.7)
Condom use	188	2 (1.1)	102	2 (2.0)	292	4 (1.4)
p value		1.000		0.060		0.299
2011						
No condom use	475	6 (1.3)	308	3 (1.0)	784	9 (1.2)
Condom use	179	4 (2.2)	82	1 (1.2)	263	5 (1.9)
p value		0.473		1.000		0.359
2012						
No condom use	475	2 (0.4)	287	2 (0.7)	767	4 (0.5)
Condom use	173	7 (4.1)	90	2 (2.2)	263	9 (3.4)
p value		0.002		0.242		0.001

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No sex work	1264	27 (2.1)	633	3 (0.5)	1905	30 (1.6)
Sex work	39	2 (5.1)	91	0 (0.0)	131	3 (2.3)
p value		0.214		1.000		0.467
2009						
No sex work	1612	26 (1.6)	790	2 (0.3)	2425	29 (1.2)
Sex work	36	2 (5.6)	90	0 (0.0)	129	2 (1.6)
p value		0.122		1.000		0.668
2010						
No sex work	1427	18 (1.3)	619	2 (0.3)	2057	20 (1.0)
Sex work	42	2 (4.8)	84	0 (0.0)	127	2 (1.6)
p value		0.110		1.000		0.369
2011						
No sex work	1452	19 (1.3)	666	6 (0.9)	2125	25 (1.2)
Sex work	29	0 (0.0)	75	1 (1.3)	108	2 (1.9)
p value		1.000		0.528		0.378
2012						
No sex work	1451	17 (1.2)	629	8 (1.3)	2090	25 (1.2)
Sex work	37	1 (2.7)	72	1 (1.4)	114	3 (2.6)
p value		0.366		1.000		0.174

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Non Indigenous	1214	26 (2.1)	631	1 (0.2)	1853	28 (1.5)
Indigenous	130	2 (1.5)	105	2 (1.9)	237	4 (1.7)
p value		1.000		0.055		0.778
2009						
Non Indigenous	1503	26 (1.7)	752	2 (0.3)	2269	28 (1.2)
Indigenous	166	1 (0.6)	145	0 (0.0)	313	2 (0.6)
p value		0.511		1.000		0.571
2010						
Non Indigenous	1388	19 (1.4)	633	2 (0.3)	2033	21 (1.0)
Indigenous	159	2 (1.3)	112	0 (0.0)	273	2 (0.7)
p value		1.000		1.000		1.000
2011						
Non Indigenous	1366	20 (1.5)	641	5 (0.8)	2016	25 (1.2)
Indigenous	158	1 (0.6)	111	2 (1.8)	271	4 (1.5)
p value		0.716		0.277		0.770
2012						
Non Indigenous	1349	18 (1.3)	598	8 (1.3)	1959	26 (1.3)
Indigenous	172	0 (0.0)	106	0 (0.0)	281	1 (0.4)
p value		0.251		0.614		0.242

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
English speaking	1299	28 (2.2)	728	3 (0.4)	2037	32 (1.6)
Non-English speaking	73	1 (1.4)	28	0 (0.0)	101	1 (1.0)
p value		1.000		1.000		1.000
2009						
English speaking	1628	27 (1.7)	869	2 (0.2)	2513	30 (1.2)
Non-English speaking	72	1 (1.4)	38	0 (0.0)	111	1 (0.9)
p value		1.000		1.000		1.000
2010						
English speaking	1485	21 (1.4)	736	2 (0.3)	2234	23 (1.0)
Non-English speaking	75	0 (0.0)	15	0 (0.0)	90	0 (0.0)
p value		0.621		1.000		1.000
2011						
English speaking	1444	20 (1.4)	731	7 (1.0)	2187	28 (1.3)
Non-English speaking	100	1 (1.0)	28	0 (0.0)	129	1 (0.8)
p value		1.000		1.000		1.000
2012						
English speaking	1446	15 (1.0)	685	9 (1.3)	2143	25 (1.2)
Non-English speaking	96	3 (3.1)	27	0 (0.0)	126	3 (2.4)
p value		0.097		1.000		0.201

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Australia	1181	24 (2.0)	650	3 (0.5)	1836	27 (1.5)
Other Oceania	34	3 (8.8)	27	0 (0.0)	63	4 (6.4)
Asia	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
UK & Ireland	68	0 (0.0)	43	0 (0.0)	113	0 (0.0)
Other	71	1 (1.4)	25	0 (0.0)	96	1 (1.0)
p value		0.063		1.000		0.033
2009						
Australia	1480	27 (1.8)	805	2 (0.3)	2298	30 (1.3)
Other Oceania	54	0 (0.0)	30	0 (0.0)	84	0 (0.0)
Asia	19	1 (5.3)	5	0 (0.0)	25	1 (4.0)
UK & Ireland	82	0 (0.0)	37	0 (0.0)	120	0 (0.0)
Other	57	0 (0.0)	30	0 (0.0)	89	0 (0.0)
p value		0.331		1.000		0.312
2010						
Australia	1366	19 (1.4)	673	2 (0.3)	2050	21 (1.0)
Other Oceania	47	1 (2.1)	28	0 (0.0)	76	1 (1.3)
Asia	22	0 (0.0)	5	0 (0.0)	27	0 (0.0)
UK & Ireland	64	0 (0.0)	29	0 (0.0)	93	0 (0.0)
Other	60	1 (1.7)	16	0 (0.0)	76	1 (1.3)
p value		0.834		0.994		0.846
2011						
Australia	1322	20 (1.5)	665	7 (1.1)	1999	28 (1.4)
Other Oceania	46	0 (0.0)	34	0 (0.0)	80	0 (0.0)
Asia	24	1 (4.2)	7	0 (0.0)	31	1 (3.2)
UK & Ireland	73	0 (0.0)	34	0 (0.0)	108	0 (0.0)
Other	77	0 (0.0)	20	0 (0.0)	97	0 (0.0)
p value		0.448		1.000		0.362
2012						
Australia	1328	12 (0.9)	630	9 (1.4)	1972	22 (1.1)
Other Oceania	49	2 (4.1)	32	0 (0.0)	81	2 (2.5)
Asia	22	0 (0.0)	3	0 (0.0)	26	0 (0.0)
UK & Ireland	73	1 (1.4)	26	0 (0.0)	99	1 (1.0)
Other	58	3 (5.2)	24	0 (0.0)	82	3 (3.7)
p value		0 (0.0)		1.000		0.179

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	1352	852 (63)	737	453 (61)	2099	1311 (62)
2009	1712	840 (49)	912	471 (52)	2641	1318 (50)
2010	1567	838 (53)	756	398 (53)	2337	1244 (53)
2011	1530	826 (54)	748	386 (52)	2290	1216 (53)
2012	1524	794 (52)	713	384 (54)	2252	1184 (53)
X ² trend p value		<0.001		0.012		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	1192	760 (64)	517	317 (61)	1711	1078 (63)
Bisexual	51	30 (59)	147	93 (63)	199	123 (62)
Homosexual	60	26 (43)	47	29 (62)	109	56 (51)
p value		0.006		0.901		0.054
2009						
Heterosexual	1506	751 (50)	681	335 (49)	2193	1090 (50)
Bisexual	79	36 (46)	146	97 (66)	228	133 (58)
Homosexual	48	13 (27)	37	15 (41)	87	28 (32)
p value		0.006		<0.001		<0.001
2010						
Heterosexual	1378	755 (55)	556	293 (53)	1940	1052 (54)
Bisexual	60	33 (55)	123	69 (56)	186	104 (56)
Homosexual	49	11 (22)	36	10 (28)	86	21 (24)
p value		<0.001		0.009		<0.001
2011						
Heterosexual	1369	750 (55)	531	273 (51)	1903	1024 (54)
Bisexual	55	24 (44)	140	71 (51)	200	96 (48)
Homosexual	51	20 (39)	37	15 (41)	90	36 (40)
p value		0.028		0.441		0.014
2012						
Heterosexual	1329	703 (53)	501	270 (54)	1833	974 (53)
Bisexual	70	33 (47)	127	71 (56)	201	105 (52)
Homosexual	41	12 (52)	31	14 (45)	76	27 (36)
p value		0.008		0.560		0.011

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	105	31 (30)	89	41 (46)	194	72 (37)
25 – 34	450	249 (55)	291	173 (59)	743	423 (57)
35+ years	792	569 (72)	356	239 (67)	1156	813 (70)
p value		<0.001		0.001		<0.001
2009						
< 25 years	157	32 (20)	117	42 (36)	276	74 (27)
25 – 34	572	246 (43)	348	184 (53)	924	431 (47)
35+ years	983	563 (57)	446	243 (54)	1440	812 (56)
p value		<0.001		0.001		<0.001
2010						
< 25 years	103	17 (17)	90	33 (37)	195	50 (26)
25 – 34	498	228 (46)	262	130 (50)	761	359 (47)
35+ years	965	593 (61)	403	235 (58)	1379	835 (61)
p value		<0.001		<0.001		<0.001
2011						
< 25 years	118	18 (15)	56	16 (29)	176	34 (19)
25 – 34	447	206 (46)	279	136 (49)	730	343 (47)
35+ years	959	599 (62)	411	234 (57)	1375	835 (61)
p value		<0.001		<0.001		<0.001
2012						
< 25 years	129	12 (9)	38	12 (32)	168	24 (14)
25 – 34	408	179 (44)	242	132 (55)	654	314 (48)
35+ years	986	602 (61)	432	239 (55)	1428	844 (59)
p value		<0.001		0.018		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	67	13 (19)	43	17 (40)	110	30 (27)
3 to 10 years	193	122 (63)	200	98 (49)	494	220 (45)
11 + years	960	699 (73)	485	336 (69)	1453	1040 (72)
p value		<0.001		<0.001		<0.001
2009						
<3 years	90	6 (7)	66	15 (23)	157	21 (13)
3 to 10 years	314	106 (34)	236	101 (43)	554	209 (38)
11 + years	1269	716 (56)	584	343 (59)	1864	1063 (57)
p value		<0.001		<0.001		<0.001
2010						
<3 years	87	9 (10)	36	9 (25)	124	18 (15)
3 to 10 years	249	86 (35)	181	77 (43)	431	163 (38)
11 + years	1197	726 (61)	524	306 (58)	1732	1039 (60)
p value		<0.001		<0.001		<0.001
2011						
<3 years	114	12 (11)	47	13 (28)	162	25 (15)
3 to 10 years	249	93 (37)	151	62 (41)	401	155 (39)
11 + years	1120	703 (63)	536	305 (57)	1665	1011 (61)
p value		<0.001		<0.001		<0.001
2012						
<3 years	125	12 (10)	35	10 (29)	161	23 (14)
3 to 10 years	238	79 (33)	126	50 (40)	366	129 (35)
11 + years	1118	681 (61)	533	313 (59)	1662	999 (60)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	22	9 (41)	688	507 (74)	721	524 (73)
Methamphetamine	43	8 (19)	538	256 (48)	587	265 (45)
Other	43	12 (28)	692	473 (68)	756	496 (66)
p value		0.106		<0.001		<0.001
2009						
Heroin	32	9 (28)	862	512 (59)	902	524 (58)
Methamphetamine	51	4 (8)	585	221 (38)	648	230 (35)
Other	71	8 (11)	929	512 (55)	1030	533 (52)
p value		0.020		<0.001		<0.001
2010						
Heroin	28	8 (29)	747	476 (64)	792	498 (63)
Methamphetamine	33	3 (9)	567	229 (40)	610	237 (39)
Other	63	7 (11)	839	492 (59)	923	504 (55)
p value		0.086		<0.001		<0.001
2011						
Heroin	27	8 (30)	729	452 (62)	773	470 (61)
Methamphetamine	29	5 (17)	577	265 (46)	620	274 (44)
Other	105	12 (11)	756	447 (59)	892	470 (53)
p value		<0.001		<0.001		<0.001
2012						
Heroin	24	5 (21)	727	459 (63)	768	478 (62)
Methamphetamine	27	9 (33)	531	234 (44)	568	249 (44)
Other	109	9 (8)	763	431 (56)	901	452 (50)
p value		0.002		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	52	9 (17)	792	490 (62)	855	505 (59)
Daily or more	36	15 (42)	951	650 (68)	1010	679 (67)
Not last month	17	3 (18)	188	110 (59)	213	116 (54)
p value		0.026		0.003		<0.001
2009						
Less than daily	63	6 (10)	940	484 (51)	1018	496 (49)
Daily or more	69	13 (19)	1232	655 (53)	1329	683 (51)
Not last month	24	2 (8)	225	119 (53)	265	123 (46)
p value		0.213		0.734		0.220
2010						
Less than daily	57	4 (7)	978	522 (53)	1047	533 (51)
Daily or more	44	12 (27)	942	556 (59)	1010	578 (57)
Not last month	19	2 (11)	222	112 (50)	252	119 (47)
p value		0.015		0.012		0.002
2011						
Less than daily	74	9 (12)	823	431 (52)	912	442 (48)
Daily or more	59	13 (22)	1012	615 (61)	1100	645 (59)
Not last month	26	2 (8)	205	105 (51)	244	110 (45)
p value		0.148		<0.001		<0.001
2012						
Less than daily	67	12 (18)	856	478 (56)	939	501 (53)
Daily or more	52	9 (17)	985	557 (57)	1069	584 (55)
Not last month	40	2 (5)	168	83 (49)	219	88 (40)
p value		0.130		0.224		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	71	17 (24)	1428	918 (64)	1529	952 (62)
Receptive sharing	16	8 (50)	278	196 (71)	296	206 (70)
p value		0.063		0.046		0.018
2009						
No receptive sharing	109	11 (10)	1784	922 (52)	1924	948 (49)
Receptive sharing	19	7 (37)	340	194 (57)	369	205 (56)
p value		0.006		0.075		0.031
2010						
No receptive sharing	84	14 (17)	1449	779 (54)	1563	808 (52)
Receptive sharing	7	2 (29)	243	154 (63)	253	157 (62)
p value		0.602		0.005		0.002
2011						
No receptive sharing	110	15 (14)	1449	811 (56)	1593	840 (53)
Receptive sharing	15	5 (33)	276	171 (62)	297	180 (61)
p value		0.051		0.066		0.012
2012						
No receptive sharing	107	19 (18)	1480	808 (55)	1620	843 (52)
Receptive sharing	10	2 (20)	292	192 (66)	315	205 (65)
p value		1.000		<0.001		<0.001

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 1.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	96	24 (25)	1555	959 (62)	1680	998 (59)
Imprisonment	7	4 (57)	250	196 (78)	264	204 (77)
p value		0.085		<0.001		<0.001
2009						
No imprisonment	140	14 (10)	2006	1006 (50)	2200	1038 (47)
Imprisonment	12	6 (50)	311	206 (66)	331	216 (65)
p value		0.001		<0.001		<0.001
2010						
No imprisonment	110	12 (11)	1580	806 (51)	1730	835 (48)
Imprisonment	2	1 (50)	211	146 (69)	217	149 (69)
p value		0.220		<0.001		<0.001
2011						
No imprisonment	149	20 (13)	1717	924 (54)	1914	964 (50)
Imprisonment	7	3 (43)	210	157 (75)	226	164 (72)
p value		0.066		<0.001		<0.001
2012						
No imprisonment	152	23 (15)	1719	913 (53)	1921	962 (50)
Imprisonment	6	0 (0)	228	156 (68)	243	161 (66)
p value		0.594		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 1.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	99	26 (26)	1715	1104 (64)	1850	1149 (62)
Sex work	4	3 (75)	117	80 (68)	123	83 (67)
p value		0.067		0.424		0.250
2009						
No sex work	153	19 (12)	2200	1149 (52)	2409	1189 (49)
Sex work	3	2 (67)	120	75 (63)	129	79 (61)
p value		0.048		0.031		0.009
2010						
No sex work	109	13 (12)	1893	1053 (56)	2044	1086 (53)
Sex work	9	4 (44)	115	52 (45)	127	57 (45)
p value		0.024		0.033		0.082
2011						
No sex work	150	24 (16)	1886	1055 (56)	2085	1098 (53)
Sex work	2	0 (0)	94	57 (61)	103	60 (58)
p value		1.000		0.370		0.267
2012						
No sex work	150	21 (14)	1857	1024 (55)	2061	1076 (52)
Sex work	6	1 (17)	103	63 (61)	115	65 (57)
p value		1.000		0.231		0.367

* Total includes people who did not report duration of drug injection

Table 1.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	1177	732 (62)	614	372 (61)	1799	1108 (62)
Indigenous	125	82 (66)	98	67 (68)	225	151 (67)
p value		0.497		0.148		0.109
2009						
Non Indigenous	1490	721 (48)	749	388 (52)	2253	1115 (49)
Indigenous	166	87 (52)	145	76 (52)	313	163 (52)
p value		0.328		0.928		0.399
2010						
Non Indigenous	1377	743 (54)	631	343 (54)	2020	1093 (54)
Indigenous	158	77 (49)	111	50 (45)	271	128 (47)
p value		0.238		0.080		0.038
2011						
Non Indigenous	1341	712 (53)	629	321 (51)	1978	1035 (52)
Indigenous	153	90 (59)	108	58 (54)	263	149 (57)
p value		0.178		0.608		0.186
2012						
Non Indigenous	1330	679 (51)	594	321 (54)	1936	1005 (52)
Indigenous	169	101 (60)	105	54 (51)	277	156 (56)
p value		0.034		0.671		0.177

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	1262	788 (62)	704	433 (62)	1976	1227 (62)
Non-English speaking	68	51 (75)	26	14 (54)	94	65 (69)
p value		0.039		0.422		0.191
2009						
English speaking	1615	790 (49)	866	449 (52)	2497	1246 (50)
Non-English speaking	72	39 (54)	38	17 (45)	111	56 (50)
p value		0.401		0.411		0.923
2010						
English speaking	1474	788 (53)	734	383 (52)	2221	1178 (53)
Non-English speaking	75	37 (49)	14	8 (57)	89	45 (51)
p value		0.553		0.792		0.666
2011						
English speaking	1415	746 (53)	716	373 (52)	2142	1122 (52)
Non-English speaking	99	67 (68)	27	11 (41)	127	79 (62)
p value		0.004		0.246		0.031
2012						
English speaking	1425	738 (52)	680	365 (54)	2177	1108 (52)
Non-English speaking	95	55 (58)	27	14 (52)	125	70 (56)
p value		0.249		0.852		0.461

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	1145	721 (63)	626	378 (60)	1776	1103 (62)
Other Oceania	34	14 (41)	26	13 (50)	62	27 (44)
Asia	19	17 (89)	6	3 (50)	25	20 (80)
UK & Ireland	66	40 (61)	43	31 (72)	111	72 (65)
Other	68	46 (68)	25	18 (72)	93	64 (69)
p value		0.008		0.259		0.006
2009						
Australia	1467	728 (50)	802	411 (51)	2282	1144 (50)
Other Oceania	54	23 (43)	30	17 (57)	84	40 (48)
Asia	19	9 (47)	5	2 (40)	25	11 (44)
UK & Ireland	82	42 (51)	37	21 (57)	120	64 (53)
Other	57	24 (42)	30	15 (50)	89	40 (45)
p value		0.672		0.904		0.734
2010						
Australia	1357	724 (53)	670	344 (51)	2038	1075 (53)
Other Oceania	46	24 (52)	28	19 (68)	75	43 (57)
Asia	22	13 (59)	5	4 (80)	27	17 (63)
UK & Ireland	64	41 (64)	29	14 (48)	93	55 (59)
Other	58	26 (45)	16	11 (69)	74	37 (50)
p value		0.293		0.170		0.503
2011						
Australia	1296	691 (53)	652	339 (52)	1959	1034 (53)
Other Oceania	44	22 (50)	33	19 (58)	77	41 (53)
Asia	24	16 (67)	7	1 (14)	31	17 (55)
UK & Ireland	73	42 (58)	32	16 (50)	106	58 (55)
Other	76	42 (55)	20	9 (45)	96	51 (53)
p value		0.654		0.309		0.995
2012						
Australia	1307	672 (51)	627	330 (53)	1948	1008 (52)
Other Oceania	48	21 (44)	31	20 (65)	79	41 (52)
Asia	22	19 (86)	2	2 (100)	25	21 (84)
UK & Ireland	72	41 (57)	26	17 (65)	98	58 (59)
Other	59	33 (56)	24	113 (54)	83	46 (55)
p value		0.011		0.332		0.011

* Total includes people whose gender was not reported or reported as transgender

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	1	1	1	1	1
N° surveyed	N=31	N=63	N=97	N=100	N=78
Response (%)	---	67%	83%	56%	65%
Gender (%)					
Male	22 (71)	39 (62)	72 (74)	68 (68)	53 (68)
Female	9 (29)	24 (38)	25 (26)	32 (32)	25 (32)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	22 (71)	52 (83)	81 (83)	83 (83)	71 (91)
Bisexual	3 (10)	7 (11)	5 (5)	5 (5)	5 (6)
Homosexual	3 (10)	1 (2)	1 (1)	5 (5)	0 (0)
Not reported	3 (10)	3 (5)	10 (10)	7 (7)	2 (3)
Age and duration of injection (years)					
<i>Median age</i>	36	32	35	35	40
<i>Age range</i>	22-56	16-60	19-64	22-65	20-66
<i>Age group (%)</i>					
<25 years	3 (10)	15 (23)	3 (3)	4 (4)	4 (5)
25+ years	28 (90)	48 (76)	94 (97)	96 (96)	74 (95)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	17	18	18	18
<i>Age range</i>	11-40	12-42	10-40	10-55	12-41
Not reported	0 (0)	1	2	2	0
<i>Median years IDU</i>	16	13	17	18	20
<i>Range</i>	2-38	1-36	2-49	1-49	<1-51
<i>Duration of drug injection (%)</i>					
<3 years	1 (3)	7 (11)	1 (1)	4 (4)	2 (3)
3+ years	30 (97)	55 (87)	94 (97)	94 (94)	76 (97)
Not reported	0 (0)	1 (2)	2 (2)	2 (2)	0 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	25 (81)	56 (89)	79 (81)	85 (85)	71 (91)
Yes	4 (13)	5 (8)	17 (18)	12 (12)	4 (5)
Not reported	2 (6)	2 (3)	1 (1)	3 (3)	3 (4)
Region/Country of birth (%)					
Australia	25 (81)	50 (79)	89 (92)	90 (90)	71 (91)
Other Oceania	0 (0)	2 (3)	2 (2)	4 (4)	1 (1)
Asia	2 (6)	1 (2)	0 (0)	0 (0)	1 (1)
UK & Ireland	1 (3)	8 (13)	4 (4)	0 (0)	5 (6)
Other	2 (6)	2 (3)	0 (0)	6 (6)	0 (0)
Not reported	1 (3)	0 (0)	2 (2)	0 (0)	0 (0)
Main language spoken at home by parents (%)					
English speaking	30 (97)	61 (97)	95 (98)	95 (95)	75 (96)
Non-English speaking	1 (3)	2 (3)	2 (2)	5 (5)	3 (4)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)					
No	26 (84)	51 (81)	67 (69)	89 (89)	67 (87)
Yes	2 (6)	9 (14)	14 (14)	6 (6)	4 (5)
Not reported	3 (10)	3 (5)	16 (16)	5 (5)	6 (8)
Injected in prison (%)	N=2	N=9	N=14	N=6	N=4
Yes	0 (0)	1 (11)	4 (29)	2 (33)	3 (75)
Frequency of injection last month (%)					
Not last month	0 (0)	4 (6)	8 (8)	10 (10)	2 (3)
Less than weekly	3 (10)	10 (16)	15 (15)	16 (16)	10 (13)
Weekly not daily	15 (48)	12 (19)	30 (31)	22 (22)	22 (28)
Daily or more	13 (42)	37 (59)	42 (43)	50 (50)	44 (56)
Not reported	0 (0)	0 (0)	2 (2)	2 (2)	0 (0)

Table 2.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=31	N=63	N=97	N=100	N=78
Cocaine	0 (0)	0 (0)	4 (4)	0 (0)	1 (1)
Heroin	14 (45)	24 (38)	28 (29)	44 (44)	30 (38)
Methadone	2 (6)	2 (3)	16 (16)	12 (12)	9 (12)
Methamphetamine	9 (29)	15 (24)	26 (27)	24 (24)	23 (29)
Performance/Image-enhancing drugs	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Pharmaceutical opioids	2 (6)	6 (10)	3 (3)	3 (3)	3 (4)
Suboxone®	--	4 (6)	1 (1)	1 (1)	0 (0)
Subutex®/Buprenorphine	3 (10)	6 (10)	10 (10)	7 (7)	3 (4)
More than one	0 (0)	2 (3)	7 (7)	5 (5)	5 (6)
Other drug	0 (0)	0 (0)	2 (2)	3 (3)	3 (4)
Not reported	1 (3)	2 (3)	0 (0)	0 (0)	1 (1)
N° Injected last month	N=31	N=59	N=87	N=88	N=76
Places injected last month (%)*					
Any public	20 (65)	30 (51)	40 (56)	40 (45)	33 (43)
All private	11 (35)	28 (47)	44 (51)	47 (53)	42 (55)
Not reported	0 (0)	1 (2)	3 (3)	1 (1)	1 (1)
Use of new sterile needles & syringes last month (%)					
All injections	24 (77)	43 (73)	58 (67)	59 (67)	56 (74)
Most of the time	6 (19)	15 (25)	24 (28)	24 (27)	17 (22)
Half of the time	1 (3)	1 (2)	0 (0)	2 (2)	0 (0)
Some of the time	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Not last month	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	4 (5)	2 (2)	1 (1)
Re-used another's used needle & syringe last month (%)					
None	25 (81)	51 (86)	62 (71)	75 (85)	60 (79)
Once	2 (6)	1 (2)	3 (3)	4 (5)	6 (8)
Twice	2 (6)	1 (2)	7 (8)	0 (0)	1 (1)
3-5 times	1 (3)	4 (7)	3 (3)	2 (2)	1 (1)
>5 times	1 (3)	1 (2)	2 (2)	3 (3)	5 (7)
Not reported	0 (0)	1 (2)	10 (11)	4 (5)	3 (4)
Number of people needle & syringe was re-used after last month (%)					
None	25 (81)	51 (86)	62 (71)	75 (85)	60 (79)
One	3 (10)	4 (7)	8 (9)	4 (5)	4 (5)
Two	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Three to five	0 (0)	2 (3)	2 (2)	0 (0)	0 (0)
More than five	0 (0)	2 (3)	1 (1)	2 (2)	3 (4)
Don't know	1 (3)	0 (0)	3 (3)	3 (3)	4 (5)
Not reported	2 (6)	1 (2)	10 (11)	4 (4)	5 (7)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	2 (6)	4 (7)	8 (9)	8 (9)	2 (3)
Casual sex partner	1 (3)	0 (0)	0 (0)	1 (1)	1 (1)
Close friend	0 (0)	2 (3)	5 (6)	3 (3)	3 (4)
Acquaintance	0 (0)	1 (2)	4 (5)	1 (1)	4 (5)
Other	1 (3)	0 (0)	2 (2)	2 (2)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	11 (37)	20 (38)	18 (21)	12 (14)	19 (25)
Water	8 (27)	14 (26)	16 (18)	14 (16)	13 (17)
Filter	6 (20)	4 (8)	8 (9)	11 (13)	6 (8)
Drug mix	7 (23)	7 (13)	9 (10)	9 (10)	5 (7)
None	19 (63)	28 (53)	53 (61)	64 (73)	51 (67)
Injected by someone after that person injected themselves or others last month (%)					
No	28 (90)	49 (83)	66 (76)	80 (91)	69 (91)
Yes	3 (10)	10 (17)	11 (13)	6 (7)	6 (8)
Not reported	0 (0)	0 (0)	10 (11)	2 (2)	1 (1)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	63 (83)
Yes	--	--	--	--	10 (13)
Not reported	--	--	--	--	3 (4)

* More than one option could be selected ** New question in 2012

Table 2.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=31	N=63	N=97	N=100	N=78
Sex with a regular partner last month (%)					
No	22 (71)	34 (54)	41 (42)	54 (54)	53 (68)
Yes	8 (26)	28 (44)	50 (52)	44 (44)	24 (31)
Not reported	1 (3)	1 (2)	6 (6)	2 (2)	1 (1)
Condom used with regular partner last month (%)					
N° surveyed	N=8	N=28	N=41	N=44	N=24
Never	3 (38)	20 (71)	23 (56)	31 (70)	13 (54)
Sometimes	2 (25)	4 (14)	7 (17)	9 (20)	9 (38)
Every time	2 (25)	3 (11)	9 (22)	3 (7)	2 (8)
Not reported	1 (12)	1 (4)	2 (5)	1 (2)	0 (0)
Sex with other partner/s last month (%)					
No	26 (84)	59 (94)	82 (85)	91 (91)	63 (81)
Yes	3 (10)	2 (3)	6 (6)	6 (6)	11 (14)
Not reported	2 (6)	2 (3)	9 (9)	3 (3)	4 (5)
Condom used with other partner/s last month (%)					
N° surveyed	N=3	N=2	N=6	N=6	N=11
Never	2 (67)	1 (50)	2 (33)	2 (33)	2 (18)
Sometimes	1 (33)	0 (0)	2 (33)	2 (33)	3 (27)
Every time	0 (0)	1 (50)	1 (17)	2 (33)	6 (55)
Not reported	0 (0)	0 (0)	1 (17)	0 (0)	0 (0)
Sex work last month (%)					
No	29 (94)	60 (95)	85 (88)	91 (91)	72 (92)
Yes	2 (6)	0 (0)	2 (2)	2 (2)	3 (4)
Not reported	0 (0)	3 (5)	10 (10)	7 (7)	3 (4)
Condom used at last sex work last month (%) *					
Yes	0 (0)	0 (0)	2 (100)	1 (100)	2 (67)

Table 2.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=31	N=63	N=97	N=100	N=78
Previous HIV test (%)					
Last year	8 (26)	30 (48)	50 (52)	43 (43)	42 (54)
> 1 year ago	21 (68)	25 (40)	21 (22)	40 (40)	30 (38)
Never tested	1 (3)	5 (8)	15 (15)	14 (14)	3 (4)
Not reported	1 (3)	3 (5)	11 (11)	3 (3)	3 (4)
Previous HCV test (%)					
Last year	11 (35)	34 (54)	49 (51)	53 (53)	44 (56)
> 1 year ago	18 (58)	24 (38)	27 (28)	38 (38)	29 (37)
Never tested	1 (3)	4 (6)	9 (9)	5 (5)	2 (3)
Not reported	1 (3)	1 (2)	12 (12)	4 (4)	3 (4)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=18	N=31	N=57	N=55	N=46
Interferon/Interferon+Ribavirin	2 (11)	2 (6)	4 (7)	6 (11)	1 (2)
Other	1 (6)	0 (0)	1 (2)	1 (2)	2 (4)
No treatment	15 (83)	29 (94)	52 (91)	48 (87)	42 (91)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Current treatment for HCV					
N°	N=0	N=0	N=3	N=1	N=0
Interferon/Interferon+Ribavirin	0	0	3	1	0
Other	0	0	0	0	0

Table 2.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=31	N=63	N=97	N=100	N=78
Any treatment/therapy for drug use (%)					
No	3 (10)	10 (16)	11 (11)	14 (14)	9 (12)
Yes	27 (87)	53 (84)	84 (87)	86 (86)	69 (88)
Not reported	1 (3)	0 (0)	2 (2)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	11 (35)	23 (37)	45 (46)	43 (43)	34 (44)
Previously	10 (32)	18 (29)	16 (16)	20 (20)	27 (35)
Never	9 (29)	22 (35)	28 (29)	33 (33)	17 (22)
Not reported	1 (3)	0 (0)	8 (8)	4 (4)	0 (0)
History of buprenorphine (Subutex®) treatment (%) *					
Currently	6 (19)	4 (6)	7 (7)	7 (7)	7 (9)
Previously	5 (16)	11 (17)	25 (26)	34 (34)	20 (26)
Never	19 (61)	46 (73)	64 (66)	57 (57)	49 (63)
Not reported	1 (3)	2 (3)	1 (1)	2 (2)	2 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	3 (10)	5 (8)	4 (4)	10 (10)	5 (6)
Previously	5 (16)	4 (6)	17 (18)	21 (21)	13 (17)
Never	22 (71)	51 (81)	75 (77)	66 (66)	60 (77)
Not reported	1 (3)	3 (5)	1 (1)	3 (3)	0 (0)

Table 2.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=31	N=59	N=87	N=88	N=76
Needle Syringe Program	29 (94)	34 (58)	82 (94)	81 (92)	70 (92)
Chemist/Pharmacy	20 (65)	30 (51)	21 (24)	17 (19)	27 (36)
Personal sources	--	21 (36)	12 (14)	8 (9)	14 (18)
Dispensing/Vending Machine	--	15 (25)	20 (23)	14 (16)	22 (29)
Other sources	--	1 (2)	4 (5)	1 (1)	0 (0)

* More than one option could be selected

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	18	0 (0.0)	8	0 (0.0)	26	0 (0.0)
2009	36	0 (0.0)	22	0 (0.0)	58	0 (0.0)
2010	72	0 (0.0)	25	0 (0.0)	97	0 (0.0)
2011	64	0 (0.0)	31	0 (0.0)	95	0 (0.0)
2012	53	0 (0.0)	25	0 (0.0)	78	0 (0.0)
X ² trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	18	12 (67)	8	6 (75)	26	18 (69)
2009	36	21 (58)	22	13 (59)	58	34 (59)
2010	70	48 (69)	25	15 (60)	95	63 (66)
2011	62	44 (71)	31	12 (39)	93	56 (60)
2012	53	34 (64)	25	16 (64)	78	50 (64)
X ² trend p value		0.720		0.436		0.871

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	13	8 (62)	6	4 (67)	19	12 (63)
Bisexual	2	1 (50)	0	0 (0)	2	1 (50)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.779
2009						
Heterosexual	32	19 (59)	18	10 (56)	50	29 (58)
Bisexual	3	1 (33)	2	1 (50)	5	2 (40)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.565		1.000		0.643
2010						
Heterosexual	61	44 (72)	18	12 (67)	79	56 (71)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.439		0.147		0.078
2011						
Heterosexual	56	41 (73)	22	9 (41)	78	50 (64)
Bisexual	2	1 (50)	3	2 (67)	5	3 (60)
Homosexual	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.585		0.777		1.000
2012						
Heterosexual	49	31 (63)	22	13 (59)	71	44 (62)
Bisexual	2	1 (50)	3	3 (100)	5	4 (80)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.646

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	1	0 (0)	1	1 (100)	2	1 (50)
25 – 34	4	2 (50)	3	3 (100)	7	5 (71)
35+ years	13	10 (77)	4	2 (50)	17	12 (71)
p value		0.211		0.264		0.828
2009						
< 25 years	8	3 (38)	5	4 (80)	13	7 (54)
25 – 34	15	12 (80)	5	3 (60)	20	15 (75)
35+ years	13	6 (46)	12	6 (50)	25	12 (48)
p value		0.077		0.518		0.174
2010						
< 25 years	3	2 (67)	0	0 (0)	3	2 (67)
25 – 34	29	19 (66)	10	6 (60)	39	25 (64)
35+ years	38	27 (71)	15	9 (60)	53	36 (68)
p value		0.905		1.000		0.920
2011						
< 25 years	1	1 (100)	3	0 (0)	4	1 (25)
25 – 34	26	17 (65)	14	5 (36)	40	22 (55)
35+ years	35	26 (74)	14	7 (50)	49	33 (67)
p value		0.696		0.321		0.171
2012						
< 25 years	4	1 (25)	0	0 (0)	4	1 (25)
25 – 34	7	3 (43)	7	3 (43)	14	6 (43)
35+ years	42	30 (71)	18	13 (72)	60	43 (72)
p value		0.091		0.170		0.040

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	4	2 (50)	1	1 (100)	5	3 (60)
11 + years	13	10 (77)	7	5 (71)	20	15 (75)
p value		0.211		0.537		0.251
2009						
<3 years	3	0 (0)	3	2 (67)	6	2 (33)
3 to 10 years	12	9 (75)	3	2 (67)	15	11 (73)
11 + years	20	11 (55)	16	9 (56)	36	20 (56)
p value		0.061		0.907		0.220
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	19	11 (58)	3	0 (0)	22	11 (50)
11 + years	48	35 (73)	22	15 (68)	70	50 (71)
p value		0.140		0.052		0.051
2011						
<3 years	5	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	11	7 (64)	7	1 (14)	18	8 (44)
11 + years	49	35 (71)	21	10 (48)	70	45 (64)
p value		0.859		0.312		0.307
2012						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	6	2 (33)	3	1 (33)	9	3 (33)
11 + years	45	31 (69)	22	15 (68)	67	46 (69)
p value		0.189		0.530		0.070

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	0	0 (0)	12	10 (83)	12	10 (83)
Methamphetamine	1	0 (0)	7	4 (57)	8	4 (50)
Other	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.446		0.283
2009						
Heroin	2	2 (100)	22	13 (59)	24	15 (63)
Methamphetamine	0	0 (0)	15	6 (40)	15	6 (40)
Other	4	0 (0)	13	11 (85)	18	12 (67)
p value		0.014		0.041		0.218
2010						
Heroin	0	0 (0)	26	18 (69)	27	19 (70)
Methamphetamine	0	0 (0)	26	13 (50)	26	13 (50)
Other	1	0 (0)	40	30 (75)	42	31 (74)
p value		--		0.105		0.120
2011						
Heroin	4	3 (75)	40	20 (50)	41	20 (49)
Methamphetamine	0	0 (0)	24	14 (58)	24	14 (58)
Other	0	0 (0)	24	19 (79)	28	22 (79)
p value		--		0.063		0.042
2012						
Heroin	0	0 (0)	30	22 (73)	30	22 (73)
Methamphetamine	1	1 (100)	22	12 (55)	23	13 (57)
Other	1	1 (100)	23	15 (65)	24	15 (63)
p value		1.000		0.372		0.435

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	0	0 (0)	14	10 (71)	14	10 (71)
Daily or more	1	1 (100)	11	8 (73)	12	8 (67)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.943		0.793
2009						
Less than daily	1	0 (0)	19	7 (37)	20	7 (35)
Daily or more	5	2 (40)	28	21 (75)	34	24 (71)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.439		0.026		0.029
2010						
Less than daily	1	0 (0)	47	34 (72)	49	35 (71)
Daily or more	0	0 (0)	35	24 (69)	36	25 (69)
Not last month	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.037		0.039
2011						
Less than daily	2	1 (50)	34	22 (65)	36	23 (64)
Daily or more	1	1 (100)	45	28 (62)	45	28 (62)
Not last month	0	0 (0)	8	2 (25)	10	3 (30)
p value		1.000		0.122		0.171
2012						
Less than daily	0	0 (0)	32	20 (63)	32	20 (63)
Daily or more	1	1 (100)	43	28 (65)	44	29 (66)
Not last month	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		1.000		0.912

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	1	0 (0)	20	13 (65)	21	13 (62)
Receptive sharing	0	0 (0)	5	5 (100)	5	5 (100)
p value		---		0.274		0.281
2009						
No receptive sharing	5	1 (20)	41	23 (56)	46	24 (52)
Receptive sharing	0	0 (0)	6	5 (83)	7	6 (86)
p value		0.123		1.000		1.000
2010						
No receptive sharing	1	0 (0)	60	39 (65)	62	40 (65)
Receptive sharing	0	0 (0)	13	12 (92)	14	13 (93)
p value		--		0.092		0.052
2011						
No receptive sharing	2	1 (50)	69	47 (68)	71	48 (68)
Receptive sharing	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.024		0.046
2012						
No receptive sharing	1	1 (100)	59	38 (64)	60	39 (65)
Receptive sharing	0	0 (0)	13	9 (69)	13	9 (69)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 2.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	1	0 (0)	20	15 (75)	21	15 (71)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		---		0.481		0.526
2009						
No imprisonment	5	2 (40)	44	27 (61)	49	29 (59)
Imprisonment	1	0 (0)	5	3 (60)	7	4 (57)
p value		1.000		1.000		1.000
2010						
No imprisonment	1	0 (0)	66	43 (65)	67	43 (64)
Imprisonment	0	0 (0)	12	9 (75)	13	10 (77)
p value		--		0.741		0.526
2011						
No imprisonment	2	1 (50)	80	47 (59)	83	48 (58)
Imprisonment	1	1 (100)	5	3 (60)	6	4 (67)
p value		1.000		1.000		1.000
2012						
No imprisonment	2	1 (50)	65	42 (65)	67	43 (64)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.617		0.620

* Total includes people who did not report duration of drug injection

Table 2.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	1	0 (0)	23	16 (70)	24	16 (67)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
No sex work	6	2 (33)	48	30 (63)	55	33 (60)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2010						
No sex work	1	0 (0)	80	53 (66)	83	55 (66)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		1.000		1.000
2011						
No sex work	4	3 (75)	81	48 (59)	86	51 (59)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.515		0.515
2012						
No sex work	2	1 (50)	70	44 (63)	72	45 (63)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.548		0.549

* Total includes people who did not report duration of drug injection

Table 2.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	13	8 (62)	7	5 (71)	20	13 (65)
Indigenous	4	3 (75)	0	0 (0)	4	3 (75)
p value		1.000		---		1.000
2009						
Non Indigenous	35	21 (60)	17	10 (59)	52	31 (60)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.417		0.566		0.303
2010						
Non Indigenous	60	43 (72)	17	12 (71)	77	55 (71)
Indigenous	9	5 (56)	8	3 (38)	17	8 (47)
p value		0.439		0.194		0.085
2011						
Non Indigenous	53	37 (70)	27	11 (41)	80	48 (60)
Indigenous	8	6 (75)	3	1 (33)	11	7 (64)
p value		1.000		1.000		1.000
2012						
Non Indigenous	46	29 (63)	25	16 (64)	71	45 (63)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.629		--		0.626

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	18	12 (67)	7	5 (71)	25	17 (68)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
English speaking	35	21 (60)	21	13 (62)	56	34 (61)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.417		0.409		0.167
2010						
English speaking	68	46 (68)	25	15 (60)	93	61 (66)
Non-English speaking	2	2 (100)	0	0 (0)	2	2 (100)
p value		1.000		--		0.548
2011						
English speaking	58	42 (72)	31	12 (39)	89	54 (61)
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.573		--		1.000
2012						
English speaking	52	34 (65)	23	15 (65)	75	49 (65)
Non-English speaking	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.358		1.000		0.291

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	16	11 (69)	6	4 (67)	22	15 (68)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	1	1(100)	1	1 (100)
p value		0.569		1.000		0.704
2009						
Australia	27	18 (67)	18	12 (67)	45	30 (67)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	1 (20)	3	1 (33)	8	2 (25)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.055		0.352		0.015
2010						
Australia	65	45 (69)	23	15 (65)	88	60 (68)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	2	0 (0)	4	2 (50)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.124		0.071		0.168
2011						
Australia	57	41 (72)	26	11 (42)	83	52 (63)
Other Oceania	2	2 (100)	2	0 (0)	4	2 (50)
Asia	0	0 (0)	0	0 (0)	4	2 (50)
UK & Ireland	1	1 (100)	3	1 (33)	0	0 (0)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.156		0.774		0.258
2012						
Australia	49	31 (63)	22	13 (59)	71	44 (62)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	1 (50)	3	3 (100)	5	4 (80)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.856

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	20	20	21	20	20
N° surveyed	N=899	N=830	N=680	N=694	N=712
Response (%)	36%	39%	40%	36%	47%
Gender (%)					
Male	582 (65)	500 (60)	427 (63)	463 (67)	476 (67)
Female	310 (34)	322 (39)	247 (36)	228 (33)	227 (32)
Transgender	4 (<1)	7 (<1)	5 (1)	3 (<1)	6 (1)
Not reported	3 (<1)	1 (<1)	1 (<1)	0 (0)	3 (<1)
Sexual identity (%)					
Heterosexual	715 (80)	669 (81)	545 (80)	563 (81)	576 (81)
Bisexual	93 (10)	77 (9)	76 (11)	61 (9)	60 (8)
Homosexual	56 (6)	40 (5)	25 (4)	38 (5)	25 (4)
Not reported	35 (4)	44 (5)	34 (5)	32 (5)	51 (7)
Age and duration of injection (years)					
<i>Median age</i>	37	38	39	38	39
<i>Age range</i>	17-70	18-64	18-69	18-63	18-64
Age group (%)					
<25 years	81 (9)	66 (8)	54 (8)	51 (7)	55 (8)
25+ years	815 (91)	764 (92)	626 (92)	640 (92)	657 (92)
Not reported	3 (<1)	0 (0)	0 (0)	3 (<1)	0 (0)
<i>Median age 1st IDU</i>	18	18	18	19	19
<i>Age range</i>	10-60	10-57	10-63	10-47	10-64
<i>N° not reported</i>	18	17	22	23	20
<i>Median years IDU</i>	17	17	18	17	18
<i>Range</i>	<1-48	<1-45	<1-45	<1-46	<1-46
Duration of drug injection (%)					
<3 years	46 (5)	47 (6)	48 (7)	64 (9)	66 (9)
>3+ years	835 (93)	766 (92)	610 (90)	606 (87)	626 (88)
Not reported	18 (2)	17 (2)	22 (3)	24 (3)	20 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	736 (82)	682 (82)	565 (83)	582 (84)	609 (86)
Yes	131 (15)	122 (15)	96 (14)	91 (13)	90 (13)
Not reported	32 (4)	26 (3)	19 (3)	21 (3)	13 (2)
Region/Country of birth (%)					
Australia	781 (87)	726 (87)	581 (85)	588 (85)	621 (87)
Other Oceania	31 (3)	18 (2)	24 (4)	21 (3)	22 (3)
Asia	8 (1)	4 (<1)	10 (1)	12 (2)	8 (1)
UK & Ireland	38 (4)	37 (4)	23 (3)	27 (4)	30 (4)
Other	28 (3)	28 (3)	24 (4)	33 (5)	21 (3)
Not reported	13 (1)	17 (2)	18 (3)	13 (2)	10 (1)
Main language spoken at home by parents (%)					
English speaking	844 (94)	787 (95)	645 (95)	643 (93)	675 (95)
Non-English speaking	40 (4)	33 (4)	23 (3)	40 (6)	32 (4)
Not reported	15 (2)	10 (1)	12 (2)	11 (2)	5 (1)
Imprisonment last year (%)*					
No	687 (76)	684 (82)	492 (72)	567 (82)	603 (87)
Yes	137 (15)	103 (12)	77 (11)	82 (12)	75 (11)
Not reported	75 (8)	43 (5)	111 (16)	45 (2)	18 (3)
Injected in prison (%)					
Yes	46 (34)	30 (29)	20 (26)	18 (22)	27 (36)
Frequency of injection last month (%)					
Not last month	126 (14)	129 (16)	119 (18)	105 (15)	110 (15)
Less than weekly	146 (16)	150 (18)	128 (19)	119 (17)	144 (20)
Weekly not daily	229 (25)	200 (24)	134 (20)	167 (24)	178 (25)
Daily or more	392 (44)	337 (41)	284 (42)	285 (41)	271 (38)
Not reported	6 (1)	14 (2)	15 (2)	18 (3)	9 (1)

Table 3.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=899	N=830	N=680	N=694	N=712
Cocaine	45 (5)	51 (6)	19 (3)	12 (2)	16 (2)
Heroin	346 (39)	306 (37)	236 (35)	211 (30)	216 (30)
Methadone	107 (12)	116 (14)	59 (9)	79 (11)	69 (10)
Methamphetamine	230 (26)	181 (22)	201 (30)	198 (29)	187 (26)
Performance/Image-enhancing drugs	20 (2)	30 (4)	29 (4)	64 (9)	83 (12)
Pharmaceutical opioids	80 (9)	80 (10)	62 (9)	70 (10)	80 (11)
Suboxone®	--	6 (<1)	2 (<1)	1 (<1)	7 (1)
Subutex®/Buprenorphine	27 (3)	16 (2)	16 (2)	16 (2)	10 (1)
More than one	21 (2)	23 (3)	36 (5)	27 (4)	33 (5)
Other drug	8 (1)	0 (0)	16 (2)	15 (2)	4 (<1)
Not reported	15 (2)	21 (3)	4 (<1)	1 (<1)	7 (1)
N° Injected last month	N=767	N=687	N=548	N=571	N=593
Places injected last month (%)*					
Any public	308 (40)	249 (36)	176 (32)	169 (30)	166 (28)
All private	446 (58)	430 (63)	331 (60)	388 (68)	412 (69)
Not reported	13 (2)	8 (1)	41 (7)	14 (2)	15 (3)
Use of new sterile needles & syringes last month (%)					
All injections	544 (71)	500 (73)	368 (67)	439 (77)	439 (74)
Most of the time	174 (23)	157 (23)	108 (20)	95 (17)	112 (19)
Half of the time	22 (3)	10 (1)	14 (3)	9 (2)	10 (2)
Some of the time	11 (1)	9 (1)	11 (2)	7 (1)	6 (1)
Not last month	7 (1)	2 (<1)	6 (1)	1 (<1)	6 (1)
Not reported	9 (1)	9 (1)	41 (7)	20 (4)	20 (3)
Re-used another's used needle & syringe last month (%)					
None	604 (79)	560 (82)	400 (73)	486 (85)	491 (83)
Once	50 (7)	44 (6)	33 (6)	25 (4)	35 (6)
Twice	42 (5)	33 (5)	19 (3)	16 (3)	12 (2)
3-5 times	26 (3)	18 (3)	16 (3)	12 (2)	20 (3)
>5 times	22 (3)	17 (2)	15 (3)	5 (1)	15 (3)
Not reported	23 (3)	15 (2)	65 (12)	27 (5)	20 (3)
Number of people needle & syringe was re-used after last month (%)					
None	604 (79)	560 (82)	400 (73)	486 (85)	491 (83)
One	66 (9)	53 (8)	33 (6)	27 (5)	41 (7)
Two	11 (1)	6 (1)	7 (1)	4 (<1)	9 (2)
Three to five	10 (1)	3 (<1)	8 (1)	2 (<1)	1 (<1)
More than five	3 (<1)	2 (<1)	4 (<1)	0 (0)	4 (<1)
Don't know	30 (4)	18 (3)	11 (2)	16 (3)	9 (2)
Not reported	43 (6)	45 (7)	85 (16)	36 (6)	38 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	56 (7)	39 (6)	53 (10)	48 (8)	33 (6)
Casual sex partner	7 (1)	3 (<1)	6 (1)	1 (<1)	1 (<1)
Close friend	39 (5)	16 (2)	23 (4)	21 (4)	25 (4)
Acquaintance	12 (2)	13 (2)	11 (2)	11 (2)	9 (2)
Other	8 (1)	11 (2)	13 (2)	12 (2)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	160 (23)	127 (20)	93 (17)	94 (16)	95 (16)
Water	114 (16)	81 (13)	64 (12)	64 (11)	75 (13)
Filter	78 (11)	52 (8)	36 (7)	39 (7)	47 (8)
Drug mix	50 (7)	52 (8)	29 (5)	35 (6)	34 (6)
None**	457 (66)	420 (68)	370 (68)	432 (76)	428 (72)
Injected by someone after that person injected themselves or others last month (%)					
No	631 (82)	592 (86)	432 (79)	484 (85)	486 (82)
Yes	110 (14)	76 (11)	52 (9)	66 (12)	80 (13)
Not reported	26 (3)	19 (3)	64 (12)	21 (4)	27 (5)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	476 (80)
Yes	--	--	--	--	81 (14)
Not reported	--	--	--	--	36 (6)

* More than one option could be selected ** New question in 2012

Table 3.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=899	N=830	N=680	N=694	N=712
Sex with a regular partner last month (%)					
No	392 (44)	369 (44)	280 (41)	307 (44)	324 (46)
Yes	481 (54)	439 (53)	370 (54)	334 (48)	360 (51)
Not reported	26 (3)	22 (3)	30 (4)	53 (8)	28 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=481	N=439	N=370	N=334	N=360
Never	330 (69)	378 (86)	273 (74)	238 (71)	254 (71)
Sometimes	61 (13)	43 (10)	42 (11)	32 (10)	47 (13)
Every time	69 (14)	2 (<1)	35 (9)	46 (14)	39 (11)
Not reported	21 (4)	16 (4)	20 (5)	18 (5)	20 (6)
Sex with other partner/s last month (%)					
No	705 (78)	665 (80)	532 (78)	557 (80)	584 (82)
Yes	165 (18)	126 (15)	103 (15)	102 (15)	94 (13)
Not reported	29 (3)	39 (5)	45 (7)	35 (5)	34 (5)
Condom used with other partner/s last month (%)					
N° surveyed	N=165	N=126	N=103	N=102	N=94
Never	38 (23)	47 (37)	44 (43)	27 (26)	28 (30)
Sometimes	39 (24)	22 (17)	17 (17)	28 (27)	29 (31)
Every time	79 (48)	55 (44)	39 (38)	46 (45)	32 (34)
Not reported	9 (5)	2 (2)	3 (3)	1 (1)	5 (5)
Sex work last month (%)					
No	771 (86)	740 (89)	568 (84)	618 (89)	637 (89)
Yes	78 (9)	57 (7)	51 (8)	38 (5)	42 (6)
Not reported	50 (6)	33 (4)	61 (9)	38 (5)	33 (5)
Condom used at last sex work last month (%)					
Yes	57 (84)	52 (91)	39 (80)	30 (83)	35 (85)

Table 3.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=899	N=830	N=680	N=694	N=712
Previous HIV test (%)					
Yes, last year	443 (49)	423 (51)	337 (50)	331 (48)	310 (44)
> 1 year ago	334 (37)	304 (37)	227 (33)	244 (35)	272 (38)
Never tested	73 (8)	69 (8)	69 (10)	92 (13)	96 (13)
Not reported	49 (5)	34 (4)	47 (7)	27 (4)	34 (5)
Previous HCV test (%)					
Yes, last year	494 (55)	497 (60)	357 (53)	354 (51)	364 (51)
> 1 year ago	327 (36)	265 (32)	216 (32)	229 (33)	243 (34)
Never tested	45 (5)	39 (5)	59 (9)	67 (10)	64 (9)
Not reported	33 (4)	29 (3)	48 (7)	44 (6)	41 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=546	N=508	N=368	N=364	N=375
Interferon/Interferon+Ribavirin	53 (10)	50 (10)	47 (13)	36 (10)	46 (12)
Other	5 (1)	3 (<1)	5 (1)	4 (1)	3 (1)
No treatment	470 (86)	432 (85)	301 (82)	296 (81)	304 (81)
Not reported	18 (3)	23 (5)	15 (4)	28 (8)	22 (6)
Current treatment for HCV					
	N=13	N=6	N=14	N=13	N=7
Interferon/Interferon+Ribavirin	9	5	11	7	5
Other	4	1	3	3	2

Table 3.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=899	N=830	N=680	N=694	N=712
Any treatment/therapy for drug use (%)					
No	128 (14)	112 (13)	111 (16)	525 (76)	526 (74)
Yes	754 (84)	704 (85)	551 (81)	138 (20)	174 (24)
Not reported	17 (2)	14 (2)	18 (3)	31 (4)	12 (2)
History of methadone maintenance treatment (%)					
Currently	379 (42)	396 (48)	279 (41)	273 (39)	289 (41)
Previously	219 (24)	177 (21)	143 (21)	128 (18)	143 (20)
Never	281 (31)	236 (28)	218 (32)	245 (35)	275 (39)
Not reported	20 (2)	21 (3)	40 (6)	48 (7)	5 (<1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	120 (13)	91 (11)	60 (9)	60 (9)	53 (7)
Previously	193 (21)	213 (26)	176 (26)	156 (22)	182 (26)
Never	564 (63)	500 (60)	435 (64)	443 (64)	466 (65)
Not reported	22 (2)	26 (3)	7 (1)	35 (5)	11 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	26 (3)	37 (4)	30 (4)	39 (6)	66 (9)
Previously	59 (7)	76 (9)	68 (10)	82 (12)	89 (13)
Never	782 (87)	687 (87)	567 (83)	535 (77)	542 (76)
Not reported	32 (4)	1 (1)	15 (2)	38 (5)	15 (2)

Table 3.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=767	N=687	N=548	N=571	N=593
Needle Syringe Program	687 (90)	474 (69)	491 (69)	521 (91)	527 (89)
Chemist/Pharmacy	334 (44)	139 (20)	139 (20)	96 (17)	101 (17)
Personal sources	--	79 (12)	79 (12)	39 (7)	56 (9)
Dispensing/Vending Machine	--	129 (19)	129 (19)	95 (17)	120 (20)
Other sources	--	22 (3)	22 (3)	18 (3)	3 (<1)

* More than one option could be selected

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	563	15 (2.7)	297	3 (1.0)	867	19 (2.2)
2009	488	12 (2.5)	320	0 (0.0)	816	13 (1.6)
2010	422	8 (1.9)	243	0 (0.0)	671	8 (1.2)
2011	455	5 (1.1)	224	1 (0.5)	682	7 (1.0)
2012	465	7 (1.5)	223	0 (0.0)	697	8 (1.2)
X ² trend p value		0.060		0.129		0.047

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Heterosexual	488	2 (0.4)	202	1 (0.5)	691	3 (0.4)
Bisexual	25	0 (0.0)	63	2 (3.2)	89	3 (3.4)
Homosexual	31	13 (41.9)	21	0 (0.0)	54	13 (24.1)
p value		<0.001		0.207		<0.001
2009						
Heterosexual	424	2 (0.5)	232	0 (0.0)	658	2 (0.3)
Bisexual	21	0 (0.0)	53	0 (0.0)	76	1 (1.3)
Homosexual	22	10 (45.5)	15	0 (0.0)	39	10 (25.6)
p value		<0.001		---		<0.001
2010						
Heterosexual	371	1 (0.3)	166	0 (0.0)	539	1 (0.2)
Bisexual	14	0 (0.0)	58	0 (0.0)	74	0 (0.0)
Homosexual	15	7 (46.7)	8	0 (0.0)	24	7 (29.2)
p value		<0.001		--		<0.001
2011						
Heterosexual	397	1 (0.3)	158	0 (0.0)	555	1 (0.2)
Bisexual	17	1 (5.6)	40	1 (2.5)	59	3 (5.1)
Homosexual	21	3 (14.3)	15	0 (0.0)	37	3 (8.1)
p value		<0.001		0.258		<0.001
2012						
Heterosexual	410	1 (0.2)	153	0 (0.0)	565	1 (0.2)
Bisexual	14	0 (0.0)	42	0 (0.0)	58	1 (1.7)
Homosexual	15	5 (33.3)	7	0 (0.0)	24	5 (20.8)
p value		0.001		--		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
< 25 years	45	0 (0.0)	34	0 (0.0)	79	0 (0.0)
25 – 34	167	4 (2.4)	101	3 (3.0)	270	8 (3.0)
35+ years	348	11 (3.2)	162	0 (0.0)	515	11 (2.1)
p value		0.449		0.053		0.284
2009						
< 25 years	26	0 (0.0)	38	0 (0.0)	64	0 (0.0)
25 – 34	135	2 (1.5)	109	0 (0.0)	244	2 (0.8)
35+ years	324	10 (3.1)	173	0 (0.0)	505	11 (2.2)
p value		0.425		--		0.217
2010						
< 25 years	27	1 (3.7)	25	0 (0.0)	53	1 (1.9)
25 – 34	107	1 (0.9)	85	0 (0.0)	192	1 (0.5)
35+ years	286	4 (1.4)	133	0 (0.0)	424	4 (0.9)
p value		0.556		--		0.504
2011						
< 25 years	40	1 (2.5)	10	0 (0.0)	50	1 (2.0)
25 – 34	123	0 (0.0)	88	1 (1.1)	212	1 (0.5)
35+ years	290	3 (8.1)	125	0 (0.0)	417	5 (1.2)
p value		<0.001		0.439		0.444
2012						
< 25 years	42	0 (0.0)	10	0 (0.0)	53	0 (0.0)
25 – 34	117	0 (0.0)	65	0 (0.0)	184	0 (0.0)
35+ years	306	7 (2.3)	148	0 (0.0)	460	8 (1.7)
p value		0.296		--		0.249

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
<3 years	33	3 (9.1)	15	0 (0.0)	48	3 (6.3)
3 to 10 years	114	2 (1.8)	64	0 (0.0)	179	2 (3.4)
11 + years	400	10 (2.5)	217	3 (1.4)	622	14 (2.3)
p value		0.056		0.580		0.087
2009						
<3 years	30	2 (6.7)	16	0 (0.0)	46	2 (4.4)
3 to 10 years	66	2 (3.0)	68	0 (0.0)	135	2 (1.5)
11 + years	382	8 (2.1)	229	0 (0.0)	618	9 (1.5)
p value		0.292		--		0.323
2010						
<3 years	30	1 (3.3)	16	0 (0.0)	47	1 (2.1)
3 to 10 years	59	0 (0.0)	50	0 (0.0)	109	0 (0.0)
11 + years	317	5 (1.6)	170	0 (0.0)	492	5 (1.0)
p value		0.521		--		0.290
2011						
<3 years	51	0 (0.0)	10	0 (0.0)	61	0 (0.0)
3 to 10 years	78	3 (3.9)	34	0 (0.0)	112	2 (2.7)
11 + years	306	2 (0.7)	177	1 (0.6)	486	4 (0.8)
p value		0.064		1.000		0.224
2012						
<3 years	52	1 (1.9)	11	0 (0.0)	64	1 (1.6)
3 to 10 years	75	1 (1.3)	43	0 (0.0)	119	1 (0.8)
11 + years	324	5 (1.5)	164	0 (0.0)	494	6 (1.2)
p value		0.840		--		0.845

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Heroin	218	1 (0.5)	116	1 (0.9)	335	2 (0.6)
Methamphetamine	138	11 (8.0)	75	1 (1.3)	217	13 (6.0)
Other	197	2 (1.0)	101	1 (1.0)	300	3 (1.0)
p value		<0.001		0.947		<0.001
2009						
Heroin	180	2 (1.1)	119	0 (0.0)	302	2 (0.7)
Methamphetamine	98	7 (7.1)	79	0 (0.0)	178	7 (3.9)
Other	198	3 (1.5)	113	0 (0.0)	315	4 (1.3)
p value		0.004		--		0.016
2010						
Heroin	136	1 (0.7)	93	0 (0.0)	231	1 (0.4)
Methamphetamine	120	3 (2.5)	75	0 (0.0)	197	3 (1.5)
Other	162	2 (1.2)	73	0 (0.0)	237	2 (0.8)
p value		0.589		--		0.523
2011						
Heroin	123	0 (0.0)	82	0 (0.0)	207	1 (0.5)
Methamphetamine	118	4 (3.4)	76	0 (0.0)	195	4 (2.1)
Other	213	1 (0.5)	66	1 (1.5)	279	2 (0.7)
p value		0.026		0.295		0.308
2012						
Heroin	144	0 (0.0)	67	0 (0.0)	214	1 (0.5)
Methamphetamine	103	4 (3.9)	74	0 (0.0)	181	4 (2.2)
Other	214	3 (1.4)	79	0 (0.0)	295	3 (1.0)
p value		0.034		--		0.308

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Less than daily	244	8 (3.3)	114	1 (0.9)	362	9 (2.5)
Daily or more	239	4 (1.7)	135	1 (0.7)	376	6 (1.6)
Not last month	77	3 (3.9)	45	1 (2.2)	123	4 (3.3)
p value		0.427		0.680		0.496
2009						
Less than daily	194	5 (2.6)	146	0 (0.0)	341	5 (1.5)
Daily or more	207	4 (1.9)	121	0 (0.0)	332	5 (1.5)
Not last month	78	3 (3.9)	48	0 (0.0)	127	3 (2.4)
p value		0.652		--		0.770
2010						
Less than daily	179	3 (1.7)	100	0 (0.0)	281	3 (1.1)
Daily or more	171	3 (1.8)	84	0 (0.0)	257	3 (1.2)
Not last month	59	0 (0.0)	56	0 (0.0)	117	0 (0)
p value		0.871		--		0.749
2011						
Less than daily	192	2 (1.0)	87	0 (0.0)	281	3 (1.1)
Daily or more	188	1 (0.5)	91	1 (1.1)	280	2 (0.7)
Not last month	60	1 (1.7)	43	0 (0.0)	103	1 (1.0)
p value		0.513		1.000		1.000
2012						
Less than daily	201	3 (1.5)	106	0 (0.0)	313	4 (1.3)
Daily or more	187	2 (1.1)	78	0 (0.0)	268	2 (0.8)
Not last month	70	2 (2.9)	37	0 (0.0)	107	2 (1.9)
p value		0.518		--		0.571

* Total includes people whose gender was not reported or reported as transgender

Table 3 HIV antibody prevalence by re-use of someone else's used needle & syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No receptive sharing	388	11 (2.8)	190	2 (1.1)	584	14 (2.4)
Receptive sharing	79	1 (1.3)	52	0 (0.0)	131	1 (0.8)
p value		0.700		1.000		0.328
2009						
No receptive sharing	337	9 (2.7)	210	0 (0.0)	554	10 (1.8)
Receptive sharing	56	0 (0.0)	53	0 (0.0)	109	0 (0.0)
p value		0.370		---		0.381
2010						
No receptive sharing	259	8 (3.1)	133	0 (0.0)	394	8 (2.0)
Receptive sharing	50	0 (0.0)	32	0 (0.0)	83	0 (0.0)
p value		0.363		--		0.361
2011						
No receptive sharing	322	2 (0.6)	154	1 (0.7)	477	3 (0.6)
Receptive sharing	39	1 (2.6)	19	0 (0.0)	58	1 (1.7)
p value		0.291		1.000		0.369
2012						
No receptive sharing	327	4 (1.2)	146	0 (0.0)	481	5 (1.0)
Receptive sharing	48	0 (0.0)	32	0 (0.0)	80	0 (0.0)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no injection last month

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No imprisonment	416	14 (3.4)	240	0 (0.0)	662	15 (2.3)
Imprisonment	98	1 (1.0)	32	2 (6.3)	131	3 (2.3)
p value		0.323		0.013		1.000
2009						
No imprisonment	394	12 (3.1)	273	0 (0.0)	675	13 (1.9)
Imprisonment	70	0 (0.0)	32	0 (0.0)	102	0 (0.0)
p value		0.228		---		0.236
2010						
No imprisonment	291	7 (2.4)	190	0 (0.0)	486	7 (1.4)
Imprisonment	54	0 (0.0)	22	0 (0.0)	76	0 (0.0)
p value		0.602		--		0.602
2011						
No imprisonment	385	5 (1.3)	185	0 (0.0)	572	6 (1.1)
Imprisonment	53	0 (0.0)	26	1 (3.9)	80	1 (1.3)
p value		1.000		0.123		0.602
2012						
No imprisonment	397	7 (1.8)	188	0 (0.0)	593	8 (1.4)
Imprisonment	46	0 (0.0)	24	0 (0.0)	71	0 (0.0)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No condom use	226	1 (0.4)	150	0 (0.0)	378	1 (0.3)
Condom use	43	1 (2.3)	22	1 (4.6)	67	3 (1.5)
p value		0.295		0.128		0.012
2009						
No condom use	197	1 (0.5)	175	0 (0.0)	374	1 (0.3)
Condom use	31	2 (6.5)	10	0 (0.0)	41	2 (4.9)
p value		0.049		---		0.027
2010						
No condom use	163	3 (1.8)	106	0 (0.0)	270	3 (1.1)
Condom use	48	0 (0.0)	27	0 (0.0)	76	0 (0.0)
p value		1.000		--		1.000
2011						
No condom use	152	3 (2.0)	83	0 (0.0)	235	3 (1.3)
Condom use	51	2 (3.9)	24	1 (4.2)	76	3 (4.0)
p value		0.601		0.224		0.159
2012						
No condom use	145	2 (1.4)	102	0 (0.0)	250	2 (0.8)
Condom use	60	2 (3.3)	22	0 (0.0)	82	2 (2.4)
p value		0.582		--		0.256

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No sex work	511	13 (2.5)	229	3 (1.3)	745	16 (2.2)
Sex work	23	2 (8.7)	49	0 (0.0)	73	3 (4.1)
p value		0.133		1.000		0.236
2009						
No sex work	462	10 (2.2)	261	0 (0.0)	729	11 (1.5)
Sex work	7	2 (28.6)	48	0 (0.0)	57	2 (3.5)
p value		0.012		---		0.243
2010						
No sex work	374	6 (1.6)	183	0 (0.0)	561	6 (1.1)
Sex work	9	1 (11.1)	41	0 (0.0)	51	1 (2.0)
p value		0.154		--		0.458
2011						
No sex work	416	4 (1.0)	192	0 (0.0)	609	4 (0.7)
Sex work	6	0 (0.0)	28	1 (3.6)	36	2 (5.6)
p value		1.000		0.127		0.039
201&						
No sex work	432	6 (1.4)	188	0 (0.0)	625	6 (1.0)
Sex work	10	1 (10)	26	0 (0.0)	40	2 (5.0)
p value		0.149		--		0.078

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Non Indigenous	469	13 (2.8)	234	1 (0.4)	709	15 (2.1)
Indigenous	71	1 (1.4)	54	2 (3.7)	126	3 (2.4)
p value		1.000		0.091		0.744
2009						
Non Indigenous	422	11 (2.6)	245	0 (0.0)	672	11 (1.6)
Indigenous	48	1 (2.1)	70	0 (0.0)	120	2 (1.7)
p value		1.000		---		1.000
2010						
Non Indigenous	357	7 (2.0)	197	0 (0.0)	558	5 (1.3)
Indigenous	52	1 (1.9)	42	0 (0.0)	96	1 (1.0)
p value		1.000		--		1.000
2011						
Non Indigenous	395	5 (1.3)	178	0 (0.0)	574	5 (0.9)
Indigenous	47	0 (0.0)	40	1 (2.5)	88	2 (2.3)
p value		1.000		0.183		0.236
2012						
Non Indigenous	413	7 (1.7)	177	0 (0.0)	597	7 (1.2)
Indigenous	45	0 (0.0)	41	0 (0.0)	88	1 (1.1)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
English speaking	525	15 (2.9)	284	3 (1.1)	816	19 (2.3)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		1.000		1.000		1.000
2009						
English speaking	461	12 (2.6)	307	0 (0.0)	776	13 (1.7)
Non-English speaking	21	0 (0.0)	11	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000
2010						
English speaking	398	8 (2.0)	234	0 (0.0)	638	8 (1.3)
Non-English speaking	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
p value		1.000		--		1.000
2011						
English speaking	67	0 (0.0)	23	0 (0.0)	91	0 (0.0)
Non-English speaking	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
p value		1.000		1.000		0.602
2012						
English speaking	440	6 (1.4)	213	0 (0.0)	660	7 (1.1)
Non-English speaking	23	1 (4.4)	7	0 (0.0)	32	1 (3.1)
p value		0.302		--		0.317

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Australia	485	12 (2.5)	266	3 (1.1)	755	15 (2.0)
Other Oceania	14	2 (14.3)	10	0 (0.0)	26	3 (11.2)
Asia	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
UK & Ireland	25	0 (0.0)	9	0 (0.0)	35	0 (0.0)
Other	27	1 (3.7)	7	0 (0.0)	34	1 (2.9)
p value		0.135		1.000		0.063
2009						
Australia	417	12 (2.9)	292	0 (0.0)	714	13 (1.8)
Other Oceania	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other	17	0 (0.0)	9	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000
2010						
Australia	355	7 (2.0)	216	0 (0.0)	575	7 (1.2)
Other Oceania	12	1 (8.3)	11	0 (0.0)	24	1 (4.2)
Asia	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
UK & Ireland	14	0 (0.0)	8	0 (0.0)	22	0 (0.0)
Other	22	0 (0.0)	4	0 (0.0)	26	0 (0.0)
p value		0.483		--		0.654
2011						
Australia	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
Other Oceania	10	0 (0.0)	11	0 (0.0)	21	0 (0.0)
Asia	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
UK & Ireland	19	0 (0.0)	6	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	4	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		1.000
2012						
Australia	402	3 (0.8)	196	0 (0.0)	606	4 (0.7)
Other Oceania	14	2 (14.2)	8	0 (0.0)	22	2 (9.1)
Asia	7	0 (0.0)	0	0 (0.0)	8	0 (0.0)
UK & Ireland	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
Other	12	2 (16.7)	9	0 (0.0)	21	2 (9.5)
p value		0.001		--		0.003

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	539	379 (70)	281	208 (74)	827	591 (71)
2009	485	272 (56)	320	193 (60)	813	468 (58)
2010	422	228 (54)	243	135 (56)	671	365 (54)
2011	448	220 (49)	219	129 (59)	670	350 (52)
2012	453	213 (47)	220	121 (55)	682	338 (50)
X ² trend p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	468	337 (72)	191	144 (75)	660	481 (73)
Bisexual	24	17 (71)	59	45 (76)	84	62 (74)
Homosexual	29	12 (41)	20	13 (65)	51	26 (51)
p value		0.003		0.564		0.005
2009						
Heterosexual	421	238 (57)	232	134 (58)	655	373 (57)
Bisexual	21	13 (62)	53	41 (77)	76	54 (71)
Homosexual	22	5 (23)	15	7 (47)	39	12 (31)
p value		0.004		0.012		<0.001
2010						
Heterosexual	371	209 (56)	166	91 (55)	539	301 (56)
Bisexual	14	8 (57)	58	35 (60)	74	44 (59)
Homosexual	15	2 (13)	8	3 (38)	24	5 (21)
p value		0.003		0.422		0.002
2011						
Heterosexual	391	192 (49)	154	91 (59)	545	283 (52)
Bisexual	17	9 (53)	40	23 (58)	59	32 (54)
Homosexual	21	7 (33)	14	8 (57)	36	16 (44)
p value		0.340		0.969		0.641
2012						
Heterosexual	339	195 (49)	152	85 (56)	553	281 (51)
Bisexual	14	4 (29)	41	23 (56)	57	27 (47)
Homosexual	15	3 (20)	6	1 (17)	23	5 (22)
p value		0.033		0.163		0.021

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	43	15 (35)	34	22 (65)	77	37 (48)
25 – 34	157	99 (63)	98	70 (71)	257	170 (66)
35+ years	336	264 (79)	149	116 (78)	490	383 (78)
p value		<0.001		0.222		<0.001
2009						
< 25 years	26	2 (8)	38	17 (45)	64	19 (30)
25 – 34	135	66 (49)	109	66 (61)	244	132 (54)
35+ years	324	202 (62)	173	109 (63)	505	314 (62)
p value		<0.001		0.109		<0.001
2010						
< 25 years	27	4 (15)	25	16 (64)	53	20 (38)
25 – 34	107	49 (46)	85	39 (46)	192	88 (46)
35+ years	288	175 (61)	133	80 (60)	426	257 (60)
p value		<0.001		0.078		<0.001
2011						
< 25 years	40	4 (10)	10	5 (50)	50	9 (18)
25 – 34	120	49 (41)	86	46 (53)	207	95 (46)
35+ years	286	167 (58)	122	78 (64)	410	246 (60)
p value		<0.001		0.261		<0.001
2012						
< 25 years	41	0 (0)	10	5 (50)	52	5 (10)
25 – 34	114	34 (30)	65	38 (58)	181	74 (41)
35+ years	298	179 (60)	145	78 (54)	449	259 (58)
p value		<0.001		0.778		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	32	7 (22)	13	6 (46)	45	13 (29)
3 to 10 years	106	55 (52)	63	40 (63)	170	95 (56)
11 + years	386	309 (80)	203	161 (79)	594	473 (80)
p value		<0.001		0.003		<0.001
2009						
<3 years	30	1 (3)	16	6 (38)	46	7 (15)
3 to 10 years	65	20 (31)	68	37 (54)	134	58 (43)
11 + years	380	249 (66)	229	147 (64)	616	398 (65)
p value		<0.001		0.052		<0.001
2010						
<3 years	30	3 (10)	16	5 (31)	47	8 (17)
3 to 10 years	59	20 (34)	50	28 (56)	109	48 (44)
11 + years	319	200 (63)	170	100 (59)	494	302 (61)
p value		<0.001		0.114		<0.001
2011						
<3 years	51	5 (10)	10	3 (30)	61	8 (13)
3 to 10 years	78	27 (35)	33	19 (58)	111	46 (41)
11 + years	299	183 (61)	173	107 (62)	475	291 (61)
p value		<0.001		0.156		<0.001
2012						
<3 years	51	3 (6)	11	3 (27)	63	7 (11)
3 to 10 years	73	18 (25)	43	26 (60)	117	44 (38)
11 + years	315	187 (59)	161	91 (57)	482	281 (58)
p value		<0.001		0.134		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	10	3 (30)	305	240 (79)	319	245 (77)
Methamphetamine	10	2 (20)	195	123 (63)	209	126 (60)
Other	25	8 (32)	252	195 (77)	286	209 (73)
p value		0.776		<0.001		<0.001
2009						
Heroin	10	3 (30)	289	187 (65)	301	190 (63)
Methamphetamine	10	3 (30)	164	85 (52)	177	90 (51)
Other	26	7 (15)	283	173 (61)	316	180 (57)
p value		0.050		0.023		0.025
2010						
Heroin	10	3 (30)	214	137 (64)	231	144 (62)
Methamphetamine	11	2 (18)	184	89 (48)	198	93 (47)
Other	26	3 (12)	201	122 (61)	238	126 (53)
p value		0.381		0.005		0.005
2011						
Heroin	5	3 (60)	196	104 (53)	206	109 (53)
Methamphetamine	7	2 (29)	178	98 (55)	190	100 (53)
Other	48	3 (6)	212	135 (64)	273	141 (52)
p value		0.004		0.068		0.961
2012						
Heroin	10	2 (20)	198	114 (58)	211	118 (56)
Methamphetamine	7	2 (29)	165	86 (52)	177	91 (51)
Other	46	3 (6)	234	124 (53)	287	128 (45)
p value		0.088		0.522		0.041

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	22	2 (9)	318	224 (70)	344	229 (67)
Daily or more	15	8 (53)	332	263 (79)	357	277 (78)
Not last month	7	2 (29)	109	77 (71)	120	80 (67)
p value		0.012		0.024		0.003
2009						
Less than daily	17	3 (18)	321	196 (61)	342	200 (58)
Daily or more	20	2 (10)	305	184 (60)	330	190 (58)
Not last month	8	2 (25)	115	69 (60)	127	71 (56)
p value		0.586		0.973		0.880
2010						
Less than daily	25	2 (8)	253	135 (53)	282	138 (49)
Daily or more	13	4 (31)	235	149 (63)	258	155 (60)
Not last month	7	2 (29)	105	59 (56)	117	64 (55)
p value		0.131		0.073		0.033
2011						
Less than daily	28	4 (14)	242	127 (52)	275	132 (48)
Daily or more	18	3 (17)	247	155 (63)	275	160 (58)
Not last month	15	1 (7)	84	47 (56)	103	48 (47)
p value		0.793		0.069		0.029
2012						
Less than daily	27	5 (19)	275	162 (59)	309	170 (55)
Daily or more	23	2 (9)	231	116 (50)	261	121 (46)
Not last month	12	0 (0)	87	44 (51)	103	44 (43)
p value		0.291		0.112		0.036

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	30	7 (23)	515	379 (74)	558	394 (71)
Receptive sharing	6	4 (67)	114	89 (78)	120	93 (78)
p value		0.057		0.345		0.146
2009						
No receptive sharing	34	3 (9)	510	307 (60)	551	314 (57)
Receptive sharing	3	2 (67)	105	66 (63)	109	68 (62)
p value		0.042		0.742		0.341
2010						
No receptive sharing	30	5 (17)	352	195 (55)	394	203 (52)
Receptive sharing	4	1 (25)	78	52 (67)	83	53 (64)
p value		0.559		0.077		0.052
2011						
No receptive sharing	42	6 (14)	414	234 (57)	468	243 (52)
Receptive sharing	1	1 (100)	55	41 (75)	56	42 (75)
p value		0.163		0.013		0.001
2012						
No receptive sharing	45	6 (13)	417	228 (55)	474	238 (50)
Receptive sharing	5	1 (20)	71	42 (59)	77	44 (57)
p value		0.546		0.520		0.271

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 3.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	39	11 (28)	582	412 (71)	632	428 (68)
Imprisonment	4	2 (50)	118	100 (85)	125	104 (83)
p value		0.572		0.001		<0.001
2009						
No imprisonment	41	4 (10)	615	360 (59)	673	369 (55)
Imprisonment	3	2 (67)	98	70 (71)	101	72 (71)
p value		0.045		0.020		0.002
2010						
No imprisonment	41	5 (12)	427	228 (53)	486	238 (49)
Imprisonment	1	0 (0)	74	55 (74)	76	56 (74)
p value		1.000		0.001		<0.001
2011						
No imprisonment	59	7 (12)	475	260 (55)	550	269 (49)
Imprisonment	1	1 (100)	73	55 (75)	77	58 (75)
p value		0.133		0.001		<0.001
2012						
No imprisonment	61	7 (11)	504	263 (52)	581	274 (47)
Imprisonment	1	0 (0)	66	40 (61)	69	41 (59)
p value		1.000		0.197		0.057

* Total includes people who did not report duration of drug injection

Table 3.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	41	12 (29)	659	483 (73)	714	502 (70)
Sex work	3	2 (67)	64	50 (78)	68	52 (76)
p value		0.234		0.459		0.330
2009						
No sex work	45	6 (13)	666	399 (60)	726	410 (56)
Sex work	1	1 (100)	55	40 (73)	57	41 (72)
p value		0.152		0.084		0.036
2010						
No sex work	39	4 (10)	504	293 (58)	561	303 (54)
Sex work	5	3 (60)	45	23 (51)	51	26 (51)
p value		0.023		0.432		0.770
2011						
No sex work	55	7 (13)	527	305 (58)	600	315 (53)
Sex work	0	0 (0)	32	18 (56)	34	19 (56)
p value		--		0.856		0.728
2012						
No sex work	56	5 (9)	537	290 (54)	610	301 (49)
Sex work	3	1 (33)	35	18 (51)	40	19 (48)
p value		0.279		0.767		0.821

* Total includes people who did not report duration of drug injection

Table 3.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non-Indigenous	449	314 (70)	225	163 (72)	680	480 (71)
Indigenous	67	50 (75)	48	40 (83)	116	91 (78)
p value		0.475		0.146		0.094
2009						
Non-Indigenous	419	231 (55)	245	152 (62)	669	385 (58)
Indigenous	48	27 (56)	70	37 (53)	120	64 (53)
p value		1.000		0.269		0.484
2010						
Non-Indigenous	357	191 (54)	197	113 (57)	558	305 (55)
Indigenous	52	31 (60)	42	21 (50)	96	53 (55)
p value		0.458		0.397		1.000
2011						
Non-Indigenous	390	187 (48)	174	102 (59)	565	289 (51)
Indigenous	45	21 (47)	39	24 (62)	85	45 (53)
p value		1.000		0.857		0.816
2012						
Non-Indigenous	401	189 (47)	175	95 (54)	583	287 (49)
Indigenous	45	21 (47)	40	24 (60)	87	46 (53)
p value		1.00		0.598		0.566

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	503	352 (70)	268	197 (74)	778	553 (71)
Non-English speaking	27	21 (78)	8	7 (88)	35	28 (80)
p value		0.517		0.685		0.339
2009						
English speaking	458	258 (56)	307	183 (60)	773	444 (57)
Non-English speaking	21	10 (48)	11	8 (73)	32	18 (56)
p value		0.823		0.536		1.000
2010						
English speaking	398	220 (55)	234	128 (55)	638	350 (55)
Non-English speaking	17	6 (35)	6	4 (67)	23	10 (43)
p value		0.136		0.693		0.295
2011						
English speaking	413	197 (48)	206	125 (61)	622	323 (52)
Non-English speaking	28	17 (61)	10	4 (40)	38	21 (55)
p value		0.241		0.207		0.740
2012						
English speaking	428	197 (46)	210	118 (56)	645	318 (49)
Non-English speaking	23	15 (65)	7	1 (14)	32	17 (53)
p value		0.087		0.048		0.720

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	464	324 (70)	251	187 (75)	719	514 (71)
Other Oceania	14	10 (71)	9	5 (56)	25	15 (60)
Asia	5	5 (100)	1	0 (0)	6	5 (83)
UK & Ireland	24	17 (71)	9	7 (78)	34	25 (74)
Other	25	18 (72)	7	5 (71)	32	23 (72)
p value		0.796		0.356		0.761
2009						
Australia	414	234 (57)	292	171 (59)	711	406 (57)
Other Oceania	11	8 (73)	7	5 (71)	18	13 (72)
Asia	3	1 (33)	1	1 (100)	4	2 (50)
UK & Ireland	28	16 (57)	8	6 (75)	37	23 (62)
Other	17	9 (53)	9	8 (89)	28	18 (64)
p value		0.771		0.280		0.649
2010						
Australia	355	195 (55)	216	119 (55)	575	316 (55)
Other Oceania	12	8 (67)	11	8 (73)	24	16 (67)
Asia	9	4 (44)	1	1 (100)	10	5 (50)
UK & Ireland	14	10 (71)	8	2 (25)	22	12 (55)
Other	22	7 (32)	4	3 (75)	26	10 (38)
p value		0.122		0.217		0.372
2011						
Australia	373	177 (47)	194	118 (61)	569	296 (52)
Other Oceania	8	6 (75)	11	7 (64)	19	13 (68)
Asia	10	6 (60)	2	0 (0)	12	6 (50)
UK & Ireland	20	10 (50)	6	2 (33)	27	12 (44)
Other	28	14 (50)	4	2 (50)	32	16 (50)
p value		0.571		0.296		0.609
2012						
Australia	392	183 (47)	194	105 (54)	594	292 (49)
Other Oceania	13	5 (38)	7	6 (86)	20	11 (55)
Asia	7	5 (71)	0	0 (0)	8	5 (63)
UK & Ireland	22	14 (64)	7	3 (43)	29	17 (59)
Other	12	3 (25)	9	5 (56)	21	8 (38)
p value		0.149		0.361		0.584

* Total includes people whose gender was not reported or reported as transgender

Northern Territory

Table 4.1.1 Number (percentage) of respondents by graphic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	3	3	3	3	3
N° surveyed	N=75	N=77	N=83	N=70	N=50
Response (%)	43%	29%	31%	33%	21%
Gender (%)					
Male	48 (64)	52 (68)	59 (71)	46 (66)	33 (66)
Female	27 (36)	25 (32)	24 (29)	23 (33)	16 (32)
Transgender	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	62 (83)	66 (86)	67 (81)	56 (80)	39 (78)
Bisexual	4 (5)	5 (6)	10 (12)	12 (17)	8 (16)
Homosexual	5 (7)	2 (3)	5 (6)	1 (1)	2 (4)
Not reported	4 (5)	4 (5)	1 (1)	1 (1)	1 (2)
Age and duration of injection (years)					
<i>Median age</i>	39	40	41	40	39
Age range	17-66	22-60	17-63	17-64	20-59
<i>Age group (%)</i>					
<25 years	3 (4)	4 (5)	6 (7)	4 (6)	2 (4)
25+ years	72 (96)	73 (95)	77 (93)	66 (94)	48 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	18	19	18
Age range	13-58	12-42	12-46	12-44	12-40
Not reported	2	4	0	3	3
<i>Median years IDU</i>	16	18	19	16	17
Range	<1-35	1-37	<1-43	1-46	1-41
<i>Duration of drug injection (%)</i>					
<3 years	1 (1)	4 (5)	7 (8)	7 (10)	3 (6)
3+ years	72 (96)	69 (90)	76 (92)	60 (86)	44 (88)
Not reported	2 (3)	4 (5)	0 (0)	3 (4)	3 (6)
Aboriginal and Torres Strait Islander origin (%)					
No	61 (81)	65 (84)	64 (77)	56 (80)	37 (74)
Yes	13 (17)	10 (13)	18 (22)	13 (19)	12 (24)
Not reported	1 (1)	2 (3)	1 (1)	1 (1)	1 (2)
Region/Country of birth (%)					
Australia	65 (87)	65 (84)	71 (86)	60 (86)	44 (88)
Other Oceania	2 (3)	2 (3)	3 (4)	0 (0)	1 (2)
Asia	0 (0)	2 (3)	0 (0)	2 (3)	0 (0)
UK & Ireland	3 (4)	2 (3)	6 (7)	8 (11)	2 (4)
Other	2 (3)	4 (5)	2 (2)	0 (0)	3 (6)
Not reported	3 (4)	2 (3)	1 (1)	0 (0)	0 (0)
Main language spoken at home by parents (%)					
English speaking	75 (100)	70 (91)	77 (93)	65 (93)	48 (96)
Non-English speaking	0 (0)	6 (7)	6 (7)	5 (7)	2 (4)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)					
No	69 (92)	72 (94)	65 (78)	65 (93)	45 (90)
Yes	3 (4)	2 (3)	2 (2)	3 (4)	4 (8)
Not reported	3 (4)	3 (4)	16 (19)	2 (3)	1 (2)
Injected in prison (%)	N=3	N=2	N=2	N=3	N=4
Yes	0 (0)	1 (50)	1 (50)	1 (33)	0 (0)
Frequency of injection last month (%)					
Not last month	4 (5)	7 (9)	10 (12)	10 (14)	5 (10)
Less than weekly	8 (11)	13 (17)	13 (16)	7 (10)	3 (6)
Weekly not daily	11 (15)	15 (19)	13 (16)	7 (10)	10 (20)
Daily or more	52 (69)	42 (55)	45 (54)	46 (66)	32 (64)
Not reported	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)

Table 4.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=75	N=77	N=83	N=70	N=50
Cocaine	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Heroin	2 (3)	2 (3)	3 (4)	2 (3)	2 (4)
Methadone	4 (5)	7 (9)	3 (4)	2 (3)	1 (2)
Methamphetamine	13 (17)	20 (26)	21 (25)	16 (23)	9 (18)
Performance/Image-enhancing drugs	0 (0)	1 (1)	1 (1)	1 (1)	1 (2)
Pharmaceutical opioids	47 (63)	38 (49)	50 (60)	44 (63)	35 (70)
Suboxone®	--	1 (1)	4 (5)	2 (3)	1 (2)
Subutex®/Buprenorphine	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)
More than one	2 (3)	1 (1)	0 (0)	1 (1)	1 (2)
Other drug	4 (5)	1 (1)	0 (0)	2 (3)	0 (0)
Not reported	2 (3)	4 (5)	0 (0)	0 (0)	0 (0)
N° Injected last month	N=71	N=70	N=71	N=60	N=45
Places injected last month (%)*					
Any public	14 (20)	28 (40)	26 (37)	18 (30)	16 (36)
All private	57 (80)	42 (60)	42 (59)	39 (65)	29 (64)
Not reported	0 (0)	0 (0)	3 (4)	3 (5)	0 (0)
Use of new sterile needles & syringes last month (%)					
All injections	61 (86)	59 (84)	57 (80)	49 (82)	33 (73)
Most of the time	9 (13)	9 (13)	10 (14)	9 (15)	9 (20)
Half of the time	0 (0)	1 (1)	2 (3)	0 (0)	0 (0)
Some of the time	1 (1)	1 (1)	0 (0)	0 (0)	1 (2)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
4)Not reported	0 (0)	0 (0)	2 (3)	2 (3)	2 (4)
Re-used another's used needle & syringe last month (%)					
None	65 (92)	62 (89)	62 (87)	48 (80)	39 (87)
Once	1 (1)	5 (7)	1 (1)	3 (5)	1 (2)
Twice	2 (3)	0 (0)	1 (1)	4 (7)	4 (9)
3-5 times	3 (4)	1 (1)	1 (1)	1 (2)	1 (2)
>5 times	0 (0)	1 (1)	0 (0)	1 (2)	0 (0)
Not reported	0 (0)	1 (1)	6 (8)	3 (5)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	65 (92)	62 (89)	62 (87)	48 (80)	39 (87)
One	2 (3)	2 (3)	2 (3)	6 (10)	4 (9)
Two	1 (1)	0 (0)	1 (1)	1 (2)	0 (0)
Three to five	1 (1)	0 (0)	0 (0)	1 (1)	2 (4)
More than five	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	1 (1)	2 (3)	0 (0)	2 (5)	0 (0)
Not reported	0 (0)	4 (6)	6 (8)	2 (5)	0 (0)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	3 (4)	1 (1)	1 (1)	8 (13)	5 (11)
Casual sex partner	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Close friend	2 (3)	0 (0)	2 (3)	5 (8)	1 (2)
Acquaintance	2 (3)	0 (0)	0 (0)	2 (3)	0 (0)
Other	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	18 (26)	12 (18)	19 (27)	17 (28)	10 (22)
Water	5 (7)	4 (6)	4 (6)	8 (13)	3 (7)
Filter	6 (9)	8 (12)	7 (10)	4 (7)	4 (9)
Drug mix	5 (7)	4 (6)	8 (11)	4 (7)	3 (7)
None**	38 (56)	47 (71)	45 (63)	38 (63)	32 (71)
Injected by someone after that person injected themselves or others last month (%)					
No	59 (83)	58 (83)	61 (86)	54 (90)	36 (80)
Yes	11 (15)	11 (16)	4 (6)	4 (6)	9 (20)
Not reported	1 (1)	1 (1)	6 (8)	2 (3)	0 (0)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	35 (78)
Yes	--	--	--	--	10 (22)
Not reported	--	--	--	--	0 (0)

* More than one option could be selected ** New question in 2012

Table 4.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=75	N=77	N=83	N=70	N=50
Sex with a regular partner last month (%)					
No	42 (56)	47 (61)	53 (64)	35 (50)	30 (60)
Yes	33 (44)	26 (34)	26 (31)	34 (49)	19 (38)
Not reported	0 (0)	4 (5)	4 (5)	1 (1)	1 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=33	N=26	N=26	N=34	N=19
Never	24 (73)	19 (73)	20 (77)	23 (68)	12 (63)
Sometimes	0 (0)	1 (4)	0 (0)	0 (0)	1 (5)
Every time	8 (24)	3 (12)	4 (15)	8 (24)	5 (26)
Not reported	1 (3)	3 (12)	2 (8)	3 (9)	1 (5)
Sex with other partner/s last month (%)					
No	66 (88)	65 (84)	65 (78)	64 (91)	40 (80)
Yes	7 (9)	6 (8)	12 (14)	6 (9)	10 (20)
Not reported	2 (3)	6 (8)	6 (7)	0 (0)	0 (0)
Condom used with other partner/s last month (%)					
N° surveyed	N=7	N=6	N=12	N=6	N=10
Never	2 (29)	2 (33)	5 (42)	1 (17)	5 (50)
Sometimes	3 (43)	1 (17)	2 (17)	1 (17)	2 (20)
Every time	2 (29)	3 (50)	4 (33)	3 (50)	3 (30)
Not reported	0 (0)	0 (0)	1 (8)	1 (17)	
Sex work last month (%)					
No	69 (92)	71 (92)	72 (87)	66 (94)	46 (92)
Yes	4 (5)	3 (4)	5 (6)	4 (6)	4 (8)
Not reported	2 (3)	3 (4)	6 (7)	0 (0)	0 (0)
Condom used at last sex work last month (%)					
Yes	4 (100)	3 (100)	4 (80)	4 (100)	3 (75)

Table 4.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=75	N=77	N=83	N=70	N=50
Previous HIV test (%)					
Yes, last year	36 (48)	32 (42)	38 (46)	32 (46)	29 (58)
> 1 year ago	25 (33)	33 (43)	28 (34)	32 (46)	15 (30)
Never tested	9 (12)	9 (12)	12 (14)	6 (9)	5 (10)
Not reported	5 (7)	3 (4)	5 (6)	0 (0)	1 (2)
Previous HCV test (%)					
Yes, last year	38 (51)	40 (52)	46 (55)	37 (53)	30 (60)
> 1 year ago	27 (36)	32 (42)	23 (28)	30 (43)	16 (32)
Never tested	5 (7)	3 (4)	8 (10)	2 (3)	3 (6)
Not reported	5 (7)	2 (3)	6 (7)	1 (1)	1 (2)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=36	N=32	N=46	N=33	N=24
Interferon/Interferon+Ribavirin	3 (9)	2 (6)	2 (4)	1 (3)	1 (4)
Other	2 (6)	0 (0)	1 (2)	2 (6)	0 (0)
No treatment	31 (86)	30 (94)	44 (96)	29 (88)	22 (92)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	1 (4)
Current treatment for HCV					
N°	N=2	N=0	N=2	N=1	N=0
Interferon/Interferon+Ribavirin	1	0	1	0	0
Other	1	0	1	1	0

Table 4.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=75	N=77	N=83	N=70	N=50
Any treatment/therapy for drug use (%)					
No	22 (29)	21 (27)	24 (29)	22 (31)	14 (28)
Yes	53 (71)	55 (71)	56 (67)	47 (67)	36 (72)
Not reported	0 (0)	1 (1)	3 (4)	1 (1)	0 (0)
History of methadone maintenance treatment					
Currently	12 (16)	12 (16)	7 (8)	7 (10)	6 (12)
Previously	18 (24)	14 (18)	25 (30)	22 (31)	11 (22)
Never	45 (60)	49 (64)	46 (55)	39 (56)	32 (64)
Not reported	0 (0)	2 (3)	5 (6)	2 (3)	1 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	13 (17)	3 (4)	5 (6)	3 (4)	6 (12)
Previously	20 (27)	18 (23)	17 (20)	21 (30)	18 (36)
Never	42 (56)	55 (71)	59 (71)	45 (64)	26 (52)
Not reported	0 (0)	1 (1)	2 (2)	1 (1)	0 (0)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	5 (7)	3 (9)	9 (11)	6 (9)	6 (12)
Previously	15 (20)	6 (8)	9 (11)	13 (19)	6 (12)
Never	54 (72)	67 (87)	64 (77)	51 (73)	38 (76)
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)

Table 4.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=71	N=70	N=71	N=60	N=45
Needle Syringe Program	60 (85)	46 (66)	59 (83)	58 (97)	43 (96)
Chemist/Pharmacy	16 (23)	7 (10)	9 (13)	8 (13)	9 (20)
Personal sources	--	21 (30)	14 (19)	8 (13)	12 (27)
Dispensing/Vending Machine	--	0 (0)	0 (0)	0 (0)	0 (0)
Other sources	--	0 (0)	4 (6)	0 (0)	0 (0)

* More than one option could be selected

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	46	1 (2.2)	27	0 (0.0)	73	1 (1.4)
2009	51	0 (0.0)	25	0 (0.0)	76	0 (0.0)
2010	55	0 (0.0)	23	0 (0.0)	78	0 (0.0)
2011	46	1 (2.2)	21	0 (0.0)	68	1 (1.5)
2012	30	1 (3.3)	15	0 (0.0)	46	1 (2.2)
χ^2 trend p value		0.512		--		0.502

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	46	23 (50)	26	15 (58)	72	38 (53)
2009	50	20 (40)	25	9 (36)	75	29 (39)
2010	55	29 (53)	23	8 (35)	78	37 (47)
2011	40	22 (50)	21	10 (48)	61	32 (52)
2012	30	11 (37)	15	5 (33)	46	16 (35)
χ^2 trend p value		0.835		0.264		0.375

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	40	22 (55)	19	11 (58)	59	33 (56)
Bisexual	1	0 (0)	3	2 (67)	4	2 (50)
Homosexual	2	0 (0)	3	2 (67)	5	2 (40)
p value		0.108		1.000		0.867
2009						
Heterosexual	46	19 (41)	18	7 (39)	64	26 (41)
Bisexual	2	1 (50)	3	1 (33)	5	2 (40)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.826
2010						
Heterosexual	48	28 (58)	15	7 (47)	63	35 (56)
Bisexual	5	1 (20)	4	1 (25)	9	2 (22)
Homosexual	1	0 (0)	4	0 (0)	5	0 (0)
p value		0.104		0.320		0.007
2011						
Heterosexual	35	21 (60)	14	7 (50)	49	28 (57)
Bisexual	4	1 (25)	7	3 (43)	11	4 (36)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.195		1.000		0.247
2012						
Heterosexual	26	11 (42)	10	4 (40)	37	15 (41)
Bisexual	3	0 (0)	3	1 (33)	6	1 (17)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.268		0.760		0.355

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	1	0 (0)	2	1 (50)	3	1 (33)
25 – 34	13	4 (31)	8	3 (38)	21	7 (33)
35+ years	32	19 (59)	16	11 (69)	48	30 (63)
p value		0.132		0.335		0.065
2009						
< 25 years	2	0 (0)	2	1 (50)	4	1 (25)
25 – 34	7	1 (14)	7	2 (29)	14	3 (21)
35+ years	41	19 (46)	16	6 (38)	57	25 (44)
p value		0.139		0.838		0.257
2010						
< 25 years	4	1 (25)	2	0 (0)	6	1 (17)
25 – 34	5	0 (0)	7	2 (29)	12	2 (17)
35+ years	46	28 (61)	14	6 (43)	60	34 (57)
p value		0.009		0.543		0.011
2011						
< 25 years	1	1 (100)	2	0 (0)	3	1 (33)
25 – 34	9	3 (33)	7	4 (57)	16	7 (44)
35+ years	30	18 (60)	12	6 (50)	42	24 (57)
p value		0.253		0.565		0.478
2012						
< 25 years	2	1 (50)	0	0 (0)	2	1 (50)
25 – 34	5	0 (0)	6	2 (33)	11	2 (18)
35+ years	23	10 (43.5)	9	3 (33)	33	13 (39)
p value		0.147		1.000		0.363

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	10	1 (10)	5	4 (80)	15	5 (33)
11 + years	34	22 (65)	20	11 (55)	54	33 (61)
p value		0.002		0.295		0.088
2009						
<3 years	2	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	1 (25)	5	1 (20)	9	2 (22)
11 + years	42	19 (45)	16	7 (44)	58	26 (45)
p value		0.349		0.603		0.352
2010						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3 to 10 years	7	3 (43)	3	3 (100)	10	6 (60)
11 + years	44	26 (59)	17	5 (29)	61	31 (51)
p value		0.042		0.034		0.020
2011						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 10 years	3	3 (100)	4	3 (75)	7	6 (86)
11 + years	30	16 (53)	15	6 (40)	45	22 (49)
p value		0.117		0.285		0.050
2012						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	3	1 (33)	0	0 (0)	3	1 (33)
11 + years	24	10 (42)	12	4 (33)	37	14 (38)
p value		0.773		1.000		0.788

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Pharmaceutical opioids	0	0 (0)	45	29 (64)	46	29 (63)
Methamphetamine	1	0 (0)	11	2 (18)	12	2 (17)
Other	0	0 (0)	13	7 (54)	13	7 (54)
p value		--		0.022		0.016
2009						
Pharmaceutical opioids	2	1 (50)	36	19 (53)	38	20 (53)
Methamphetamine	2	0 (0)	17	3 (18)	19	3 (16)
Other	0	0 (0)	12	4 (33)	14	4 (29)
p value		0.248		0.053		0.023
2010						
Pharmaceutical opioids	2	0 (0)	46	25 (54)	48	25 (52)
Methamphetamine	3	0 (0)	15	7 (47)	18	7 (39)
Other	2	0 (0)	10	5 (50)	12	5 (42)
p value		--		0.866		0.618
2011						
Pharmaceutical opioids	1	0 (0)	33	21 (64)	36	23 (64)
Methamphetamine	2	0 (0)	13	5 (38)	15	5 (33)
Other	3	1 (33)	6	2 (33)	10	4 (40)
p value		1.000		0.203		0.103
2012						
Pharmaceutical opioids	1	0 (0)	30	12 (40)	33	12 (36)
Methamphetamine	1	0 (0)	5	1 (20)	7	2 (30)
Other	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		0.564		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	1	0 (0)	17	7 (41)	18	7 (39)
Daily or more	0	0 (0)	49	30 (61)	51	30 (59)
Not last month	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.266		0.273
2009						
Less than daily	1	0 (0)	26	14 (54)	28	14 (50)
Daily or more	2	1 (50)	38	14 (37)	41	15 (37)
Not last month	1	0 (0)	3	0 (0)	6	0 (0)
p value		0.513		0.129		0.068
2010						
Less than daily	2	0 (0)	26	15 (58)	28	15 (54)
Daily or more	3	0 (0)	37	18 (49)	40	18 (45)
Not last month	2	0 (0)	6	2 (33)	8	2 (25)
p value		--		0.549		0.377
2011						
Less than daily	3	0 (0)	10	3 (30)	13	3 (28)
Daily or more	2	1 (50)	36	21 (58)	40	24 (60)
Not last month	1	0 (0)	6	4 (67)	8	5 (63)
p value		0.500		0.239		0.062
2012						
Less than daily	0	0 (0)	12	6 (50)	12	6 (50)
Daily or more	1	0 (0)	25	9 (36)	29	10 (34)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		--		0.299		0.170

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	0	0 (0)	61	33 (54)	63	33 (52)
Receptive sharing	1	1 (100)	5	4 (80)	6	4 (67)
p value		---		0.375		0.679
2009						
No receptive sharing	3	1 (33)	57	23 (40)	61	24 (39)
Receptive sharing	0	0 (0)	6	4 (67)	7	4 (57)
p value		--		0.388		0.435
2010						
No receptive sharing	3	0 (0)	56	30 (54)	59	30 (51)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.112		0.238
2011						
No receptive sharing	4	0 (0)	35	19 (54)	41	21 (51)
Receptive sharing	1	1 (100)	8	2 (25)	9	3 (33)
p value		0.200		0.240		0.467
2012						
No receptive sharing	1	0 (0)	32	13 (41)	35	13 (37)
Receptive sharing	0	0 (0)	5	2 (40)	6	3 (50)
p value		--		1.000		0.662

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 4.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	1	0 (0)	65	35 (54)	66	35 (53)
Imprisonment	0	0 (0)	2	2 (100)	3	2 (67)
p value		---		0.498		1.000
2009						
No imprisonment	4	1 (25)	62	24 (39)	70	25 (36)
Imprisonment	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		0.161		0.137
2010						
No imprisonment	5	0 (0)	57	30 (53)	62	30 (48)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.237		0.494
2011						
No imprisonment	5	0 (0)	49	26 (53)	57	29 (51)
Imprisonment	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.167		1.000		1.000
2012						
No imprisonment	3	0 (0)	35	13 (37)	41	14 (34)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.631		0.608

* Total includes people who did not report duration of drug injection

Table 4.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	1	0 (0)	65	35 (54)	66	35 (53)
Sex work	0	0 (0)	2	2 (100)	3	2 (67)
p value		---		0.498		1.000
2009						
No sex work	4	1 (25)	61	26 (43)	69	27 (39)
Sex work	0	0 (0)	3	0 (0)	3	0 (0)
p value		---		0.265		0.287
2010						
No sex work	5	0 (0)	63	35 (56)	68	35 (51)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.023		0.055
2011						
No sex work	5	1 (20)	49	27 (55)	57	31 (54)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
p value		1.000		0.590		0.338
2012						
No sex work	3	0 (0)	36	14 (39)	42	15 (36)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 4.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	39	21 (54)	20	12 (60)	59	33 (56)
Indigenous	7	2 (29)	6	3 (50)	13	5 (38)
p value		0.414		1.000		0.359
2009						
Non Indigenous	40	17 (43)	23	9 (39)	63	26 (41)
Indigenous	8	1 (13)	2	0 (0)	10	1 (10)
p value		0.229		0.520		0.080
2010						
Non Indigenous	43	24 (56)	18	6 (33)	61	30 (49)
Indigenous	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.517		1.000		0.595
2011						
Non Indigenous	32	18 (56)	16	7 (44)	48	25 (52)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		0.682		0.635		1.000
2012						
Non Indigenous	26	9 (35)	10	3 (30)	36	12 (33)
Indigenous	4	2 (50)	4	1 (25)	9	3 (33)
p value		0.611		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	46	23 (50)	26	15 (58)	72	38 (53)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
English speaking	44	16 (36)	24	9 (38)	68	25 (37)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		0.363		1.000		0.667
2010						
English speaking	49	27 (55)	23	8 (35)	72	35 (49)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.406		--		0.678
2011						
English speaking	36	19 (53)	20	10 (50)	56	29 (52)
Non-English speaking	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.613		1.000		1.000
2012						
English speaking	30	11 (37)	13	5 (38)	44	16 (36)
Non-English speaking	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.524		0.536

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	39	20 (51)	23	13 (57)	62	33 (53)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	3	1 (33)	1	0 (0)	4	1 (25)
p value		1.000		0.697		0.747
2009						
Australia	40	14 (35)	23	8 (35)	63	22 (35)
Other Oceania	1	1 (100)	1	1 (100)	2	2 (100)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.283		0.600		0.109
2010						
Australia	46	24 (52)	20	6 (30)	66	30 (45)
Other Oceania	2	1 (50)	1	1 (100)	3	2 (67)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	5	3 (60)	1	1 (100)	6	4 (67)
Other	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.802		0.214		0.698
2011						
Australia	35	18 (51)	18	9 (50)	53	27 (50)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	2	0 (0)	2	2 (100)
UK & Ireland	5	4 (80)	1	1 (100)	6	5 (83)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.355		0.476		0.111
2012						
Australia	25	9 (36)	14	5 (36)	40	14 (35)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	2	1 (50)	1	0 (0)	3	1 (33)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	8	8	8	8	8
N° surveyed	N=508	N=801	N=550	N=552	N=624
Response (%)	37%	59%	34%	40%	45%
Gender (%)					
Male	341 (67)	585 (73)	419 (76)	394 (71)	454 (73)
Female	165 (32)	211 (26)	126 (23)	154 (28)	168 (27)
Transgender	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
Not reported	1 (<1)	4 (<1)	4 (<1)	2 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	436 (86)	868 (86)	457 (83)	467 (85)	529 (85)
Bisexual	40 (8)	63 (8)	39 (7)	44 (8)	49 (8)
Homosexual	21 (4)	10 (1)	28 (5)	20 (4)	18 (3)
Not reported	11 (2)	42 (5)	26 (5)	21 (4)	28 (4)
Age and duration of injection (years)					
<i>Median age</i>	34	34	35	35	36
<i>Age range</i>	16-60	15-66	15-73	17-62	16-71
<i>Age group (%)</i>					
<25 years	68 (13)	117 (15)	61 (11)	59 (11)	73 (12)
25+ years	438 (86)	684 (85)	487 (86)	492 (89)	551 (88)
Not reported	2 (<1)	0 (0)	2 (<1)	1 (<1)	0 (0)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	10-57	10-58	10-59	11-56	10-70
Not reported	7	19	13	12	15
<i>Median years IDU</i>	14	14	15	15	16
<i>Range</i>	<1-40	<1-46	<1-60	<1-47	<1-53
<i>Duration of drug injection</i>					
<3 years	29 (6)	58 (7)	40 (7)	55 (10)	71 (11)
3+ years	471 (93)	724 (90)	496 (90)	486 (88)	538 (86)
Not reported	8 (2)	19 (2)	14 (3)	11 (2)	15 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	459 (90)	675 (84)	479 (87)	481 (87)	537 (86)
Yes	32 (6)	105 (13)	62 (11)	55 (10)	78 (13)
Not reported	17 (3)	21 (3)	9 (2)	16 (3)	9 (1)
Region/Country of birth (%)					
Australia	431 (85)	698 (87)	490 (89)	465 (84)	549 (88)
Other Oceania	25 (5)	40 (5)	20 (4)	29 (5)	35 (6)
Asia	5 (1)	5 (<1)	5 (1)	4 (1)	1 (<1)
UK & Ireland	22 (4)	24 (3)	17 (3)	22 (4)	22 (4)
Other	14 (3)	21 (3)	15 (3)	22 (4)	14 (2)
Not reported	11 (2)	13 (2)	3 (<1)	10 (2)	3 (<1)
Main language spoken at home by parents (%)					
English speaking	489 (96)	768 (96)	535 (97)	530 (96)	606 (97)
Non-English speaking	13 (3)	24 (3)	9 (2)	15 (3)	16 (3)
Not reported	6 (1)	9 (1)	6 (1)	7 (1)	2 (<1)
Imprisonment last year (%)					
No	418 (82)	656 (82)	410 (75)	474 (86)	543 (88)
Yes	56 (11)	111 (14)	51 (9)	49 (9)	64 (10)
Not reported	34 (7)	34 (4)	89 (16)	29 (5)	11 (2)
Injected in prison (%)	N=56	N=111	N=51	N=49	N=64
Yes	20 (36)	51 (46)	25 (49)	26 (53)	30 (47)
Frequency of injection last month (%)					
Not last month	50 (10)	74 (9)	59 (11)	51 (9)	67 (11)
Less than weekly	80 (16)	123 (15)	103 (19)	99 (18)	112 (18)
21)Weekly not daily	137 (27)	173 (22)	131 (24)	136 (25)	133 (21)
Daily or more	234 (46)	426 (53)	252 (46)	260 (47)	305 (49)
Not reported	7 (1)	5 (<1)	5 (1)	6 (1)	7 (1)

Table 5.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=508	N=801	N=550	N=552	N=624
Cocaine	2 (<1)	7 (<1)	2 (<1)	6 (1)	3 (<1)
Heroin	124 (24)	218 (27)	123 (22)	112 (20)	129 (21)
Methadone	32 (6)	38 (5)	36 (7)	22 (4)	45 (7)
Methamphetamine	171 (34)	232 (29)	149 (27)	162 (29)	165 (26)
Performance/Image-enhancing drugs	11 (2)	9 (1)	24 (4)	41 (7)	70 (11)
Pharmaceutical opioids	120 (24)	177 (22)	141 (26)	130 (24)	124 (20)
Suboxone®	--	10 (1)	13 (2)	10 (2)	17 (3)
Subutex®/Buprenorphine	26 (5)	53 (7)	32 (6)	39 (7)	41 (7)
More than one	11 (2)	30 (4)	19 (3)	24 (4)	20 (3)
Other drug	6 (1)	10 (1)	9 (2)	6 (1)	8 (1)
Not reported	5 (1)	17 (2)	2 (<1)	0 (0)	2 (<1)
N° Injected last month	N=451	N=722	N=487	N=495	N=550
Places injected last month (%)*					
Any public	164 (36)	347 (48)	174 (36)	174 (35)	193 (35)
All private	285 (63)	367 (51)	280 (57)	303 (61)	347 (63)
Not reported	2 (<1)	8 (1)	33 (7)	18 (4)	10 (2)
Use of new sterile needles & syringes last month (%)					
All injections	329 (73)	532 (74)	348 (71)	368 (74)	426 (77)
Most of the time	107 (24)	151 (21)	91 (19)	92 (19)	85 (15)
Half of the time	7 (2)	10 (1)	8 (2)	12 (2)	12 (2)
Some of the time	2 (<1)	14 (2)	5 (1)	6 (1)	2 (<1)
Not last month	2 (<1)	5 (<1)	1 (<1)	2 (<1)	4 (<1)
Not reported	4 (1)	10 (1)	34 (7)	15 (3)	21 (4)
Re-used another's used needle & syringe last month (%)					
None	388 (86)	579 (80)	377 (77)	379 (77)	463 (84)
Once	24 (5)	37 (5)	13 (3)	29 (6)	31 (6)
Twice	14 (3)	23 (5)	9 (2)	15 (3)	12 (2)
3-5 times	7 (2)	32 (4)	11 (2)	19 (4)	12 (2)
>5 times	13 (3)	31 (4)	10 (2)	18 (4)	21 (4)
Not reported	5 (1)	20 (3)	67 (14)	35 (7)	11 (2)
Number of people needle & syringe was re-used after last month (%)					
None	388 (86)	579 (80)	377 (77)	379 (77)	463 (84)
One	35 (8)	63 (9)	26 (5)	43 (9)	36 (7)
Two	0 (0)	11 (2)	1 (<1)	6 (1)	4 (<1)
Three to five	3 (1)	7 (1)	7 (1)	3 (<1)	1 (<1)
More than five	3 (1)	5 (<1)	3 (<1)	4 (1)	6 (1)
Don't know	9 (2)	16 (2)	10 (2)	9 (2)	10 (2)
Not reported	13 (3)	41 (6)	63 (13)	51 (10)	30 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	26 (6)	52 (7)	29 (6)	45 (9)	27 (5)
Casual sex partner	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
Close friend	13 (3)	43 (6)	17 (3)	28 (6)	19 (3)
Acquaintance	7 (2)	8 (1)	7 (1)	11 (2)	8 (1)
Other	3 (1)	6 (<1)	6 (1)	10 (2)	7 (1)
Equipment used after someone else last month (%)*					
Spoon	85 (21)	187 (28)	97 (20)	111 (22)	114 (21)
Water	61 (15)	132 (20)	74 (15)	77 (16)	73 (13)
Filter	48 (12)	100 (15)	56 (12)	54 (11)	58 (11)
Drug mix	32 (8)	65 (10)	41 (8)	42 (8)	51 (9)
None**	280 (68)	389 (59)	317 (65)	318 (64)	387 (70)
Injected by someone after that person injected themselves or others last month (%)					
No	381 (84)	575 (80)	382 (78)	404 (82)	466 (85)
Yes	62 (14)	133 (18)	49 (10)	69 (14)	73 (13)
Not reported	8 (2)	14 (2)	56 (12)	22 (4)	11 (2)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	427 (78)
Yes	--	--	--	--	98 (18)
Not reported	--	--	--	--	25 (5)

* More than one option could be selected ** New question in 2012

Table 5.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=508	N=801	N=487	N=552	N=624
Sex with a regular partner last month (%)					
No	228 (45)	358 (45)	241 (44)	250 (45)	280 (45)
Yes	261 (51)	414 (52)	284 (52)	280 (51)	334 (54)
Not reported	19 (4)	29 (4)	25 (5)	22 (4)	10 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=261	N=414	N=284	N=280	N=334
Never	191 (73)	293 (71)	194 (68)	199 (71)	256 (77)
Sometimes	25 (10)	58 (14)	42 (15)	34 (12)	39 (12)
Every time	27 (10)	41 (10)	33 (12)	30 (11)	31 (9)
Not reported	18 (7)	22 (5)	15 (5)	17 (6)	8 (2)
Sex with other partner/s last month (%)					
No	417 (82)	653 (82)	440 (80)	449 (81)	526 (84)
Yes	68 (13)	117 (15)	79 (14)	81 (15)	77 (12)
Not reported	23 (5)	31 (4)	31 (6)	22 (4)	21 (3)
Condom used with other partner/s last month (%)					
N° surveyed	N=68	N=117	N=79	N=81	N=77
Never	21 (31)	40 (34)	25 (32)	30 (37)	24 (31)
Sometimes	16 (24)	40 (34)	20 (25)	20 (25)	20 (26)
Every time	28 (41)	36 (31)	31 (39)	24 (30)	23 (30)
Not reported	3 (4)	1 (<1)	3 (4)	7 (9)	10 (13)
Sex work last month (%)					
No	455 (90)	740 (92)	489 (89)	509 (92)	593 (95)
Yes	14 (3)	30 (4)	14 (3)	19 (3)	17 (3)
Not reported	39 (8)	31 (4)	47 (9)	24 (4)	14 (2)
Condom used at last sex work last month (%)					
Yes	12 (86)	18 (69)	10 (83)	12 (80)	13 (76)

Table 5.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=508	N=801	N=550	N=552	N=624
Previous HIV test (%)					
Yes, last year	258 (51)	410 (51)	239 (43)	281 (51)	291 (47)
> 1 year ago	176 (35)	239 (30)	205 (37)	193 (35)	226 (36)
Never tested	49 (10)	126 (16)	73 (13)	63 (11)	87 (14)
Not reported	25 (5)	26 (3)	33 (6)	15 (3)	20 (3)
Previous HCV test (%)					
Yes, last year	289 (57)	446 (56)	281 (51)	290 (53)	328 (53)
> 1 year ago	160 (32)	249 (31)	187 (34)	182 (33)	205 (33)
Never tested	36 (7)	85 (11)	44 (8)	47 (9)	60 (10)
Not reported	23 (5)	21 (9)	38 (7)	33 (6)	31 (5)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=238	N=351	N=263	N=255	N=289
Interferon/Interferon+Ribavirin	11 (5)	18 (5)	27 (10)	20 (8)	24 (8)
Other	2 (1)	6 (2)	2 (1)	5 (2)	1 (<1)
No treatment	211 (89)	300 (85)	222 (84)	217 (85)	257 (89)
Not reported	7 (3)	20 (6)	12 (5)	13 (5)	7 (2)
Current treatment for HCV					
	N=1	N=8	N=2	N=4	N=6
Interferon/Interferon+Ribavirin	1	6	2	2	6
Other	0	2	0	2	0

Table 5.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2011	2012
N° surveyed	N=801	N=550	N=552	N=552	N=624
Any treatment/therapy for drug use (%)					
No	182 (23)	119 (22)	152 (28)	152 (28)	176 (28)
Yes	606 (76)	410 (75)	380 (69)	380 (69)	442 (71)
Not reported	13 (2)	21 (4)	20 (4)	20 (4)	6 (1)
History of methadone maintenance treatment (%)					
Currently	143 (18)	98 (18)	92 (17)	92 (17)	106 (17)
Previously	189 (24)	133 (24)	121 (22)	121 (22)	151 (24)
Never	453 (57)	292 (53)	322 (58)	322 (58)	362 (58)
Not reported	16 (2)	27 (5)	17 (3)	17 (3)	5 (1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	115 (14)	77 (14)	67 (12)	67 (12)	74 (12)
Previously	173 (22)	121 (22)	120 (22)	120 (22)	144 (23)
Never	497 (62)	345 (63)	343 (62)	343 (62)	401 (64)
Not reported	16 (2)	7 (1)	22 (4)	22 (4)	5 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	70 (9)	47 (9)	46 (8)	46 (8)	60 (10)
Previously	153 (19)	109 (20)	110 (20)	110 (20)	132 (21)
Never	560 (70)	379 (69)	376 (68)	376 (68)	427 (68)
Not reported	18 (2)	15 (3)	20 (4)	20 (4)	5 (1)

Table 5.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=451	N=722	N=487	N=495	N=550
Needle Syringe Program	411 (91)	461 (64)	430 (88)	444 (90)	500 (91)
Chemist/Pharmacy	187 (41)	234 (32)	112 (23)	118 (24)	159 (29)
Personal sources	--	133 (18)	47 (10)	38 (7)	50 (9)
Dispensing/Vending Machine	--	71 (10)	56 (12)	72 (15)	78 (14)
Other sources	--	18 (2)	4 (6)	5 (1)	6 (1)

* More than one option could be selected

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	335	9 (2.7)	161	0 (0.0)	498	9 (1.8)
2009	581	10 (1.7)	209	0 (0.0)	795	10 (1.3)
2010	407	11 (2.1)	123	0 (0.0)	535	11 (2.1)
2011	376	8 (2.1)	148	0 (0.0)	528	8 (1.5)
2012	415	7 (1.7)	153	2 (1.3)	570	9 (1.6)
χ^2 trend p value		0.579		0.037		0.998

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Heterosexual	302	0 (0.0)	127	0 (0.0)	430	0 (0.0)
Bisexual	10	2 (20)	27	0 (0.0)	37	2 (5.4)
Homosexual	17	7 (41)	4	0 (0.0)	21	7 (33)
p value		<0.001		---		<0.001
2009						
Heterosexual	519	1 (0.2)	162	0 (0.0)	682	1 (0.2)
Bisexual	24	2 (8.3)	37	0 (0.0)	62	2 (3.2)
Homosexual	9	6 (67.0)	1	0 (0.0)	10	6 (60.0)
p value		<0.001		---		<0.001
2010						
Heterosexual	345	2 (0.6)	97	0 (0.0)	445	2 (0.5)
Bisexual	21	2 (9.5)	16	0 (0.0)	37	2 (5.4)
Homosexual	21	7 (33)	6	0 (0.0)	27	27(25.9)
p value		<0.001		---		<0.001
2011						
Heterosexual	340	2 (0.6)	109	0 (0.0)	451	2 (0.4)
Bisexual	13	0 (0.0)	29	0 (0.0)	43	0 (0.0)
Homosexual	11	6 (54.6)	6	0 (0.0)	17	6 (35.3)
p value		<0.001		---		<0.001
2012						
Heterosexual	368	1 (0.3)	112	2 (1.8)	480	3 (0.6)
Bisexual	20	2 (10.0)	27	0 (0.0)	48	2 (4.2)
Homosexual	11	2 (18.2)	6	0 (0.0)	17	2 (11.8)
p value		<0.001		1.000		0.002

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
< 25 years	38	0 (0.0)	26	0 (0.0)	64	0 (0.0)
25 – 34	127	2 (1.6)	60	0 (0.0)	187	2 (1.1)
35+ years	169	7 (4.1)	74	0 (0.0)	245	7 (2.9)
p value		0.222		--		0.196
2009						
< 25 years	75	0 (0.0)	39	0 (0.0)	116	0 (0.0)
25 – 34	220	3 (1.4)	82	0 (0.0)	304	3 (1.0)
35+ years	283	7 (2.5)	85	0 (0.0)	369	7 (1.9)
p value		0.305		--		0.242
2010						
< 25 years	44	0 (0.0)	13	0 (0.0)	58	0 (0.0)
25 – 34	155	2 (1.3)	50	0 (0.0)	205	2 (1.0)
35+ years	208	10 (4.8)	59	0 (0.0)	271	10 (3.7)
p value		0.090		--		0.092
2011						
< 25 years	45	0 (0.0)	9	0 (0.0)	56	0 (0.0)
25 – 34	129	0 (0.0)	67	0 (0.0)	197	0 (0.0)
35+ years	201	8 (4.0)	72	0 (0.0)	274	8 (2.9)
p value		0.039		---		0.023
2012						
< 25 years	56	0 (0.0)	13	0 (0.0)	69	0 (0.0)
25 – 34	128	1 (0.8)	63	0 (0.0)	192	1 (0.5)
35+ years	231	2 (2.6)	77	2 (2.6)	309	8 (2.6)
p value		0.408		0.583		0.181

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
<3 years	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
3 to 10 years	95	1 (1.1)	61	0 (0.0)	156	1 (0.6)
11 + years	215	7 (3.3)	88	0 (0.0)	305	7 (2.3)
p value		0.430		--		0.366
2009						
<3 years	36	0 (0.0)	20	0 (0.0)	57	0 (0.0)
3 to 10 years	128	1 (0.8)	67	0 (0.0)	197	1 (0.5)
11 + years	404	9 (2.2)	116	0 (0.0)	522	9 (1.7)
p value		0.394		--		0.291
2010						
<3 years	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
3 to 10 years	82	3 (3.7)	28	0 (0.0)	111	3 (2.7)
11 + years	288	9 (3.1)	83	0 (0.0)	375	9 (2.4)
p value		0.782		--		0.891
2011						
<3 years	41	1 (2.4)	12	0 (0.0)	84	1 (1.9)
3 to 10 years	71	1 (1.4)	36	0 (0.0)	108	1 (0.9)
11 + years	254	6 (2.4)	99	0 (0.0)	355	6 (1.7)
p value		1.000		---		1.000
2012						
<3 years	52	0 (0.0)	11	0 (0.0)	63	0 (0.0)
3 to 10 years	77	1 (1.3)	31	0 (0.0)	108	1 (0.9)
11 + years	275	6 (2.2)	109	2 (1.8)	386	8 (2.1)
p value		0.847		1.000		0.653

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Heroin	83	1 (1.2)	41	0 (0.0)	124	1 (0.8)
Methamphetamine	107	4 (3.7)	56	0 (0.0)	163	4 (2.5)
Other	142	4 (2.8)	62	0 (0.0)	206	4 (1.9)
p value		0.562		--		0.579
2009						
Heroin	158	1 (0.6)	57	0 (0.0)	216	1 (0.5)
Methamphetamine	169	7 (4.1)	60	0 (0.0)	231	7 (3.0)
Other	242	2 (0.8)	84	0 (0.0)	328	2 (0.6)
p value		0.016		--		0.016
2010						
Heroin	93	3 (3.2)	30	0 (0.0)	123	3 (2.4)
Methamphetamine	107	7 (6.6)	33	0 (0.0)	143	7 (4.9)
Other	207	2 (1.0)	59	0 (0.0)	268	2 (0.8)
p value		0.014		--		0.019
2011						
Heroin	75	0 (0.0)	32	0 (0.0)	107	0 (0.0)
Methamphetamine	102	4 (3.9)	54	0 (0.0)	156	4 (2.6)
Other	199	4 (2.0)	62	0 (0.0)	265	4 (1.5)
p value		0.267		--		0.284
2012						
Heroin	70	0 (0.0)	48	1 (2.1)	118	1 (0.9)
Methamphetamine	103	2 (1.9)	46	0 (0.0)	149	2 (1.3)
Other	240	5 (2.1)	59	1 (1.7)	301	6 (2.0)
p value		0.666		1.000		0.905

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Less than daily	145	7 (4.8)	69	0 (0.0)	214	7 (3.3)
Daily or more	154	2 (1.3)	73	0 (0.0)	229	2 (0.9)
Not last month	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
p value		0.107		--		0.104
2009						
Less than daily	218	6 (2.8)	76	0 (0.0)	296	6 (2.0)
Daily or more	305	3 (1.0)	112	0 (0.0)	420	3 (0.7)
Not last month	56	1 (1.8)	18	0 (0.0)	74	1 (1.4)
p value		0.310		--		0.301
2010						
Less than daily	181	4 (2.2)	58	0 (0.0)	242	4 (1.7)
Daily or more	174	1 (0.6)	57	0 (0.0)	232	1 (0.4)
Not last month	49	7 (14.3)	8	0 (0.0)	58	7 (12.1)
p value		<0.001		--		<0.001
2011						
Less than daily	162	4 (2.5)	61	0 (0.0)	224	4 (1.8)
Daily or more	169	2 (1.2)	76	0 (0.0)	247	2 (0.8)
Not last month	41	2 (4.9)	10	0 (0.0)	51	2 (3.9)
p value		0.196		---		0.176
2012						
Less than daily	163	2 (1.2)	60	0 (0.0)	224	2 (0.9)
Daily or more	201	4 (2.0)	78	2 (2.6)	279	6 (2.2)
Not last month	47	1 (2.1)	14	0 (0.0)	61	1 (1.6)
p value		0.756		0.592		0.484

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No receptive sharing	255	8 (3.1)	123	0 (0.0)	380	8 (2.1)
Receptive sharing	40	1 (2.5)	18	0 (0.0)	58	1 (1.7)
p value		1.000		---		1.000
2009						
No receptive sharing	418	9 (2.2)	152	0 (0.0)	574	9 (1.6)
Receptive sharing	94	0 (0.0)	28	0 (0.0)	123	0 (0.0)
p value		0.377		---		0.373
2010						
No receptive sharing	279	4 (1.4)	88	0 (0.0)	369	4 (1.1)
Receptive sharing	28	1 (2.6)	13	0 (0.0)	41	1 (2.4)
p value		0.382		--		0.411
2011						
No receptive sharing	260	6 (2.3)	101	0 (0.0)	363	6 (1.7)
Receptive sharing	48	0 (0.0)	28	0 (0.0)	77	0 (0.0)
p value		0.595		---		0.596
2012						
No receptive sharing	307	6 (2.0)	115	2 (1.7)	422	8 (1.9)
Receptive sharing	52	0 (0.0)	19	0 (0.0)	71	0 (0.0)
p value		0.599		1.000		0.609

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No imprisonment	276	7 (2.5)	134	0 (0.0)	411	7 (1.7)
Imprisonment	36	1 (2.8)	47	0 (0.0)	53	1 (1.9)
p value		1.000		---		1.000
2009						
No imprisonment	465	10 (2.2)	182	0 (0.0)	652	10 (1.5)
Imprisonment	86	0 (0.0)	24	0 (0.0)	110	0 (0.0)
p value		0.375		---		0.372
2010						
No imprisonment	302	10 (3.3)	94	0 (0.0)	401	10 (2.5)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0.0)
p value		0.610		---		0.609
2011						
No imprisonment	325	8 (2.5)	135	0 (0.0)	463	8 (1.7)
Imprisonment	40	0 (0.0)	8	0 (0.0)	48	0 (0.0)
p value		0.606		---		1.000
2012						
No imprisonment	350	6 (1.7)	141	2 (1.4)	493	8 (1.6)
Imprisonment	52	1 (1.9)	9	0 (0.0)	61	1 (1.6)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No condom use	133	2 (1.5)	78	0 (0.0)	212	2 (0.9)
Condom use	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000
2009						
No condom use	224	3 (1.3)	118	0 (0.0)	347	3 (0.9)
Condom use	33	2 (6.1)	8	0 (0.0)	41	2 (4.9)
p value		0.125		---		0.089
2010						
No condom use	131	3 (2.3)	56	0 (0.0)	189	3 (1.6)
Condom use	56	2 (3.8)	15	0 (0.0)	71	2 (2.8)
p value		0.637		--		0.616
2011						
No condom use	121	2 (1.7)	70	0 (0.0)	192	2 (1.0)
Condom use	44	1 (2.3)	14	0 (0.0)	59	1 (1.7)
p value		1.000		---		0.554
2012						
No condom use	155	0 (0.0)	73	0 (0.0)	229	0 (0.0)
Condom use	48	3 (6.3)	18	1 (5.6)	66	4 (6.1)
p value		0.013		0.198		0.002

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
No sex work	300	9 (3.0)	144	0 (0.0)	446	9 (2.0)
Sex work	2	0 (0.0)	11	0 (0.0)	13	0 (0.0)
p value		1.000		---		1.000
2009						
No sex work	545	10 (1.8)	188	0 (0.0)	737	10 (1.4)
Sex work	13	0 (0.0)	16	0 (0.0)	30	0 (0.0)
p value		1.000		---		1.000
2010						
No sex work	370	11 (3.0)	103	0 (0.0)	477	11 (2.3)
Sex work	4	0 (0.0)	9	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2011						
No sex work	355	7 (2.0)	135	0 (0.0)	492	7 (1.4)
Sex work	4	0 (0.0)	11	0 (0.0)	16	0 (0.0)
p value		1.000		---		1.000
2012						
No sex work	399	7 (1.8)	141	1 (0.7)	542	8 (1.5)
Sex work	4	0 (0.0)	11	1 (9.1)	15	1 (6.7)
p value		1.000		0.140		0.219

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Non Indigenous	316	9 (2.9)	136	0 (0.0)	453	9 (1.9)
Indigenous	7	0 (0.0)	20	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000
2009						
Non Indigenous	495	10 (2.0)	172	0 (0.0)	672	10 (1.5)
Indigenous	67	0 (0.0)	35	0 (0.0)	102	0 (0.0)
p value		0.617		---		0.375
2010						
Non Indigenous	358	10 (2.8)	103	0 (0.0)	466	10 (2.2)
Indigenous	42	1 (2.4)	19	0 (0.0)	61	1 (1.6)
p value		1.000		--		1.000
2011						
Non Indigenous	329	8 (2.4)	128	0 (0.0)	460	8 (1.8)
Indigenous	36	0 (0.0)	18	0 (0.0)	54	0 (0.0)
p value		1.000		---		1.000
2012						
Non Indigenous	357	7 (2.0)	128	1 (0.8)	487	8 (1.6)
Indigenous	52	0 (0.0)	22	0 (0.0)	74	0 (0.0)
p value		0.603		1.000		0.605

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
English speaking	321	8 (2.5)	156	0 (0.0)	479	8 (1.7)
Non-English speaking	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
p value		0.223		---		0.216
2009						
English speaking	558	10 (1.8)	199	0 (0.0)	762	10 (1.3)
Non-English speaking	14	0 (0.0)	10	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000
2010						
English speaking	396	11 (2.8)	120	0 (0.0)	521	11 (2.1)
Non-English speaking	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
p value		1.000		---	0	1.000
2011						
English speaking	360	8 (2.2)	145	0 (0.0)	509	8 (1.6)
Non-English speaking	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		1.000		---		1.000
2012						
English speaking	405	5 (1.2)	148	2 (1.4)	554	7 (1.3)
Non-English speaking	9	2 (22.2)	4	0 (0.0)	14	2 (14.3)
p value		0.008		1.000		0.018

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008						
Australia	283	8 (2.8)	138	0 (0.0)	422	8 (1.9)
Other Oceania	8	1 (12.5)	6	0 (0.0)	14	1 (7.1)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
Other	21	0 (0.0)	6	0 (0.0)	27	0 (0.0)
p value		0.459		---		0.455
2009						
Australia	504	10 (2.0)	183	0 (0.0)	692	10 (1.5)
Other Oceania	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
p value		1.000		---		0.455
2010						
Australia	361	10 (2.8)	110	0 (0.0)	476	10 (2.1)
Other Oceania	16	0 (0.0)	4	0 (0.0)	20	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)
Other	11	1 (9.1)	5	0 (0.0)	16	1 (6.3)
p value		0.618		--		0.689
2011						
Australia	316	8 (2.5)	126	0 (0.0)	446	8 (1.8)
Other Oceania	18	0 (0.0)	11	0 (0.0)	29	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
Other	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
p value		1.000		---		1.000
2012						
Australia	369	5 (1.4)	134	2 (1.5)	505	7 (1.4)
Other Oceania	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	14	1 (7.1)	5	0 (0.0)	19	1 (5.3)
Other	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.080		1.000		0.122

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	333	182 (55)	159	91 (57)	494	275 (56)
2009	576	244 (42)	209	94 (45)	790	339 (43)
2010	403	180 (45)	121	58 (48)	529	241 (46)
2011	368	158 (43)	146	63 (43)	518	221 (43)
2012	409	183 (45)	154	83 (54)	565	267 (47)
X ² trend p value		<0.001		0.058		0.047

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	300	164 (55)	126	67 (53)	427	232 (54)
Bisexual	10	5 (50)	26	18 (69)	36	23 (64)
Homosexual	17	8 (47)	4	3 (75)	21	11 (52)
p value		0.819		0.292		0.556
2009						
Heterosexual	514	222 (43)	162	67 (41)	677	289 (43)
Bisexual	24	7 (29)	37	22 (59)	62	29 (47)
Homosexual	9	3 (33)	1	1 (100)	10	4 (40)
p value		0.375		0.054		0.808
2010						
Heterosexual	340	150 (44)	96	45 (47)	439	197 (45)
Bisexual	21	10 (48)	15	9 (60)	36	19 (53)
Homosexual	22	7 (32)	6	2 (33)	28	9 (32)
p value		0.486		0.490		0.267
2011						
Heterosexual	334	145 (43)	107	45 (42)	443	190 (43)
Bisexual	12	4 (33)	28	13 (46)	41	17 (41)
Homosexual	10	3 (30)	6	1 (17)	16	4 (25)
p value		0.620		0.440		0.403
2012						
Heterosexual	363	161 (44)	112	59 (53)	474	220 (46)
Bisexual	20	10 (50)	27	16 (59)	48	26 (54)
Homosexual	11	5 (45)	7	3 (43)	18	8 (44)
p value		0.916		0.736		0.604

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	38	10 (26)	26	13 (50)	64	23 (36)
25 – 34	125	56 (45)	58	32 (55)	183	88 (48)
35+ years	169	115 (68)	74	46 (62)	245	163 (67)
p value		<0.001		0.500		<0.001
2009						
< 25 years	75	17 (23)	39	15 (38)	116	32 (28)
25 – 34	218	75 (34)	85	39 (46)	305	114 (37)
35+ years	283	152 (54)	85	40 (47)	369	193 (52)
p value		<0.001		0.655		<0.001
2010						
< 25 years	43	7 (16)	13	3 (23)	57	10 (18)
25 – 34	154	55 (36)	50	25 (50)	204	80 (39)
35+ years	205	118 (58)	57	30 (53)	266	151 (57)
p value		<0.001		0.166		<0.001
2011						
< 25 years	45	3 (7)	9	3 (33)	56	6 (11)
25 – 34	128	44 (34)	65	24 (37)	194	68 (35)
35+ years	194	110 (57)	72	36 (50)	267	146 (55)
p value		<0.001		0.248		<0.001
2012						
< 25 years	55	6 (11)	13	4 (31)	68	10 (15)
25 – 34	129	49 (38)	64	38 (59)	194	88 (45)
35+ years	225	128 (57)	77	41 (53)	303	169 (56)
p value		<0.001		0.166		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	19	2 (11)	10	4 (40)	29	6 (21)
3 to 10 years	94	28 (30)	61	29 (48)	155	57 (37)
11 + years	214	149 (70)	86	58 (67)	302	209 (69)
p value		<0.001		0.027		<0.001
2009						
<3 years	36	3 (8)	20	3 (15)	57	6 (11)
3 to 10 years	127	41 (32)	67	27 (40)	196	68 (35)
11 + years	400	196 (49)	116	63 (54)	518	260 (50)
p value		<0.001		0.003		<0.001
2010						
<3 years	29	2 (7)	7	0 (0)	36	2 (6)
3 to 10 years	80	25 (31)	28	9 (32)	109	34 (31)
11 + years	285	149 (52)	81	47 (58)	370	199 (54)
p value		<0.001		0.001		<0.001
2011						
<3 years	41	3 (7)	11	2 (18)	53	5 (9)
3 to 10 years	70	18 (26)	36	11 (31)	107	29 (27)
11 + years	247	136 (55)	98	50 (51)	347	186 (54)
p value		<0.001		0.023		<0.001
2012						
<3 years	52	4 (8)	11	3 (27)	63	7 (11)
3 to 10 years	76	17 (22)	31	6 (19)	107	23 (22)
11 + years	271	157 (58)	110	72 (65)	383	230 (60)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	2	1 (50)	120	82 (68)	123	84 (68)
Methamphetamine	15	2 (13)	146	62 (42)	162	65 (40)
Other	11	3 (27)	187	118 (63)	204	122 (60)
p value		0.432		<0.001		<0.001
2009						
Heroin	12	3 (25)	202	114 (56)	216	117 (54)
Methamphetamine	22	0 (0)	206	65 (32)	231	65 (28)
Other	11	3 (14)	296	143 (48)	327	151 (46)
p value		0.067		<0.001		<0.001
2010						
Heroin	5	0 (0)	113	66 (58)	122	70 (57)
Methamphetamine	11	1 (9)	128	46 (36)	142	47 (33)
Other	20	1 (5)	237	121 (51)	263	124 (47)
p value		1.000		0.001		<0.001
2011						
Heroin	7	2 (29)	98	53 (54)	106	55 (52)
Methamphetamine	11	1 (9)	139	50 (36)	152	52 (34)
Other	35	2 (6)	217	112 (52)	260	114 (44)
p value		0.178		0.005		0.015
2012						
Heroin	3	1 (33)	113	72 (64)	118	75 (64)
Methamphetamine	10	3 (30)	134	51 (38)	146	56 (38)
Other	49	3 (6)	242	130 (54)	299	136 (45)
p value		0.055		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	14	4 (29)	199	106 (53)	214	110 (51)
Daily or more	9	2 (22)	213	140 (66)	225	143 (64)
Not last month	6	0 (0)	39	16 (41)	48	18 (38)
p value		0.349		0.003		0.001
2009						
Less than daily	22	1 (5)	268	105 (39)	294	107 (36)
Daily or more	26	5 (19)	383	186 (49)	417	194 (47)
Not last month	9	0 (0)	59	34 (58)	74	35 (47)
p value		0.136		0.010		0.019
2010						
Less than daily	19	0 (0)	216	89 (41)	237	90 (38)
Daily or more	10	2 (20)	212	116 (55)	230	122 (53)
Not last month	5	0 (0)	50	28 (56)	58	28 (48)
p value		0.098		0.011		0.004
2011						
Less than daily	29	2 (7)	187	80 (43)	220	82 (37)
Daily or more	16	3 (19)	221	118 (53)	241	122 (51)
Not last month	7	0 (0)	41	16 (39)	51	16 (31)
p value		0.396		0.055		0.003
2012						
Less than daily	25	3 (12)	193	94 (49)	219	97 (44)
Daily or more	16	2 (13)	256	138 (54)	279	146 (52)
Not last month	21	2 (10)	37	19 (51)	61	22 (36)
p value		1.000		0.551		0.035

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	17	3 (18)	356	209 (59)	376	213 (57)
Receptive sharing	6	3 (50)	52	34 (65)	58	37 (64)
p value		0.279		0.450		0.322
2009						
No receptive sharing	33	1 (3)	529	225 (43)	569	228 (40)
Receptive sharing	13	5 (38)	106	57 (54)	123	63 (51)
p value		0.005		0.042		0.027
2010						
No receptive sharing	25	2 (8)	331	149 (45)	365	156 (43)
Receptive sharing	1	0 (0)	38	24 (63)	40	24 (60)
p value		1.000		0.040		0.044
2011						
No receptive sharing	38	4 (11)	311	141 (45)	356	146 (41)
Receptive sharing	5	0 (0)	68	39 (57)	74	39 (53)
p value		1.000		0.082		0.071
2012						
No receptive sharing	37	5 (14)	376	184 (49)	417	192 (46)
Receptive sharing	3	0 (0)	64	45 (70)	71	48 (68)
p value		0.002		0.002		0.001

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 5.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	26	4 (15)	375	207 (55)	407	213 (52)
Imprisonment	2	2 (100)	50	40 (80)	53	43 (81)
p value		0.040		0.001		<0.001
2009						
No imprisonment	48	2 (4)	587	250 (43)	648	254 (39)
Imprisonment	7	4 (57)	99	58 (59)	110	64 (58)
p value		0.001		0.004		<0.001
2010						
No imprisonment	35	2 (0)	351	154 (44)	397	160 (40)
Imprisonment	0	0 (0)	47	29 (62)	48	29 (60)
p value		--		0.028		0.009
2011						
No imprisonment	51	5 (10)	385	170 (44)	446	176 (39)
Imprisonment	0	0 (0)	46	31 (67)	47	31 (66)
p value		--		0.004		0.001
2012						
No imprisonment	58	7 (12)	423	207 (49)	489	219 (45)
Imprisonment	3	0 (0)	37	37 (69)	60	39 (65)
p value		1.000		0.009		0.003

* Total includes people who did not report duration of drug injection

Table 5.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	27	5 (19)	408	238 (58)	442	246 (56)
Sex work	1	1 (100)	12	6 (50)	13	7 (54)
p value		0.214		0.568		1.000
2009						
No sex work	55	5 (9)	663	294 (44)	732	302 (41)
Sex work	1	1 (100)	26	19 (73)	30	21 (70)
p value		0.107		0.005		0.002
2010						
No sex work	36	2 (6)	426	200 (47)	472	206 (44)
Sex work	0	0 (0)	12	7 (58)	13	7 (54)
p value		--		0.561		0.574
2011						
No sex work	50	5 (10)	422	199 (47)	482	205 (43)
Sex work	1	0 (0)	14	7 (50)	16	7 (44)
p value		1.000		1.000		1.000
2012						
No sex work	61	7 (11)	464	234 (50)	535	248 (46)
Sex work	1	0 (0)	13	9 (69)	16	9 (56)
p value		1.000		0.261		0.457

* Total includes people who did not report duration of drug injection

Table 5.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	314	168 (54)	135	72 (53)	450	241 (54)
Indigenous	7	3 (43)	20	16 (80)	28	20 (71)
p value		0.709		0.030		0.079
2008						
Non Indigenous	490	203 (41)	172	78 (45)	667	282 (42)
Indigenous	67	33 (49)	35	16 (46)	102	49 (48)
p value		0.237		1.000		0.284
2010						
Non Indigenous	354	159 (45)	101	52 (51)	460	214 (47)
Indigenous	42	17 (40)	19	6 (32)	61	23 (38)
p value		0.625		0.137		0.219
2011						
Non Indigenous	323	133 (41)	126	51 (40)	452	184 (41)
Indigenous	34	19 (56)	19	11 (58)	53	30 (57)
p value		0.105		0.213		0.028
2012						
Non Indigenous	352	152 (43)	129	67 (52)	483	220 (46)
Indigenous	51	28 (55)	22	14 (64)	73	42 (58)
p value		0.132		0.360		0.060

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	319	174 (55)	155	89 (57)	476	265 (56)
Non-English speaking	9	5 (56)	4	2 (50)	13	7 (54)
p value		1.000		1.000		1.000
2009						
English speaking	553	231 (42)	199	90 (45)	757	322 (43)
Non-English speaking	14	9 (64)	10	4 (40)	24	13 (54)
p value		0.106		1.000		0.297
2010						
English speaking	392	173 (44)	118	57 (48)	515	233 (45)
Non-English speaking	7	3 (43)	2	0 (0)	9	3 (33)
p value		1.000		0.497		0.523
2011						
English speaking	352	147 (42)	144	62 (43)	500	209 (42)
Non-English speaking	11	7 (64)	2	1 (50)	13	8 (62)
p value		0.215		1.000		0.167
2012						
English speaking	400	178 (45)	149	79 (53)	550	258 (47)
Non-English speaking	8	5 (63)	4	3 (75)	13	8 (62)
p value		0.476		0.624		0.401

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	281	154 (55)	137	75 (55)	419	230 (55)
Other Oceania	8	1 (13)	6	5 (83)	14	6 (43)
Asia	4	4 (100)	1	0 (0)	5	4 (80)
UK & Ireland	12	6 (50)	7	3 (43)	19	9 (47)
Other	21	12 (57)	6	6 (100)	27	18 (67)
p value		0.054		0.053		0.425
2009						
Australia	499	215 (43)	183	85 (46)	687	301 (44)
Other Oceania	28	6 (21)	12	5 (42)	40	11 (28)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	19	10 (53)	5	2 (40)	24	12 (50)
Other	14	4 (29)	7	1 (14)	21	5 (24)
p value		0.057		0.459		0.071
2010						
Australia	358	157 (44)	108	49 (45)	471	209 (44)
Other Oceania	16	6 (38)	4	3 (75)	20	9 (45)
Asia	3	1 (33)	1	0 (0)	4	1 (25)
UK & Ireland	15	8 (53)	2	1 (50)	17	9 (53)
Other	10	7 (70)	5	4 (80)	15	11 (73)
p value		0.458		0.350		0.200
2011						
Australia	308	131 (43)	125	55 (44)	437	186 (43)
Other Oceania	18	5 (28)	10	4 (40)	28	9 (32)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	15	8 (53)	6	2 (33)	21	10 (48)
Other	18	9 (50)	2	1 (50)	20	10 (50)
p value		0.428		0.877		0.335
2012						
Australia	362	167 (46)	135	73 (54)	499	241 (48)
Other Oceania	19	5 (26)	12	7 (58)	31	12 (39)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	14	4 (29)	5	2 (40)	19	6 (32)
Other	10	5 (50)	2	1 (50)	12	6 (50)
p value		0.235		0.923		0.406

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	7	7	7	7	7
N° surveyed	N=196	N=248	N=216	N=213	N=203
Response (%)	45%	53%	41%	51%	42%
Gender (%)					
Male	101 (52)	156 (63)	129 (60)	133 (62)	127 (63)
Female	93 (47)	92 (37)	86 (40)	78 (37)	75 (37)
Transgender	1 (1)	0 (0)	1 (<1)	2 (1)	1 (<1)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	146 (74)	204 (82)	185 (86)	178 (84)	155 (76)
Bisexual	29 (15)	23 (9)	11 (5)	22 (10)	18 (9)
Homosexual	13 (7)	13 (5)	12 (6)	6 (3)	12 (6)
Not reported	8 (4)	8 (3)	8 (4)	7 (3)	18 (9)
Age and duration of injection (years)					
<i>Median age</i>	36	38	38	39	40
Age range	17-56	16-61	18-62	17-61	18-60
<i>Age group (%)</i>					
<25 years	19 (10)	25 (10)	18 (8)	13 (6)	14 (7)
25+ years	177 (90)	222 (90)	198 (92)	200 (94)	189 (93)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	18	19	18
Age range	11-45	12-46	12-44	11-45	10-55
Not reported	4	5	2	4	3
<i>Median years IDU</i>	15	17	17	20	20
Range	1-41	<1-44	<1-45	<1-37	<1-43
<i>Duration of drug injection (%)</i>					
<3 years	13 (7)	15 (6)	5 (2)	12 (6)	8 (4)
3+ years	179 (91)	228 (92)	209 (97)	197 (92)	192 (95)
Not reported	4 (2)	5 (2)	2 (1)	4 (2)	3 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	158 (81)	206 (83)	185 (86)	183 (86)	183 (90)
Yes	28 (14)	31 (13)	23 (11)	29 (14)	17 (8)
Not reported	10 (5)	11 (4)	8 (4)	1 (<1)	3 (1)
Region/Country of birth (%)					
Australia	160 (82)	219 (88)	191 (88)	185 (87)	178 (88)
Other Oceania	4 (2)	5 (2)	3 (1)	4 (2)	1 (<1)
Asia	5 (3)	1 (<1)	4 (2)	4 (2)	1 (<1)
UK & Ireland	17 (9)	17 (7)	11 (5)	9 (4)	10 (5)
Other	7 (4)	5 (2)	4 (2)	9 (4)	12 (6)
Not reported	3 (2)	1 (<1)	3 (1)	2 (1)	1 (<1)
Main language spoken at home by parents (%)					
English speaking	179 (91)	224 (90)	198 (92)	193 (91)	182 (90)
Non-English speaking	12 (6)	19 (8)	16 (7)	18 (8)	21 (10)
Not reported	5 (3)	5 (2)	2 (1)	2 (1)	0 (0)
Imprisonment last year (%)					
No	158 (81)	199 (80)	168 (78)	175 (82)	184 (92)
Yes	21 (11)	37 (15)	16 (7)	19 (9)	15 (8)
Not reported	17 (9)	12 (5)	32 (15)	19 (9)	1 (<1)
Injected in prison (%)	N=21	N=37	N=16	N=19	N=15
Yes	7 (33)	5 (14)	1 (6)	4 (21)	2 (13)
Frequency of injection last month (%)					
Not last month	20 (10)	22 (9)	13 (6)	12 (6)	10 (5)
Less than weekly	30 (15)	38 (15)	42 (19)	41 (19)	41 (20)
Weekly not daily	51 (26)	59 (24)	61 (28)	49 (23)	57 (28)
Daily or more	93 (47)	127 (51)	99 (46)	108 (51)	95 (47)
Not reported	2 (1)	2 (1)	1 (<1)	3 (1)	0 (0)

Table 6.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=196	N=248	N=216	N=213	N=203
Cocaine	4 (2)	3 (1)	2 (1)	2 (1)	0 (0)
Heroin	49 (25)	84 (34)	86 (40)	77 (36)	74 (36)
Methadone	10 (5)	8 (3)	7 (3)	13 (6)	9 (4)
Methamphetamine	100 (51)	91 (37)	87 (40)	75 (35)	72 (35)
Performance/Image-enhancing drugs	1 (1)	0 (0)	0 (0)	1 (<1)	4 (2)
Pharmaceutical opioids	20 (10)	34 (14)	26 (12)	28 (13)	26 (13)
Suboxone®	--	3 (1)	3 (1)	2 (1)	1 (<1)
Subutex®/Buprenorphine	7 (4)	14 (6)	2 (1)	3 (1)	4 (2)
More than one	2 (1)	5 (2)	3 (1)	8 (4)	11 (5)
Other drug	0 (0)	3 (1)	3 (1)	4 (2)	1 (<1)
Not reported	3 (2)	6 (2)	0 (0)	0 (0)	1 (<1)
N° Injected last month	N=174	N=224	N=202	N=198	N=193
Places injected last month (%)*					
Any public	83 (48)	82 (37)	94 (47)	91 (46)	91 (47)
All private	89 (51)	141 (63)	97 (48)	98 (50)	91 (47)
Not reported	2 (1)	1 (<1)	11 (5)	9 (5)	11 (6)
Use of new sterile needles & syringes last month (%)					
All injections	126 (72)	184 (82)	151 (75)	146 (74)	149 (77)
Most of the time	34 (20)	31 (14)	32 (16)	36 (18)	28 (15)
Half of the time	6 (3)	4 (2)	4 (2)	3 (2)	0 (0)
Some of the time	5 (3)	3 (1)	4 (2)	1 (<1)	1 (<1)
Not last month	1 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)
Not reported	2 (1)	2 (1)	11 (5)	11 (6)	14 (7)
Re-used another's used needle & syringe last month (%)					
None	138 (79)	197 (88)	154 (76)	163 (82)	162 (84)
Once	7 (4)	7 (3)	8 (4)	5 (3)	12 (6)
Twice	10 (6)	7 (3)	4 (2)	6 (3)	5 (3)
3-5 times	11 (6)	3 (1)	7 (3)	6 (3)	0 (0)
>5 times	2 (1)	4 (2)	5 (2)	5 (3)	1 (<1)
Not reported	6 (3)	6 (3)	24 (12)	13 (7)	13 (7)
Number of people needle & syringe was re-used after last month (%)					
None	138 (79)	197 (88)	154 (76)	163 (82)	162 (84)
One	17 (10)	11 (5)	7 (3)	14 (7)	7 (4)
Two	3 (2)	3 (1)	3 (1)	2 (1)	1 (<1)
Three to five	0 (0)	0 (0)	3 (1)	1 (<1)	1 (<1)
More than five	0 (0)	0 (0)	3 (1)	0 (0)	0 (0)
Don't know	8 (5)	4 (2)	4 (2)	4 (2)	2 (1)
Not reported	8 (5)	9 (4)	28 (14)	14 (7)	20 (10)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	10 (6)	9 (4)	19 (9)	18 (9)	7 (4)
Casual sex partner	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)
Close friend	7 (4)	3 (1)	13 (6)	7 (4)	3 (2)
Acquaintance	3 (2)	2 (1)	2 (1)	3 (2)	2 (1)
Other	4 (2)	0 (0)	6 (3)	4 (2)	1 (<1)
Equipment used after someone else last month (%)*					
Spoon	25 (16)	36 (18)	46 (23)	33 (17)	21 (11)
Water	36 (23)	28 (14)	42 (21)	27 (14)	22 (11)
Filter	16 (10)	19 (9)	24 (12)	19 (10)	13 (7)
Drug mix	9 (6)	20 (10)	16 (8)	17 (9)	15 (8)
None**	100 (63)	141 (69)	121 (60)	131 (66)	134 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	143 (82)	183 (82)	148 (73)	156 (79)	164 (85)
Yes	24 (14)	34 (15)	31 (15)	32 (16)	15 (8)
Not reported	7 (4)	7 (3)	23 (11)	10 (5)	14 (7)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	151 (78)
Yes	--	--	--	--	27 (14)
Not reported	--	--	--	--	15 (8)

* More than one option could be selected ** New question in 2012

Table 6.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=196	N=248	N=216	N=213	N=203
Sex with a regular partner last month (%)					
No	81 (41)	112 (45)	100 (46)	96 (45)	91 (45)
Yes	107 (55)	124 (50)	106 (49)	102 (48)	108 (53)
Not reported	8 (4)	12 (5)	10 (5)	15 (7)	4 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=107	N=124	N=106	N=102	N=108
Never	78 (73)	80 (64)	71 (67)	69 (68)	73 (68)
Sometimes	17 (16)	23 (19)	13 (12)	10 (10)	11 (10)
Every time	8 (7)	12 (10)	10 (9)	15 (15)	13 (12)
Not reported	4 (4)	9 (7)	12 (11)	8 (8)	11 (10)
Sex with other partner/s last month (%)					
No	153 (78)	205 (83)	170 (79)	179 (84)	176 (87)
Yes	31 (16)	31 (13)	33 (15)	22 (10)	22 (11)
Not reported	12 (6)	12 (5)	13 (6)	12 (6)	5 (2)
Condom used with other partner/s last month (%)					
N° surveyed	N=31	N=31	N=33	N=22	N=22
Never	5 (16)	9 (29)	7 (21)	6 (27)	9 (41)
Sometimes	12 (39)	9 (29)	7 (21)	6 (27)	4 (18)
Every time	14 (45)	13 (42)	16 (48)	10 (45)	8 (36)
Not reported	0 (0)	0 (0)	3 (9)	0 (0)	1 (5)
Sex work last month (%)					
No	170 (87)	229 (92)	184 (85)	194 (91)	192 (95)
Yes	13 (7)	10 (4)	20 (9)	9 (4)	6 (3)
Not reported	13 (7)	9 (4)	12 (6)	9 (4)	5 (2)
Condom used at last sex work last month (%)					
Yes	11 (85)	9 (90)	13 (68)	8 (89)	6 (100)

Table.6.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	201&
N° surveyed	N=196	N=248	N=216	N=213	N=203
Previous HIV test (%)					
Yes, last year	94 (48)	130 (52)	88 (41)	93 (44)	101 (50)
> 1 year ago	62 (32)	81 (33)	92 (43)	81 (38)	74 (36)
Never tested	30 (15)	28 (11)	25 (12)	29 (14)	21 (10)
Not reported	10 (5)	9 (4)	11 (5)	10 (5)	7 (3)
Previous HCV test (%)					
Yes, last year	104 (53)	139 (56)	99 (46)	105 (49)	112 (55)
> 1 year ago	57 (29)	67 (27)	73 (34)	77 (36)	70 (34)
Never tested	29 (15)	28 (11)	23 (11)	15 (7)	13 (6)
Not reported	6 (3)	14 (6)	21 (10)	16 (8)	8 (4)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=59	N=102	N=92	N=101	N=95
Interferon/Interferon+Ribavirin	7 (12)	14 (14)	6 (7)	12 (12)	10 (11)
Other	0 (0)	1 (1)	0 (0)	1 (1)	2 (2)
No treatment	50 (85)	81 (79)	83 (90)	80 (79)	78 (82)
Not reported	2 (3)	6 (6)	3 (3)	8 (8)	5 (5)
Current treatment for HCV	N=1	N=3	N=2	N=2	N=1
Interferon/Interferon+Ribavirin	1	2	2	2	1
Other	0	1	0	0	

Table 6.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=196	N=248	N=216	N=213	N=203
Any treatment/therapy for drug use (%)					
No	66 (34)	67 (27)	46 (21)	49 (23)	60 (30)
Yes	123 (63)	176 (71)	163 (75)	163 (77)	142 (70)
Not reported	7 (4)	5 (2)	7 (3)	1 (<1)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	39 (20)	61 (25)	57 (26)	48 (22)	58 (29)
Previously	40 (20)	46 (19)	53 (25)	61 (29)	44 (22)
Never	112 (57)	135 (54)	92 (42)	96 (45)	100 (49)
Not reported	5 (3)	6 (2)	14 (6)	8 (4)	1 (<1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	26 (13)	40 (16)	23 (11)	13 (6)	18 (9)
Previously	33 (17)	58 (23)	60 (28)	55 (26)	46 (23)
Never	130 (66)	148 (60)	131 (61)	138 (65)	139 (68)
Not reported	7 (4)	2 (1)	2 (1)	7 (3)	0 (0)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	7 (4)	12 (5)	7 (4)	21 (10)	26 (13)
Previously	21 (11)	36 (15)	21 (11)	37 (17)	29 (14)
Never	160 (82)	194 (78)	160 (82)	149 (70)	144 (71)
Not reported	8 (4)	6 (2)	8 (4)	6 (3)	4 (2)

Table 6.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=174	N=224	N=202	N=198	N=193
Needle Syringe Program	144 (83)	150 (67)	183 (91)	176 (89)	159 (82)
Chemist/Pharmacy	66 (38)	36 (16)	26 (13)	30 (15)	41 (21)
Personal sources	--	39 (17)	24 (12)	19 (10)	23 (12)
Dispensing/Vending Machine	--	0 (0)	0 (0)	17 (9)	27 (14)
Other sources	--	9 (4)	5 (2)	3 (2)	2 (1)

* More than one option could be selected

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	96	0 (0.0)	92	0 (0.0)	189	0 (0.0)
2009	155	2 (1.3)	91	1 (1.1)	246	3 (1.2)
2010	129	0 (0.0)	84	1 (1.2)	214	1 (0.5)
2011	129	2 (1.6)	76	3 (4.0)	207	5 (2.4)
2012	123	2 (1.6)	73	4 (5.5)	197	6 (3.1)
X ² trend p value		0.258		0.008		0.007

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heterosexual	118	2 (1.7)	56	2 (3.6)	174	4 (2.3)
Bisexual	6	0 (0.0)	14	1 (7.1)	21	1 (4.8)
Homosexual	1	0 (0.0)	4	0 (0.0)	6	0 (0.0)
p value		1.000		0.572		0.518
2012						
Heterosexual	99	0 (0.0)	54	4 (7.4)	153	4 (2.6)
Bisexual	6	0 (0.0)	10	0 (0.0)	16	0 (0.0)
Homosexual	8	2 (25.0)	2	0 (0.0)	11	2 (18.2)
p value		0.007		1.000		0.072

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
< 25 years	5	0 (0.0)	8	2 (25.0)	13	2 (15.4)
25 – 34	25	0 (0.0)	13	0 (0.0)	39	0 (0.0)
35+ years	99	2 (2.0)	55	1 (1.8)	155	3 (1.9)
p value		1.000		0.041		0.044
2012						
< 25 years	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
25 – 34	22	0 (0.0)	18	2 (11.1)	40	2 (5.0)
35+ years	92	2 (2.2)	50	2 (4.0)	143	4 (2.8)
p value		1.000		0.464		0.753

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	14	0 (0.0)	12	2 (16.7)	26	2 (7.7)
11 + years	107	2 (1.9)	56	1 (1.8)	165	3 (1.8)
p value		1.000		0.087		0.235
2012						
<3 years	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
3 to 10 years	14	1 (7.1)	17	2 (11.8)	32	3 (9.4)
11 + years	100	1 (1.0)	54	2 (3.7)	154	3 (2.0)
p value		0.307		0.322		0.113

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heroin	51	0 (0.0)	24	1 (4.2)	75	1 (1.3)
Methamphetamine	43	0 (0.0)	28	1 (3.6)	72	1 (1.4)
Other	35	2 (5.7)	24	1 (4.2)	60	3 (5.0)
p value		0.072		1.000		0.444
2012						
Heroin	42	1 (2.4)	29	2 (6.9)	72	3 (4.2)
Methamphetamine	42	1 (2.4)	27	2 (7.4)	69	3 (4.4)
Other	38	0 (0.0)	17	0 (0.0)	55	0 (0.0)
p value		1.000		0.670		0.286

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Less than daily	61	0 (0.0)	28	2 (7.1)	89	2 (2.3)
Daily or more	60	2 (3.3)	42	1 (2.4)	104	3 (2.9)
Not last month	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		0.325		0.643		1.000
2012						
Less than daily	60	2 (3.3)	35	4 (11.4)	95	6 (6.3)
Daily or more	60	0 (0.0)	31	0 (0.0)	92	0 (0.0)
Not last month	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		0.520		0.192		0.067

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No receptive sharing	103	2 (1.9)	56	3 (5.4)	160	5 (3.1)
Receptive sharing	11	0 (0.0)	9	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000
2012						
No receptive sharing	99	1 (1.0)	56	4 (7.1)	156	5 (3.2)
Receptive sharing	14	0 (0.0)	4	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No imprisonment	106	2 (1.9)	69	3 (4.4)	177	5 (2.8)
Imprisonment	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2012						
No imprisonment	110	2 (1.8)	68	4 (5.9)	179	6 (3.4)
Imprisonment	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No condom use	40	0 (0.0)	27	1 (3.7)	67	1 (1.5)
Condom use	16	0 (0.0)	8	0 (0.0)	24	0 (0.0)
p value		---		1.000		1.000
2012						
No condom use	42	0 (0.0)	28	2 (7.1)	70	2 (2.9)
Condom use	12	1 (8.3)	11	1 (9.1)	23	2 (8.7)
p value		0.222		1.000		0.255

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No sex work	124	2 (1.6)	65	3 (4.6)	191	5 (2.6)
Sex work	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		1.000		1.000
2012						
No sex work	118	2 (1.7)	68	4 (5.9)	187	6 (3.2)
Sex work	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	112	2 (1.8)	63	2 (3.2)	177	4 (2.3)
Indigenous	17	0 (0.0)	12	1 (8.3)	29	1 (3.5)
p value		1.000		0.412		0.535
2012						
Non Indigenous	113	2 (1.8)	64	4 (6.3)	178	6 (3.4)
Indigenous	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	117	2 (1.7)	69	3 (4.4)	188	5 (2.7)
Non-English speaking	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)
p value		1.000		1.000		1.000
2012						
English speaking	103	2 (1.9)	72	4 (5.6)	176	6 (3.4)
Non-English speaking	20	0 (0.0)	1	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Australia	112	2 (1.8)	66	3 (4.6)	180	5 (2.8)
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
Other	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		1.000		1.000		1.000
2012						
Australia	103	2 (1.9)	69	4 (5.8)	173	6 (3.5)
Other Oceania	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
UK & Ireland	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
Other	12	0 (0.0)	0	0 (0.0)	12	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	95	30 (32)	90	24 (27)	186	54 (29)
2009	155	65 (42)	91	36 (40)	246	101 (41)
2010	127	54 (43)	84	38 (45)	212	93 (44)
2011	128	67 (52)	75	31 (41)	205	98 (48)
2012	122	51 (42)	71	28 (39)	194	79 (41)
X ² trend p value		0.053		0.086		0.009

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	84	29(35)	55	17 (31)	139	46 (33)
Bisexual	5	1 (20)	23	4 (17)	28	5 (18)
Homosexual	3	0 (0)	10	3 (30)	13	3 (23)
p value		0.592		0.462		0.238
2009						
Heterosexual	134	59 (44)	68	27 (40)	202	86 (43)
Bisexual	11	3 (27)	12	6 (50)	23	9 (36)
Homosexual	4	0 (0)	9	3 (33)	13	3 (23)
p value		0.138		0.756		0.410
2010						
Heterosexual	113	51 (45)	69	31 (45)	182	82 (45)
Bisexual	1	1 (100)	8	4 (50)	10	6 (60)
Homosexual	7	0 (0)	5	1 (20)	12	1 (8)
p value		0.10		0.661		0.019
2011						
Heterosexual	117	60 (51)	55	23 (42)	172	83 (48)
Bisexual	6	4 (67)	14	5 (36)	21	9 (43)
Homosexual	1	0 (0)	4	1 (25)	6	1 (17)
p value		0.553		0.756		0.325
2012						
Heterosexual	98	44 (45)	52	19 (37)	150	63 (42)
Bisexual	7	3 (43)	10	5 (50)	17	8 (47)
Homosexual	7	2 (29)	2	1 (50)	10	3 (30)
p value		0.767		0.653		0.692

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	6	0 (0)	11	2 (18)	17	2 (12)
25 – 34	23	5 (22)	37	7 (19)	60	12 (20)
35+ years	66	25 (38)	42	15 (36)	109	40 (37)
p value		0.082		0.192		0.019
2009						
< 25 years	14	1 (7)	10	4 (40)	24	5 (21)
25 – 34	37	13 (35)	30	11 (37)	67	24 (36)
35+ years	104	51 (49)	50	21 (42)	154	72 (47)
p value		0.007		0.895		0.032
2010						
< 25 years	8	0 (0)	10	2 (20)	18	2 (11)
25 – 34	30	8 (27)	23	11 (48)	53	19 (36)
35+ years	89	46 (52)	51	25 (49)	141	72 (51)
p value		0.001		0.266		0.002
2011						
< 25 years	5	0 (0)	8	1 (13)	13	1 (8)
25 – 34	25	9 (36)	13	3 (23)	39	12 (31)
35+ years	98	58 (59)	54	27 (50)	153	85 (56)
p value		0.005		0.045		<0.001
2012						
< 25 years	9	0 (0)	5	1 (20)	14	1 (7)
25 – 34	22	7 (32)	18	5 (28)	40	12 (30)
35+ years	91	44 (48)	48	22 (46)	140	66 (47)
p value		0.007		0.334		0.003

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	5	0 (0)	7	1 (14)	12	1 (8)
3 to 10 years	16	4 (25)	24	3 (13)	40	7 (18)
11 + years	74	26 (35)	57	20 (35)	132	46 (35)
p value		0.216		0.082		0.027
2009						
<3 years	4	0 (0)	10	1 (10)	14	1 (7)
3 to 10 years	26	4 (15)	20	8 (40)	46	12 (26)
11 + years	122	59 (48)	59	27 (46)	181	86 (48)
p value		0.002		0.103		0.001
2010						
<3 years	3	0 (0)	2	0 (0)	5	0 (0)
3 to 10 years	18	0 (0)	20	7 (35)	38	7 (18)
11 + years	105	54 (51)	61	31 (51)	167	86 (52)
p value		<0.001		0.242		<0.001
2011						
<3 years	5	0 (0)	7	0 (0)	12	0 (0)
3 to 10 years	14	3 (21)	12	1 (8)	26	4 (15)
11 + years	106	63 (59)	55	29 (53)	163	92 (56)
p value		0.001		0.001		<0.001
2012						
<3 years	6	0 (0)	2	1 (50)	8	1 (13)
3 to 10 years	13	3 (23)	16	4 (25)	30	7 (23)
11 + years	100	47 (47)	53	23 (43)	153	70 (46)
p value		0.023		0.361		0.016

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	3	1 (33)	45	22 (49)	48	23 (48)
Methamphetamine	7	0 (0)	85	12 (14)	92	12 (13)
Other	2	0 (0)	41	19 (46)	43	19 (44)
p value		0.195		<0.001		<0.001
2009						
Heroin	3	0 (0)	79	40 (51)	83	41 (49)
Methamphetamine	6	1 (17)	83	28 (34)	90	29 (32)
Other	5	0 (0)	61	29 (48)	67	30 (44)
p value		0.488		0.080		0.069
2010						
Heroin	2	0 (0)	83	41 (49)	85	41 (48)
Methamphetamine	3	0 (0)	82	26 (32)	86	26 (30)
Other	0	0 (0)	40	26 (65)	41	26 (63)
p value		--		0.002		0.001
2011						
Heroin	4	0 (0)	68	46 (68)	74	47 (64)
Methamphetamine	3	0 (0)	66	20 (30)	71	21 (30)
Other	5	0 (0)	55	30 (55)	60	30 (50)
p value		--		<0.001		<0.001
2012						
Heroin	1	0 (0)	68	30 (44)	71	31 (44)
Methamphetamine	2	0 (0)	64	15 (23)	66	15 (23)
Other	5	1 (20)	50	31 (62)	56	32 (57)
p value		1.000		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	6	0 (0)	68	19 (28)	74	19 (26)
Daily or more	4	1 (25)	87	30 (34)	91	31 (34)
Not last month	2	0 (0)	16	4 (25)	19	4 (21)
p value		0.336		0.589		0.352
2009						
Less than daily	6	1 (17)	89	43 (48)	96	44 (46)
Daily or more	5	0 (0)	118	51 (43)	126	53 (42)
Not last month	3	0 (0)	18	3 (17)	22	3 (14)
p value		0.488		0.047		0.020
2010						
Less than daily	3	0 (0)	100	46 (46)	104	46 (44)
Daily or more	1	0 (0)	92	43 (47)	94	43 (46)
Not last month	1	0 (0)	12	4 (33)	13	4 (31)
p value		--		0.763		0.613
2011						
Less than daily	3	0 (0)	83	43 (52)	88	44 (50)
Daily or more	7	0 (0)	96	49 (51)	103	49 (48)
Not last month	1	0 (0)	10	4 (40)	12	4 (33)
p value		--		0.812		0.568
2012						
Less than daily	5	1 (20)	86	36 (42)	92	38 (41)
Daily or more	1	0 (0)	89	40 (45)	92	40 (43)
Not last month	2	0 (0)	8	1 (13)	10	1 (10)
p value		1.000		0.237		0.127

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	7	0 (0)	125	40 (32)	132	40 (30)
Receptive sharing	3	1 (33)	26	8 (31)	29	9 (31)
p value		0.300		1.000		1.000
2009						
No receptive sharing	10	1 (10)	181	85 (47)	195	88 (45)
Receptive sharing	0	0 (0)	21	7 (33)	21	7 (33)
p value		1.000		0.484		0.588
2010						
No receptive sharing	4	0 (0)	146	66 (45)	151	66 (44)
Receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
p value		--		0.515		0.660
2011						
No receptive sharing	8	0 (0)	149	79 (53)	159	80 (50)
Receptive sharing	1	0 (0)	19	9 (47)	20	9 (45)
p value		--		0.808		0.813
2012						
No receptive sharing	6	1 (17)	146	61 (42)	155	63 (41)
Receptive sharing	0	0 (0)	17	8 (47)	17	8 (47)
p value		--		0.797		0.614

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 6.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	11	1 (9)	139	42 (30)	151	43 (28)
Imprisonment	0	0 (0)	21	8 (38)	21	8 (38)
p value		---		0.460		0.445
2009						
No imprisonment	13	1 (8)	180	72 (40)	197	74 (38)
Imprisonment	1	0 (0)	35	20 (57)	37	21 (57)
p value		1.000		0.065		0.044
2010						
No imprisonment	5	0 (0)	159	62 (39)	166	62 (37)
Imprisonment	0	0 (0)	16	10 (63)	16	10 (63)
p value		--		0.107		0.062
2011						
No imprisonment	10	0 (0)	156	78 (50)	170	80 (47)
Imprisonment	1	0 (0)	16	13 (81)	17	13 (76)
p value		--		0.019		0.023
2012						
No imprisonment	7	1 (14)	169	69 (41)	178	71 (40)
Imprisonment	1	0 (0)	11	5 (45)	13	5 (38)
p value		1.000		0.762		1.000

* Total includes people who did not report duration of drug injection

Table 6.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	11	1 (9)	150	48 (32)	162	49 (30)
Sex work	0	0 (0)	13	5 (38)	13	5 (38)
p value		---		0.759		0.543
2009						
No sex work	14	1 (7)	208	93 (45)	227	96 (42)
Sex work	0	0 (0)	10	2 (20)	10	2 (20)
p value		---		0.192		0.202
2010						
No sex work	5	0 (0)	174	80 (46)	181	80 (44)
Sex work	0	0 (0)	20	5 (25)	20	5 (25)
p value		--		0.096		0.151
2011						
No sex work	10	0 (0)	176	91 (52)	189	92 (49)
Sex work	0	0 (0)	7	2 (29)	8	3 (38)
p value		--		0.273		0.722
2012						
No sex work	8	1 (13)	173	73 (42)	184	75 (41)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.79		0.159

* Total includes people who did not report duration of drug injection

Table 6.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	75	23 (31)	77	23 (30)	153	46 (30)
Indigenous	17	6 (35)	8	0 (0)	25	6 (24)
p value		0.775		0.101		0.640
2009						
Non Indigenous	128	50 (39)	76	28 (37)	204	78 (38)
Indigenous	20	12 (60)	11	7 (64)	31	19 (61)
p value		0.091		0.109		0.019
2010						
Non Indigenous	108	46 (43)	72	33 (46)	181	80 (44)
Indigenous	15	5 (33)	8	3 (38)	23	8 (35)
p value		0.584		0.724		0.504
2011						
Non Indigenous	112	56 (50)	62	25 (40)	176	81 (46)
Indigenous	16	11 (69)	12	5 (42)	28	16 (57)
p value		0.189		1.000		0.312
2012						
Non Indigenous	112	47 (42)	62	26 (42)	175	73 (42)
Indigenous	9	4 (44)	7	1 (14)	16	5 (31)
p value		1.000		0.233		0.596

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	87	26 (30)	83	21 (25)	171	47 (27)
Non-English speaking	5	4 (80)	6	2 (33)	11	6 (55)
p value		0.037		0.646		0.083
2009						
English speaking	140	63 (45)	83	33 (40)	223	96 (43)
Non-English speaking	11	1 (9)	7	2 (29)	18	3 (17)
p value		0.025		0.701		0.044
2010						
English speaking	112	46 (41)	81	37 (46)	194	84 (43)
Non-English speaking	13	6 (46)	3	1 (33)	16	7 (44)
p value		0.772		1.000		1.000
2011						
English speaking	116	59 (51)	68	28 (41)	186	87 (47)
Non-English speaking	11	7 (64)	6	2 (33)	17	9 (53)
p value		0.534		1.000		0.801
2012						
English speaking	102	47 (46)	70	28 (40)	173	75 (43)
Non-English speaking	20	4 (20)	1	0 (0)	21	4 (19)
p value		0.046		1.000		0.036

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	79	24 (30)	73	15 (21)	152	39 (26)
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)
Asia	2	2 (100)	3	2 (67)	5	4 (80)
UK & Ireland	7	1 (14)	8	4 (50)	16	5 (31)
Other	3	2 (67)	2	2 (100)	5	4 (80)
p value		0.091		0.010		0.009
2009						
Australia	137	60 (44)	80	29 (36)	217	89 (41)
Other Oceania	3	2 (67)	2	1 (50)	5	3 (60)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	11	3 (27)	6	5 (83)	17	8 (47)
Other	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.345		0.057		0.255
2010						
Australia	113	45 (40)	74	32 (43)	188	78 (41)
Other Oceania	0	0 (0)	3	3 (100)	3	3 (100)
Asia	3	3 (100)	1	1 (100)	4	4 (100)
UK & Ireland	6	4 (67)	5	2 (40)	11	6 (55)
Other	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.090		0.172		0.033
2011						
Australia	111	57 (51)	66	23 (35)	179	80 (45)
Other Oceania	2	0 (0)	2	2 (100)	4	2 (50)
Asia	4	4 (100)	0	0 (0)	4	4 (100)
UK & Ireland	5	2 (40)	3	3 (100)	8	5 (63)
Other	6	4 (67)	3	2 (67)	9	6 (67)
p value		0.164		0.008		0.124
2012						
Australia	102	38 (37)	68	26 (38)	171	64 (37)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	7	5 (71)	2	2 (100)	9	7 (78)
Other	12	7 (58)	0	0 (0)	12	7 (58)
p value		0.092		0.152		0.030

* Total includes people whose gender was not reported or reported as transgender

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	4	4	4	4	4
N° surveyed	N=57	N=122	N=106	N=68	N=75
Response (%)	25%	22%	39%	28%	28%
Gender (%)					
Male	33 (58)	74 (61)	68 (64)	43 (63)	37 (49)
Female	24 (42)	47 (39)	38 (36)	25 (37)	38 (51)
Transgender	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	46 (81)	101 (83)	96 (91)	61 (90)	62 (83)
Bisexual	6 (11)	12 (10)	4 (4)	2 (3)	7 (9)
Homosexual	3 (5)	5 (4)	1 (1)	3 (4)	4 (5)
Not reported	2 (4)	4 (3)	5 (5)	2 (3)	2 (3)
Age and duration of injection (years)					
<i>Median age</i>	36	33	35	38	38
Age range	21-58	17-59	20-60	17-58	18-57
<i>Age group (%)</i>					
<25 years	3 (5)	13 (11)	7 (7)	4 (6)	3 (4)
25+ years	54 (95)	109 (89)	99 (93)	64 (94)	72 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	19	19	19	18
Age range	11-38	11-44	12-42	13-49	13-45
Not reported	1	5	0	3	3
<i>Median years IDU</i>	16.5	13	14	15	15
Range	1-41	<1-39	<1-42	<1-40	<1-38
<i>Duration of drug injection (%)</i>					
<3 years	1 (2)	9 (7)	4 (4)	7 (10)	5 (7)
3+ years	55 (96)	108 (89)	102 (96)	58 (85)	67 (89)
Not reported	1 (2)	5 (4)	0 (0)	3 (4)	3 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	50 (88)	100 (82)	94 (89)	59 (87)	64 (85)
Yes	5 (9)	15 (12)	12 (11)	8 (12)	10 (13)
Not reported	2 (4)	7 (6)	0 (0)	1 (1)	1 (1)
Region/Country of birth (%)					
Australia	48 (84)	111 (91)	98 (92)	64 (94)	69 (92)
Other Oceania	0 (0)	2 (2)	2 (2)	0 (0)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	6 (11)	2 (2)	4 (4)	2 (3)	1 (1)
Other	0 (0)	2 (2)	2 (2)	2 (3)	3 (4)
Not reported	3 (5)	5 (4)	0 (0)	0 (0)	2 (3)
Main language spoken at home by parents (%)					
English speaking	55 (96)	119 (98)	105 (99)	68 (100)	73 (97)
Non-English speaking	2 (4)	1 (1)	1 (1)	0 (0)	1 (1)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)
Imprisonment last year (%)					
No	45 (79)	98 (80)	81 (76)	63 (93)	68 (94)
Yes	7 (12)	17 (14)	5 (5)	4 (6)	4 (6)
Not reported	5 (9)	7 (6)	20 (19)	1 (1)	0 (0)
Injected in prison (%)	N=7	N=17	N=5	N=4	N=4
Yes	3 (43)	6 (35)	0 (0)	1 (25)	2 (50)
Frequency of injection last month (%)					
Not last month	2 (4)	7 (6)	9 (8)	5 (7)	7 (9)
Less than weekly	8 (14)	18 (15)	21 (20)	10 (15)	14 (19)
Weekly not daily	23 (40)	47 (39)	45 (42)	27 (40)	19 (25)
Daily or more	24 (42)	46 (38)	31 (29)	26 (38)	35 (47)
Not reported	0 (0)	4 (3)	0 (0)	0 (0)	0 (0)

Table 7.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=57	N=122	N=106	N=68	N=75
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	4 (7)	4 (3)	1 (1)	1 (1)	1 (1)
Methadone	24 (42)	40 (33)	30 (28)	21 (31)	13 (17)
Methamphetamine	13 (23)	30 (25)	29 (27)	18 (26)	24 (32)
Performance/Image-enhancing drugs	0 (0)	1 (<1)	1 (1)	0 (0)	1 (1)
Pharmaceutical opioids	12 (21)	33 (27)	35 (33)	23 (34)	30 (40)
Suboxone®	--	4 (3)	0 (0)	0 (0)	1 (1)
Subutex®/Buprenorphine	1 (2)	2 (2)	0 (0)	1 (1)	2 (3)
More than one	1 (2)	4 (3)	8 (8)	3 (4)	0 (0)
Other drug	1 (2)	5 (4)	2 (2)	1 (1)	3 (4)
Not reported	1 (2)	3 (2)	0 (0)	0 (0)	0 (0)
N° Injected last month	N=55	N=111	N=97	N=63	N=68
Places injected last month (%)*					
Any public	30 (36)	43 (39)	32 (33)	23 (37)	17 (25)
All private	33 (60)	67 (60)	52 (54)	39 (62)	48 (71)
Not Reported	2 (4)	1 (1)	13 (13)	1 (2)	3 (4)
Use of new sterile needles & syringes last month (%)					
All injections	40 (73)	93 (84)	75 (77)	55 (87)	53 (78)
Most of the time	13 (24)	15 (14)	10 (10)	7 (11)	11 (16)
Half of the time	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	2 (4)	1 (1)	12 (12)	1 (1)	4 (6)
Re-used another's used needle & syringe last month (%)					
None	44 (80)	94 (85)	82 (85)	51 (81)	54 (79)
One	2 (4)	1 (1)	1 (1)	5 (8)	5 (7)
Twice	2 (4)	4 (4)	1 (1)	1 (1)	1 (1)
3-5 times	3 (5)	7 (6)	0 (0)	4 (6)	1 (1)
>5 times	2 (4)	2 (2)	0 (0)	0 (0)	3 (4)
Not reported	2 (4)	3 (3)	13 (13)	2 (3)	4 (6)
Number of people needle & syringe was re-used after last month (%)					
None	44 (80)	94 (85)	82 (85)	51 (81)	54 (79)
One	3 (5)	3 (3)	2 (2)	3 (5)	2 (3)
Two	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Three to five	1 (2)	1 (1)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)
Don't know	1 (2)	3 (3)	0 (0)	6 (10)	2 (3)
Not reported	6 (11)	9 (8)	13 (13)	3 (5)	8 (12)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	4 (7)	4 (4)	5 (5)	3 (5)	1 (1)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Close friend	2 (4)	1 (1)	1 (1)	3 (5)	3 (4)
Acquaintance	0 (0)	1 (1)	0 (0)	3 (5)	1 (1)
Other	0 (0)	2 (2)	1 (1)	2 (3)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	4 (9)	6 (6)	9 (9)	9 (14)	9 (13)
Water	5 (11)	7 (7)	12 (12)	5 (8)	5 (7)
Filter	0 (0)	6 (6)	6 (6)	2 (3)	3 (4)
Drug mix	1 (2)	3 (3)	4 (4)	3 (5)	4 (6)
None**	36 (82)	86 (84)	67 (69)	51 (81)	54 (79)
Injected by someone after that person injected themselves or others last month (%)					
No	47 (85)	83 (75)	76 (78)	54 (86)	53 (78)
Yes	4 (7)	27 (24)	8 (8)	7 (11)	10 (15)
Not reported	4 (7)	1 (1)	13 (13)	2 (3)	5 (7)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	54 (79)
Yes	--	--	--	--	8 (12)
Not reported	--	--	--	--	6 (9)

* More than one option could be selected ** New question in 2012

Table 7.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=57	N=122	N=106	N=68	N=75
Sex with a regular partner last month (%)					
No	23 (40)	52 (43)	59 (56)	28 (41)	34 (45)
Yes	34 (60)	59 (48)	43 (41)	37 (54)	37 (49)
Not reported	---	11 (9)	4 (4)	3 (4)	4 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=34	N=59	N=59	N=37	N=37
Never	21 (62)	51 (86)	44 (75)	24 (65)	27 (73)
Sometimes	5 (15)	1 (2)	7 (12)	9 (24)	4 (11)
Every time	7 (21)	4 (7)	6 (10)	4 (11)	6 (16)
Not reported	1 (3)	3 (5)	2 (3)	0 (0)	0 (0)
Sex with other partner/s last month (%)					
No	48 (84)	86 (70)	94 (89)	57 (84)	58 (77)
Yes	7 (12)	19 (16)	7 (7)	8 (12)	8 (11)
Not reported	2 (4)	17 (14)	5 (5)	3 (4)	9 (12)
Condom used with other partner/s last month (%)					
N° surveyed	N=7	N=19	N=7	N=8	N=8
Never	2 (29)	4 (21)	4 (57)	3 (28)	3 (38)
Sometimes	2 (29)	5 (26)	1 (14)	2 (25)	2 (25)
Every time	3 (43)	9 (47)	2 (29)	3 (38)	2 (25)
Not reported	0 (0)	1 (5)	0 (0)	0 (0)	1 (13)
Sex work last month (%)					
No	54 (95)	107 (88)	101 (95)	64 (94)	68 (91)
Yes	2 (4)	2 (2)	2 (2)	1 (1)	2 (3)
Not reported	1 (2)	13 (11)	3 (3)	3 (4)	5 (7)
Condom used at last sex work last month (%)					
Yes	1 (100)	1 (50)	1 (50)	1 (100)	2 (100)

Table 7.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=57	N=122	N=106	N=68	N=75
Previous HIV test (%)					
Yes, last year	35 (61)	50 (41)	43 (41)	24 (35)	29 (39)
> 1 year ago	16 (28)	41 (34)	42 (40)	30 (44)	26 (35)
Never tested	5 (9)	18 (15)	15 (14)	12 (18)	15 (20)
Not reported	1 (2)	13 (11)	6 (6)	2 (3)	5 (7)
Previous HCV test (%)					
Yes, last year	37 (65)	71 (58)	56 (53)	30 (44)	36 (48)
> 1 year ago	17 (30)	37 (30)	36 (34)	27 (40)	27 (36)
Never tested	3 (5)	8 (7)	10 (9)	7 (10)	7 (9)
Not reported	0 (0)	6 (5)	4 (4)	4 (6)	5 (7)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=31	N=68	N=48	N=32	N=34
Interferon/Interferon+Ribavirin	0 (0)	6 (9)	2 (4)	2 (6)	6 (18)
Other	29 (94)	1 (1)	1 (2)	0 (0)	0 (0)
No treatment	0 (0)	61 (90)	40 (83)	29 (91)	26 (76)
Not reported	1 (3)	0 (0)	1 (1)	1 (3)	2 (6)
Current treatment for HCV	N=0	N=0	N=0	N=0	N=3
Interferon/Interferon+Ribavirin	0	0	0	0	3

Table 7.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=57	N=122	N=106	N=68	N=75
Any treatment/therapy for drug use (%)					
No	13 (23)	31 (25)	28 (26)	13 (19)	19 (25)
Yes	43 (75)	88 (72)	77 (73)	53 (78)	55 (73)
Not reported	1 (2)	3 (2)	1 (1)	2 (3)	1 (1)
History of methadone maintenance treatment (%)					
Currently	24 (42)	47 (39)	44 (42)	20 (30)	22 (29)
Previously	12 (21)	24 (20)	19 (18)	18 (26)	21 (28)
Never	21 (37)	46 (38)	40 (38)	25 (37)	31 (41)
Not reported	0 (0)	5 (4)	3 (3)	5 (7)	1 (1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	4 (7)	7 (6)	5 (5)	5 (7)	7 (9)
Previously	10 (18)	27 (22)	25 (24)	19 (28)	18 (24)
Never	39 (68)	85 (70)	75 (71)	42 (62)	47 (63)
Not reported	4 (7)	3 (2)	1 (1)	2 (3)	3 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	2 (4)	5 (4)	4 (4)	1 (1)	6 (8)
Previously	2 (4)	14 (11)	13 (12)	13 (19)	12 (16)
Never	48 (84)	99 (81)	88 (83)	53 (78)	54 (72)
Not reported	5 (9)	4 (3)	1 (1)	1 (1)	3 (4)

Table 7.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=55	N=111	N=97	N=63	N=68
Needle Syringe Program	54 (98)	73 (66)	96 (99)	58 (92)	61 (90)
Chemist/Pharmacy	15 (27)	21 (19)	9 (9)	10 (16)	18 (26)
Personal sources	--	15 (14)	3 (3)	2 (3)	4 (6)
Dispensing/Vending Machine	--	3 (3)	0 (0)	1 (2)	5 (7)
Other sources	--	1 (1)	0 (0)	1 (2)	0 (0)

* More than one option could be selected

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	33	0 (0.0)	24	0 (0.0)	57	0 (0.0)
2009	73	0 (0.0)	47	0 (0.0)	121	0 (0.0)
2010	68	0 (0.0)	38	0 (0.0)	106	0 (0.0)
2011	43	0 (0.0)	25	0 (0.0)	68	0 (0.0)
2012	36	0 (0.0)	38	0 (0.0)	74	0 (0.0)
X ² trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	32	26 (81)	24	19 (79)	56	45 (80)
2009	73	38 (52)	45	24 (53)	119	63 (53)
2010	68	30 (44)	38	18 (47)	106	48 (45)
2011	42	17 (40)	25	14 (56)	67	31 (46)
2012	36	17 (47)	37	17 (46)	73	34 (47)
X ² trend p value		0.005		0.050		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	31	25 (81)	14	11 (79)	45	36 (80)
Bisexual	0	0 (0)	6	5 (83)	6	5 (83)
Homosexual	1	1 (100)	2	2 (100)	3	3 (100)
p value		1.000		1.000		1.000
2009						
Heterosexual	64	33 (52)	33	18 (55)	98	52 (53)
Bisexual	4	3 (75)	8	5 (63)	12	8 (67)
Homosexual	4	2 (50)	1	0 (0)	5	2 (40)
p value		0.853		0.691		0.602
2010						
Heterosexual	66	28 (42)	30	15 (50)	96	43 (45)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2011						
Heterosexual	38	15 (39)	22	11 (50)	60	26 (43)
Bisexual	0	0 (0)	2	2 (100)	2	2 (100)
Homosexual	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.560		0.482		0.236
2012						
Heterosexual	30	15 (50)	30	16 (53)	60	31 (52)
Bisexual	2	1 (50)	5	1 (20)	7	2 (29)
Homosexual	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.298		0.252		0.100

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	2	2 (100)	1	1 (100)	3	3 (100)
25 – 34	10	8 (80)	14	11 (79)	24	19 (79)
35+ years	20	16 (80)	9	19 (79)	29	23 (79)
p value		0.782		0.871		0.679
2009						
< 25 years	9	4 (44)	3	0 (0)	12	4 (33)
25 – 34	29	12 (41)	30	18 (60)	59	30 (51)
35+ years	35	22 (63)	12	6 (50)	48	29 (60)
p value		0.205		0.134		0.220
2010						
< 25 years	2	0 (0)	5	2 (40)	7	2 (29)
25 – 34	30	12 (40)	13	7 (54)	43	19 (44)
35+ years	36	18 (50)	20	9 (45)	56	27 (48)
p value		0.442		0.906		0.677
2011						
< 25 years	2	0 (0)	2	1 (50)	4	1 (25)
25 – 34	12	3 (25)	10	6 (60)	22	9 (41)
35+ years	28	14 (50)	13	7 (54)	41	21 (51)
p value		0.177		1.000		0.616
2012						
< 25 years	1	0 (0)	2	0 (0)	3	0 (0)
25 – 34	11	5 (45)	13	7 (54)	24	12 (50)
35+ years	24	12 (50)	22	10 (45)	46	22 (48)
p value		1.000		0.563		0.369

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	5	5 (500)	8	6 (75)	13	11 (85)
11 + years	26	20 (77)	15	12 (80)	41	32 (78)
p value		0.427		0.782		0.771
2009						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 10 years	16	8 (50)	15	6 (40)	31	14 (45)
11 + years	51	29 (57)	22	15 (68)	74	45 (61)
p value		0.052		0.116		0.012
2010						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3 to 10 years	13	5 (38)	12	4 (33)	25	9 (36)
11 + years	51	25 (49)	26	14 (54)	77	39 (51)
p value		0.181		0.307		0.108
2011						
<3 years	3	1 (33)	4	1 (25)	7	2 (29)
3 to 10 years	5	0 (0)	7	5 (71)	12	5 (42)
11 + years	32	15 (47)	13	8 (62)	45	23 (51)
p value		0.156		0.388		0.535
2012						
<3 years	1	0 (0)	4	1 (25)	5	1 (20)
3 to 10 years	5	2 (40)	5	2 (40)	10	4 (40)
11 + years	29	15 (52)	26	14 (54)	55	29 (53)
p value		1.000		0.643		0.356

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Pharmaceutical opioids	0	0 (0)	12	9 (75)	12	9 (75)
Methamphetamine	0	0 (0)	12	11 (92)	12	11 (92)
Other	1	1 (100)	29	22 (76)	31	24 (77)
p value		--		0.498		0.524
2009						
Pharmaceutical opioids	1	0 (0)	30	19 (63)	32	19 (59)
Methamphetamine	7	0 (0)	23	9 (39)	30	9 (30)
Other	1	1 (100)	49	28 (57)	54	32 (59)
p value		0.011		0.166		0.014
2010						
Pharmaceutical opioids	1	0 (0)	34	16 (47)	35	16 (46)
Methamphetamine	2	0 (0)	27	9 (33)	29	9 (31)
Other	1	0 (0)	41	23 (56)	42	23 (55)
p value		--		0.187		0.153
2011						
Pharmaceutical opioids	2	0 (0)	19	7 (37)	22	8 (36)
Methamphetamine	3	1 (33)	13	6 (46)	18	7 (39)
Other	2	1 (50)	25	15 (60)	27	16 (59)
p value		1.000		0.326		0.236
2012						
Pharmaceutical opioids	1	0 (0)	28	15 (54)	30	15 (50)
Methamphetamine	2	1 (50)	19	8 (42)	22	9 (41)
Other	2	0 (0)	18	10 (56)	21	10 (48)
p value		1.000		0.700		0.798

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	0	0 (0)	30	23 (77)	31	24 (77)
Daily or more	1	1 (100)	22	19 (86)	23	20 (87)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.395		0.373
2009						
Less than daily	6	1 (17)	57	34 (60)	65	37 (57)
Daily or more	1	0 (0)	40	23 (58)	44	24 (55)
Not last month	2	0 (0)	5	1 (20)	7	1 (14)
p value		0.755		0.228		0.098
2010						
Less than daily	1	0 (0)	67	30 (45)	68	30 (44)
Daily or more	1	0 (0)	28	16 (57)	29	16 (55)
Not last month	2	0 (0)	7	2 (29)	9	2 (22)
p value		--		0.356		0.220
2011						
Less than daily	4	1 (25)	31	14 (45)	37	15 (41)
Daily or more	2	1 (50)	22	13 (59)	25	15 (60)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		1.000		0.345		0.162
2012						
Less than daily	2	1 (50)	31	14 (45)	33	15 (45)
Daily or more	2	0 (0)	29	16 (55)	34	16 (47)
Not last month	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		0.693		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	1	1 (100)	42	34 (81)	43	35 (81)
Receptive sharing	0	0 (0)	8	8 (100)	9	9 (100)
p value		---		0.324		0.323
2009						
No receptive sharing	6	1 (17)	82	49 (60)	93	53 (57)
Receptive sharing	1	0 (0)	12	8 (67)	13	8 (62)
p value		1.000		0.759		1.000
2010						
No receptive sharing	1	0 (0)	81	38 (47)	82	38 (46)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.229		0.224
2011						
No receptive sharing	1	0 (0)	47	26 (55)	50	27 (54)
Receptive sharing	5	2 (40)	4	1 (25)	10	3 (30)
p value		1.000		0.331		0.299
2012						
No receptive sharing	3	1 (33)	47	25 (53)	53	26 (49)
Receptive sharing	0	0 (0)	10	5 (50)	10	5 (50)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 7.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	1	1 (100)	43	33 (77)	44	34 (77)
Imprisonment	0	0 (0)	6	6 (100)	7	7 (100)
p value		---		0.324		0.320
2009						
No imprisonment	8	1 (13)	85	48 (56)	96	51 (53)
Imprisonment	0	0 (0)	15	10 (67)	16	10 (63)
p value		---		0.575		0.592
2010						
No imprisonment	3	0 (0)	78	29 (37)	81	29 (36)
Imprisonment	0	0 (0)	5	5 (100)	5	5 (100)
p value		--		0.010		0.008
2011						
No imprisonment	7	2 (29)	54	26 (48)	62	28 (45)
Imprisonment	0	0 (0)	2	2 (100)	4	3 (75)
p value		--		0.491		0.335
2012						
No imprisonment	5	1 (20)	58	31 (53)	66	32 (48)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 7.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	1	1 (100)	51	40 (78)	53	42 (79)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2009						
No sex work	9	1 (11)	92	54 (59)	104	57 (55)
Sex work	0	0 (0)	1	1 (100)	2	2 (100)
p value		---		1.000		0.502
2010						
No sex work	3	0 (0)	98	47 (48)	101	47 (47)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.497		0.499
2011						
No sex work	7	2 (29)	54	27 (50)	63	30 (48)
Sex work	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		1.000
2012						
No sex work	5	1 (20)	59	31 (53)	66	32 (48)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 7.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	29	23 (79)	20	16 (80)	49	39 (80)
Indigenous	3	3 (100)	2	1 (50)	5	4 (80)
p value		1.000		0.411		1.000
2009						
Non Indigenous	61	30 (49)	36	20 (56)	98	51 (52)
Indigenous	9	6 (67)	6	3 (50)	15	9 (60)
p value		0.479		1.000		0.593
2010						
Non Indigenous	61	27 (44)	33	15 (45)	94	42 (45)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		1.000		0.653		0.766
2011						
Non Indigenous	38	16 (42)	20	10 (50)	58	26 (45)
Indigenous	3	1 (33)	5	4 (80)	8	5 (63)
p value		1.000		0.341		0.459
2012						
Non Indigenous	33	17 (52)	29	12 (41)	62	29 (47)
Indigenous	2	0 (0)	8	5 (63)	10	5 (50)
p value		0.486		0.428		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	32	26 (81)	22	17 (77)	54	43 (80)
Non-English speaking	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2009						
English speaking	70	37 (53)	44	24 (55)	117	63 (54)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		0.467		0.466
2010						
English speaking	67	30 (45)	38	18 (47)	105	48 (46)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2011						
English speaking	42	17 (40)	25	14 (56)	67	31 (46)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2012						
English speaking	34	16 (47)	37	17 (46)	71	33 (46)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.486		--		0.472

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	30	24 (80)	17	13 (76)	47	37 (79)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	5	4 (80)	6	5 (83)
Other	0	0 (0)	1	1 (100)	1	1 (100)
p value		1.000		1.000		1.000
2009						
Australia	68	36 (53)	40	21 (53)	109	58 (53)
Other Oceania	1	0 (0)	1	1 (100)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.724		1.000		0.874
2010						
Australia	65	28 (43)	33	15 (45)	98	43 (44)
Other Oceania	0	0 (0)	2	2 (100)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	2	1 (50)	4	3 (75)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.187		0.365		0.134
2011						
Australia	39	14 (36)	24	13 (54)	63	27 (43)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.059		1.000		0.041
2012						
Australia	33	15 (45)	34	15 (44)	67	30 (45)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	1 (100)	1	1 (100)
Other	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.471		0.723		0.403

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	6	6	5	6	6
N° surveyed	N=308	N=334	N=445	N=506	N=463
Response (%)	37%	--	58%	55%	52%
Gender (%)					
Male	206 (67)	216 (65)	310 (70)	341 (67)	322 (70)
Female	102 (33)	116 (35)	133 (30)	163 (32)	140 (30)
Transgender	0 (0)	2 (<1)	1 (<1)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	1 (<1)	1 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	258 (84)	273 (82)	373 (84)	415 (82)	367 (79)
Bisexual	22 (7)	34 (10)	36 (8)	45 (9)	46 (10)
Homosexual	7 (2)	8 (2)	8 (2)	14 (3)	17 (4)
Not reported	21 (7)	19 (6)	28 (6)	32 (6)	33 (7)
Age and duration of injection (years)					
<i>Median age</i>	34	34	35	37	37
Age range	16-65	17-61	18-62	18-63	17-64
<i>Age group (%)</i>					
<25 years	19 (6)	29 (9)	46 (10)	38 (8)	21 (5)
25+ years	289 (94)	305 (91)	399 (90)	464 (92)	440 (95)
Not reported	0 (0)	0 (0)	0 (0)	4 (1)	2 (<1)
<i>Median age 1st IDU</i>	18	18	17	18	18
Age range	10-45	11-51	10-50	10-50	10-59
Not reported	9	9	9	11	17
<i>Median years IDU</i>	15	14	15	17	18
Range	<1-40	<1-40	<1-42	<1-47	<1-43
<i>Duration of drug injection (%)</i>					
<3 years	19 (6)	13 (91)	15 (3)	13 (3)	14 (3)
3+ years	280 (91)	312 (93)	421 (95)	481 (95)	431 (93)
Not reported	9 (3)	9 (3)	9 (2)	12 (2)	18 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	266 (86)	304 (91)	405 (91)	442 (87)	389 (84)
Yes	28 (9)	23 (7)	36 (8)	55 (11)	67 (14)
Not reported	14 (5)	7 (2)	4 (1)	9 (2)	7 (2)
Region/Country of birth (%)					
Australia	259 (84)	285 (85)	392 (88)	444 (88)	388 (84)
Other Oceania	5 (2)	8 (2)	9 (2)	11 (2)	14 (3)
Asia	10 (3)	7 (2)	7 (2)	6 (1)	14 (3)
UK & Ireland	20 (6)	12 (4)	13 (3)	20 (4)	21 (5)
Other	8 (3)	20 (6)	15 (3)	24 (5)	24 (5)
Not reported	6 (2)	2 (<1)	9 (2)	1 (<1)	2 (<1)
Main language spoken at home by parents (%)					
English speaking	270 (88)	303 (91)	412 (93)	457 (90)	417 (90)
Non-English speaking	32 (10)	23 (7)	26 (6)	45 (9)	45 (10)
Not reported	6 (2)	8 (2)	7 (2)	4 (1)	1 (<1)
Imprisonment last year (%)					
No	241 (78)	285 (85)	319 (72)	403 (80)	368 (80)
Yes	40 (13)	39 (12)	45 (10)	59 (12)	75 (16)
Not reported	27 (9)	10 (3)	81 (18)	44 (9)	15 (3)
Injected in prison (%)					
Yes	N=40 12 (30)	N=39 12 (31)	N=45 15 (33)	N=59 19 (32)	N=75 22 (29)
Frequency of injection last month (%)					
Not last month	21 (7)	21 (6)	30 (7)	46 (9)	26 (6)
Less than weekly	53 (17)	44 (13)	72 (16)	68 (13)	93 (20)
Weekly not daily	61 (20)	69 (21)	101 (23)	109 (22)	99 (21)
Daily or more	167 (54)	196 (59)	235 (53)	278 (55)	236 (51)
Not reported	6 (2)	4 (1)	7 (2)	5 (1)	9 (2)

Table 8.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=308	N=334	N=445	N=506	N=463
Cocaine	2 (1)	0 (0)	4 (1)	2 (<1)	0 (0)
Heroin	180 (58)	205 (61)	265 (60)	307 (61)	299 (65)
Methadone	8 (3)	9 (3)	13 (3)	12 (2)	7 (2)
Methamphetamine	55 (18)	45 (13)	57 (13)	91 (18)	82 (18)
Performance/Image-enhancing drugs	3 (1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)
Pharmaceutical opioids	22 (7)	21 (6)	34 (8)	26 (5)	15 (3)
Suboxone®	--	3 (1)	13 (3)	16 (3)	10 (2)
Subutex®/Buprenorphine	21 (7)	26 (8)	31 (7)	20 (4)	13 (3)
More than one	6 (2)	10 (3)	23 (5)	26 (5)	32 (7)
Other drug	2 (1)	8 (2)	4 (1)	2 (<1)	2 (<1)
Not reported	9 (3)	6 (2)	0 (0)	3 (<1)	1 (<1)
N° Injected last month	N=281	N=309	N=409	N=455	N=428
Places injected last month (%)*					
Any public	174 (62)	195 (63)	257 (63)	292 (64)	259 (61)
All private	100 (36)	113 (37)	126 (31)	149 (33)	148 (35)
Not reported	7 (2)	1 (<1)	26 (6)	14 (3)	21 (5)
Use of new sterile needles & syringes last month (%)					
All injections	186 (66)	224 (72)	289 (71)	327 (72)	319 (75)
Most of the time	76 (27)	69 (22)	76 (19)	87 (19)	70 (16)
Half of the time	7 (2)	7 (2)	5 (1)	13 (3)	9 (2)
Some of the time	6 (2)	5 (2)	6 (1)	5 (1)	4 (1)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Not reported	6 (2)	4 (1)	33 (8)	23 (5)	24 (6)
Re-used another's used needle & syringe last month (%)					
None	226 (80)	252 (82)	307 (75)	330 (73)	316 (74)
Once	11 (4)	16 (5)	20 (5)	30 (7)	43 (10)
Twice	19 (7)	13 (4)	16 (4)	25 (5)	18 (4)
3-5 times	11 (4)	9 (3)	16 (4)	21 (5)	17 (4)
>5 times	7 (2)	11 (4)	11 (3)	16 (4)	16 (4)
Not reported	7 (2)	8 (3)	39 (10)	33 (7)	18 (4)
Number of people needle & syringe was re-used after last month (%)					
None	226 (80)	252 (82)	307 (75)	330 (73)	316 (74)
One	27 (10)	26 (8)	33 (8)	49 (11)	50 (12)
Two	2 (1)	1 (<1)	4 (1)	9 (2)	5 (1)
Three to five	1 (<1)	2 (<1)	4 (1)	5 (1)	5 (1)
More than five	0 (0)	1 (<1)	7 (2)	5 (1)	3 (1)
Don't know	13 (5)	7 (2)	8 (2)	20 (4)	16 (4)
Not reported	12 (4)	20 (6)	46 (11)	37 (8)	33 (8)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	19 (7)	24 (8)	41 (10)	47 (10)	28 (7)
Casual sex partner	0 (0)	0 (0)	4 (1)	3 (1)	3 (1)
Close friend	13 (5)	8 (3)	33 (8)	50 (11)	29 (7)
Acquaintance	2 (1)	2 (<1)	8 (2)	23 (5)	13 (3)
Other	3 (1)	4 (1)	6 (1)	13 (3)	10 (2)
Equipment used after someone else last month (%)*					
Spoon	96 (36)	105 (36)	128 (31)	163 (36)	143 (33)
Water	56 (21)	55 (19)	76 (19)	100 (22)	90 (21)
Filter	45 (17)	49 (17)	52 (13)	76 (17)	68 (16)
Drug mix	31 (12)	31 (11)	51 (12)	53 (12)	60 (14)
None	151 (57)	167 (58)	220 (54)	246 (54)	228 (53)
Injected by someone after that person injected themselves or others last month (%)					
No	234 (83)	246 (80)	314 (77)	359 (79)	336 (79)
Yes	37 (13)	57 (18)	64 (16)	72 (16)	65 (15)
Not reported	10 (4)	6 (2)	31 (8)	24 (5)	27 (6)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	341 (80)
Yes	--	--	--	--	63 (15)
Not reported	--	--	--	--	24 (6)

* More than one option could be selected ** New question in 2012

Table 8.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=308	N=334	N=445	N=506	N=463
Sex with a regular partner last month (%)					
No	146 (47)	140 (42)	216 (49)	249 (49)	256 (55)
Yes	153 (50)	179 (54)	215 (48)	209 (41)	196 (42)
Not reported	9 (3)	15 (4)	14 (3)	48 (9)	11 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=153	N=179	N=215	N=209	N=196
Never	101 (66)	126 (70)	138 (64)	146 (70)	124 (63)
Sometimes	22 (14)	23 (13)	31 (14)	29 (14)	28 (14)
Every time	19 (12)	24 (13)	36 (17)	25 (12)	25 (13)
Not reported	11 (7)	6 (3)	10 (5)	9 (4)	19 (10)
Sex with other partner/s last month (%)					
No	259 (84)	273 (82)	353 (79)	406 (80)	359 (78)
Yes	35 (11)	45 (13)	65 (15)	81 (16)	86 (19)
Not reported	14 (5)	16 (5)	27 (6)	19 (4)	18 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=35	N=45	N=65	N=81	N=86
Never	9 (26)	14 (31)	21 (32)	28 (35)	30 (35)
Sometimes	14 (40)	10 (22)	17 (26)	16 (20)	24 (28)
Every time	10 (29)	20 (44)	23 (35)	32 (40)	30 (35)
Not reported	2 (6)	1 (2)	4 (6)	5 (6)	2 (2)
Sex work last month (%)					
No	266 (86)	308 (92)	393 (88)	454 (90)	418 (90)
Yes	17 (6)	17 (5)	28 (6)	31 (6)	34 (7)
Not reported	25 (8)	9 (3)	24 (5)	21 (4)	11 (2)
Condom used at last sex work last month (%)					
Yes	11 (73)	15 (88)	21 (78)	25 (89)	29 (85)

Table 8.1.4 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=308	N=334	N=445	N=506	N=463
Previous HIV test (%)					
Yes, last year	151 (49)	174 (52)	233 (52)	264 (52)	274 (59)
> 1 year ago	109 (35)	121 (36)	144 (32)	166 (33)	130 (28)
Never tested	34 (11)	29 (9)	40 (9)	52 (10)	44 (10)
Not reported	14 (5)	10 (3)	28 (6)	24 (5)	15 (3)
Previous HCV test (%)					
Yes, last year	176 (57)	194 (58)	268 (60)	305 (60)	295 (64)
> 1 year ago	98 (32)	110 (33)	125 (28)	153 (30)	122 (26)
Never tested	20 (6)	14 (4)	24 (5)	18 (4)	22 (5)
Not reported	14 (5)	16 (5)	28 (6)	30 (6)	24 (5)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=185	N=201	N=280	N=321	N=313
Interferon/Interferon+Ribavirin	15 (8)	14 (7)	16 (9)	23 (7)	22 (7)
Other	6 (3)	5 (2)	5 (2)	2 (<1)	4 (1)
No treatment	158 (85)	176 (88)	238 (85)	278 (87)	272 (87)
Not reported	6 (3)	6 (3)	11 (4)	18 (6)	15 (5)
Current treatment for HCV					
	N=5	N=2	N=4	N=6	N=6
Interferon/Interferon+Ribavirin	3	2	1	6	2
Other	2	0	3	0	4

Table 8.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=334	N=445	N=506	N=506	N=463
Any treatment/therapy for drug use (%)					
No	29 (9)	36 (8)	58 (11)	58 (11)	38 (8)
Yes	304 (91)	404 (91)	441 (87)	441 (87)	423 (91)
Not reported	1 (<1)	5 (1)	7 (1)	7 (1)	2 (<1)
History of methadone maintenance treatment (%)					
Currently	88 (26)	140 (31)	169 (33)	169 (33)	162 (35)
Previously	125 (37)	155 (35)	157 (31)	157 (31)	176 (38)
Never	114 (34)	133 (30)	162 (32)	162 (32)	123 (27)
Not reported	7 (2)	17 (4)	18 (4)	18 (4)	2 (<1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	52 (16)	69 (16)	57 (11)	57 (11)	55 (12)
Previously	136 (41)	169 (38)	197 (39)	197 (39)	198 (43)
Never	141 (42)	200 (45)	234 (46)	234 (46)	203 (44)
42)Not reported	5 (2)	7 (2)	18 (4)	18 (4)	7 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	54 (16)	66 (15)	69 (14)	69 (14)	53 (11)
Previously	94 (28)	123 (28)	137 (27)	137 (27)	165 (36)
Never	181 (54)	248 (56)	281 (56)	281 (56)	238 (51)
Not reported	5 (2)	8 (2)	19 (4)	19 (4)	7 (2)

Table 8.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=281	N=309	N=409	N=455	N=428
Needle Syringe Program	263 (94)	229 (74)	385 (94)	425 (93)	394 (92)
Chemist/Pharmacy	112 (40)	62 (20)	75 (18)	92 (20)	88 (21)
Personal sources	--	64 (21)	58 (14)	46 (10)	65 (15)
Dispensing/Vending Machine	--	0 (0)	0 (0)	0 (0)	0 (0)
Other sources	--	13 (4)	13 (3)	4 (1)	7 (2)

* More than one option could be selected

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	199	2 (1.0)	93	0 (0.0)	292	2 (0.7)
2009	215	3 (1.4)	116	0 (0.0)	333	3 (0.9)
2010	305	2 (0.7)	131	0 (0.0)	438	2 (0.5)
2011	335	4 (1.2)	162	0 (0.0)	499	4 (0.8)
2012	304	1 (0.3)	128	0 (0.0)	433	1 (0.2)
X ² trend p value		0.399		--		0.428

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	188	141 (75)	90	58 (64)	278	199 (72)
2009	212	120 (57)	115	60 (52)	329	182 (55)
2010	303	204 (67)	130	72 (55)	435	278 (64)
2011	332	229 (69)	158	93 (59)	492	324 (66)
2012	301	214 (71)	127	83 (65)	429	297 (69)
X ² trend p value		0.386		0.397		0.220

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	165	122 (74)	67	44 (66)	232	166 (72)
Bisexual	5	4 (80)	16	9 (56)	21	13 (62)
Homosexual	4	3 (75)	3	3 (100)	7	6 (86)
p value		1.000		0.435		0.481
2009						
Heterosexual	186	108 (58)	82	40 (49)	270	150 (56)
Bisexual	11	5 (45)	22	14 (64)	33	19 (58)
Homosexual	4	1 (25)	4	2 (50)	8	3 (38)
p value		0.344		0.412		0.637
2010						
Heterosexual	269	183 (68)	97	52 (54)	367	236 (64)
Bisexual	13	10 (77)	21	13 (62)	34	23 (68)
Homosexual	3	2 (67)	4	1 (25)	7	3 (43)
p value		0.893		0.409		0.442
2011						
Heterosexual	300	212 (71)	102	60 (59)	403	273 (68)
Bisexual	10	5 (50)	35	18 (51)	45	23 (51)
Homosexual	9	5 (56)	5	2 (40)	14	7 (50)
p value		0.893		0.409		0.442
2012						
Heterosexual	259	182 (70)	80	50 (63)	339	232 (68)
Bisexual	16	12 (75)	28	19 (68)	44	31 (70)
Homosexual	5	2 (40)	9	7 (78)	15	9 (60)
p value		0.308		0.665		0.717

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	9	3 (33)	9	1 (11)	18	4 (22)
25 – 34	79	54 (68)	48	32 (67)	127	86 (68)
35+ years	100	84 (84)	33	25 (76)	133	109 (82)
p value		0.001		0.001		<0.001
2009						
< 25 years	15	2 (13)	14	1 (7)	29	3 (10)
25 – 34	95	49 (52)	49	27 (55)	145	77 (53)
35+ years	102	69 (68)	52	32 (62)	155	102 (66)
p value		<0.001		0.001		<0.001
2010						
< 25 years	14	3 (21)	29	7 (24)	43	10 (23)
25 – 34	112	69 (62)	44	26 (59)	157	96 (61)
35+ years	177	132 (75)	57	39 (68)	235	172 (73)
p value		<0.001		<0.001		<0.001
2011						
< 25 years	18	8 (44)	20	5 (25)	38	13 (34)
25 – 34	102	68 (67)	60	40 (67)	163	109 (67)
35+ years	210	152 (72)	77	48 (62)	287	200 (70)
p value		0.046		0.004		<0.001
2012						
< 25 years	14	3 (21)	7	2 (29)	21	5 (24)
25 – 34	91	63 (69)	50	32 (64)	142	95 (67)
35+ years	195	147 (75)	70	49 (70)	265	196 (74)
p value		<0.001		0.101		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	8	2 (25)	9	4 (44)	17	6 (35)
3 to 10 years	35	19 (54)	21	10 (48)	56	29 (52)
11 + years	139	115 (83)	57	43 (75)	196	158 (81)
p value		<0.001		0.027		<0.001
2009						
<3 years	6	2 (33)	6	0 (0)	12	2 (17)
3 to 10 years	44	16 (36)	36	13 (36)	81	30 (37)
11 + years	159	101 (64)	68	43 (63)	227	144 (63)
p value		0.003		0.001		<0.001
2010						
<3 years	10	4 (40)	4	2 (50)	14	6 (43)
3 to 10 years	40	18 (45)	44	15 (34)	84	33 (39)
11 + years	247	177 (71)	81	54 (67)	329	323 (71)
p value		0.001		0.001		<0.001
2011						
<3 years	5	0 (0)	8	3 (38)	13	3 (23)
3 to 10 years	49	29 (59)	37	15 (41)	86	44 (51)
11 + years	274	198 (72)	107	71 (66)	382	270 (71)
p value		0.001		0.008		<0.001
2012						
<3 years	9	2 (22)	4	1 (25)	13	3 (23)
3 to 10 years	46	27 (59)	18	7 (39)	64	34 (53)
11 + years	236	175 (74)	99	70 (71)	336	245 (73)
p value		0.001		0.008		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	6	3 (50)	151	114 (76)	161	120 (75)
Methamphetamine	7	3 (43)	42	29 (69)	50	32 (64)
Other	4	0 (0)	52	38 (73)	59	40 (68)
p value		0.232		0.698		0.338
2009						
Heroin	4	0 (0)	194	117 (60)	201	119 (59)
Methamphetamine	1	0 (0)	41	18 (44)	45	21 (47)
Other	6	2 (33)	68	36 (53)	77	39 (51)
p value		0.424		0.130		0.188
2010						
Heroin	8	4 (50)	246	169 (69)	257	176 (68)
Methamphetamine	1	0 (0)	52	22 (42)	56	25 (45)
Other	5	2 (54)	115	74 (64)	122	77 (63)
p value		1.000		0.002		0.004
2011						
Heroin	8	1 (13)	283	202 (71)	297	208 (70)
Methamphetamine	1	1 (100)	87	49 (56)	89	50 (56)
Other	4	1 (25)	95	61 (64)	103	64 (62)
p value		0.245		0.026		0.037
2012						
Heroin	9	2 (22)	268	188 (70)	287	199 (69)
Methamphetamine	1	0 (0)	68	45 (66)	69	45 (65)
Other	3	1 (33)	64	46 (72)	72	52 (72)
p value		1.000		0.738		0.663

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	8	3 (38)	96	74 (77)	108	79 (73)
Daily or more	5	2 (40)	137	101 (73)	147	107 (73)
Not last month	2	1 (50)	15	10 (67)	17	11 (65)
p value		0.949		0.648		0.761
2009						
Less than daily	5	0 (0)	104	62 (60)	111	64 (58)
Daily or more	7	2 (29)	182	100 (55)	193	104 (54)
Not last month	0	0 (0)	19	9 (47)	21	10 (48)
p value		0.190		0.547		0.648
2010						
Less than daily	2	1 (50)	189	127 (67)	195	132 (68)
Daily or more	11	5 (45)	193	123 (64)	206	129 (63)
Not last month	1	0 (0)	26	13 (50)	29	15 (52)
p value		1.000		0.225		0.204
2011						
Less than daily	3	0 (0)	168	106 (63)	173	106 (61)
Daily or more	10	3 (30)	251	176 (70)	269	186 (69)
Not last month	0	0 (0)	44	28 (64)	45	28 (62)
p value		0.528		0.276		0.206
2012						
Less than daily	6	1 (17)	167	116 (69)	179	123 (69)
Daily or more	6	2 (33)	206	146 (71)	219	154 (70)
Not last month	1	0 (0)	21	14 (67)	24	16 (67)
p value		1.000		0.901		0.900

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	13	5 (38)	188	140 (74)	209	150 (72)
Receptive sharing	0	0 (0)	40	32 (80)	41	33 (80)
p value		---		0.547		0.335
2009						
No receptive sharing	11	2 (18)	234	135 (58)	249	140 (56)
Receptive sharing	1	0 (0)	44	23 (52)	47	24 (51)
p value		1.000		0.512		0.526
2010						
No receptive sharing	11	5 (45)	287	184 (64)	303	193 (64)
Receptive sharing	2	1 (50)	57	37 (65)	59	38 (64)
p value		1.000		1.000		1.000
2011						
No receptive sharing	10	2 (20)	306	197 (64)	323	203 (63)
Receptive sharing	1	0 (0)	84	64 (76)	87	66 (76)
p value		1.000		0.049		0.030
2012						
No receptive sharing	10	2 (20)	282	195 (69)	299	203 (68)
Receptive sharing	2	1 (50)	76	57 (75)	84	64 (76)
p value		0.455		0.321		0.179

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 8.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	15	6 (40)	198	141 (71)	220	152 (69)
Imprisonment	1	0 (0)	33	27 (82)	35	27 (77)
p value		1.000		0.291		0.427
2009						
No imprisonment	12	2 (17)	261	140 (54)	282	148 (52)
Imprisonment	0	0 (0)	38	28 (74)	38	28 (74)
p value		---		0.023		0.015
2010						
No imprisonment	10	3 (30)	299	183 (61)	315	192 (61)
Imprisonment	1	1 (100)	40	27 (68)	42	28 (67)
p value		0.364		0.492		0.505
2011						
No imprisonment	12	3 (25)	372	238 (64)	392	248 (63)
Imprisonment	1	0 (0)	53	42 (79)	56	42 (75)
p value		1.000		0.030		0.100
2012						
No imprisonment	12	3 (25)	315	210 (67)	341	226 (66)
Imprisonment	1	0 (0)	66	52 (79)	69	54 (78)
p value		1.000		0.058		0.065

* Total includes people who did not report duration of drug injection

Table 8.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	15	6 (40)	219	164 (75)	241	175 (73)
Sex work	0	0 (0)	14	11 (79)	15	11 (73)
p value		---		1.000		1.000
2009						
No sex work	11	2 (18)	284	160 (56)	303	168 (55)
Sex work	1	0 (0)	15	8 (53)	17	8 (47)
p value		1.000		1.000		0.618
2010						
No sex work	11	5 (45)	366	239 (65)	384	250 (65)
Sex work	3	1 (33)	24	12 (50)	28	14 (50)
p value		1.000		0.185		0.152
2011						
No sex work	12	3 (23)	421	274 (65)	442	283 (64)
Sex work	0	0 (0)	28	23 (82)	29	23 (79)
p value		--		0.097		0.110
2012						
No sex work	11	3 (27)	359	249 (69)	384	265 (69)
Sex work	2	0 (0)	31	24 (77)	34	25 (74)
p value		1.000		0.418		0.584

* Total includes people who did not report duration of drug injection

Table 8.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	165	121 (73)	77	50 (65)	242	171 (71)
Indigenous	16	14 (88)	10	6 (60)	26	20 (77)
p value		0.366		0.739		0.650
2009						
Non Indigenous	195	52 (51)	102	52 (51)	299	164 (55)
Indigenous	12	8 (73)	11	8 (73)	23	15 (65)
p value		1.000		0.213		0.389
2010						
Non Indigenous	281	192 (68)	113	66 (58)	396	260 (66)
Indigenous	18	10 (56)	17	6 (35)	35	16 (46)
p value		0.301		0.115		0.026
2011						
Non Indigenous	292	201 (69)	136	82 (60)	429	284 (66)
Indigenous	33	25 (76)	20	9 (45)	54	35 (65)
p value		0.550		0.229		0.879
2012						
Non Indigenous	251	173 (69)	109	75 (69)	361	248 (69)
Indigenous	46	39 (85)	16	6 (38)	62	45 (73)
p value		0.029		0.014		0.540

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	162	120 (74)	85	57 (67)	247	177 (72)
Non-English speaking	21	17 (81)	5	1 (20)	26	18 (69)
p value		0.601		0.052		0.821
2009						
English speaking	193	107 (55)	103	54 (52)	298	163 (55)
Non-English speaking	16	11 (69)	7	3 (43)	23	14 (61)
p value		0.432		0.702		0.666
2010						
English speaking	277	188 (68)	126	69 (55)	404	258 (64)
Non-English speaking	23	13 (57)	2	2 (100)	25	15 (60)
p value		0.356		0.502		0.675
2011						
English speaking	293	200 (68)	150	88 (59)	444	289 (65)
Non-English speaking	36	27 (75)	7	4 (57)	44	32 (73)
p value		0.452		1.000		0.405
2012						
English speaking	266	186 (70)	117	75 (64)	384	261 (68)
Non-English speaking	35	28 (80)	9	7 (78)	44	35 (80)
p value		0.216		0.493		0.115

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	159	120 (75)	76	47 (62)	235	167 (71)
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)
Asia	5	4 (80)	1	1 (100)	6	5 (83)
UK & Ireland	11	7 (64)	8	8 (100)	19	15 (79)
Other	9	8 (89)	3	1 (33)	12	9 (75)
p value		0.142		0.068		0.311
2009						
Australia	180	105 (58)	99	51 (52)	281	158 (56)
Other Oceania	5	3 (60)	2	1 (50)	7	4 (57)
Asia	5	2 (40)	2	1 (50)	7	3 (43)
UK & Ireland	7	3 (43)	5	4 (80)	12	7 (58)
Other	14	6 (43)	6	3 (50)	20	9 (45)
p value		0.650		0.873		0.832
2010						
Australia	260	178 (68)	122	65 (53)	383	244 (64)
Other Oceania	8	7 (88)	1	0 (0)	9	7 (78)
Asia	5	3 (60)	1	1 (100)	6	4 (67)
UK & Ireland	11	6 (55)	2	2 (100)	13	8 (62)
Other	15	7 (47)	1	1 (100)	18	10 (56)
p value		0.242		0.179		0.855
2011						
Australia	283	198 (70)	148	87 (59)	431	287 (66)
Other Oceania	10	6 (60)	1	1 (100)	11	7 (64)
Asia	6	4 (67)	0	0 (0)	6	4 (67)
UK & Ireland	15	9 (60)	4	2 (50)	19	11 (58)
Other	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.808		1.000		0.939
2012						
Australia	245	169 (69)	110	71 (65)	356	240 (67)
Other Oceania	9	6 (67)	4	2 (50)	13	8 (62)
Asia	13	13 (100)	1	1 (100)	14	14 (100)
UK & Ireland	15	11 (73)	5	4 (80)	20	15 (75)
Other	17	14 (82)	7	5 (71)	24	19 (79)
p value		0.090		0.881		0.042

* Total includes people whose gender was not reported or reported as transgender

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2008	2009	2010	2011	2012
Number of sites	2	2	3	3	3
N° surveyed	N=196	N=222	N=219	N=192	N=186
Response (%)	73%	80%	56%	77%	79%
Gender (%)					
Male	123 (63)	134 (60)	127 (58)	114 (59)	121 (65)
Female	73 (37)	87 (39)	92 (42)	77 (40)	64 (34)
Transgender	0 (0)	1 (<1)	0 (0)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	158 (81)	185 (83)	183 (84)	159 (83)	150 (81)
Bisexual	22 (11)	15 (7)	14 (6)	17 (9)	17 (9)
Homosexual	7 (4)	10 (5)	8 (4)	9 (5)	4 (2)
Not reported	9 (5)	12 (5)	14 (6)	7 (4)	15 (8)
Age and duration of injection (years)					
<i>Median age</i>	35	36	40	40	40
Age range	17-65	15-62	18-63	16-64	20-65
<i>Age group (%)</i>					
<25 years	12 (6)	16 (7)	8 (4)	8 (4)	4 (2)
25+ years	183 (93)	206 (93)	211 (96)	183 (95)	181 (97)
Not reported	1 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)
<i>Median age 1st IDU</i>	18	18	18	19	19
Age range	11-47	11-52	11-50	11-47	10-53
Not reported	5	7	3	5	6
<i>Median years IDU</i>	15	16	18	18	19
Range	<1-42	<1-44	<1-47	<1-45	<1-47
<i>Duration of drug injection (%)</i>					
<3 years	3 (2)	9 (4)	11 (5)	6 (3)	4 (2)
3+ years	188 (96)	206 (93)	205 (94)	180 (94)	176 (95)
Not reported	5 (3)	7 (3)	3 (1)	6 (3)	6 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	179 (91)	208 (94)	200 (91)	177 (92)	166 (89)
Yes	9 (5)	12 (5)	11 (5)	13 (7)	16 (9)
Not reported	8 (4)	2 (1)	8 (4)	2 (1)	4 (2)
Region/Country of birth (%)					
Australia	149 (76)	179 (81)	176 (80)	150 (78)	150 (95)
Other Oceania	16 (8)	8 (4)	13 (6)	11 (6)	12 (6)
Asia	2 (1)	5 (2)	3 (1)	3 (2)	1 (<1)
UK & Ireland	18 (9)	18 (8)	16 (7)	19 (10)	14 (8)
Other	7 (4)	7 (3)	7 (3)	9 (5)	8 (4)
Not reported	4 (2)	5 (2)	4 (2)	0 (0)	1 (<1)
Main language spoken at home by parents (%)					
English speaking	186 (95)	216 (97)	208 (95)	186 (97)	176 (95)
Non-English speaking	10 (5)	5 (2)	7 (3)	6 (3)	9 (5)
Not reported	0 (0)	1 (<1)	4 (2)	0 (0)	1 (<1)
Imprisonment last year (%)					
No	168 (86)	193 (87)	160 (73)	162 (84)	159 (87)
Yes	21 (11)	21 (9)	16 (7)	16 (8)	20 (11)
Not reported	7 (4)	8 (4)	43 (20)	14 (7)	4 (2)
Injected in prison (%)	N=21	N=21	N=16	N=16	N=20
Yes	8 (38)	7 (33)	3 (19)	4 (25)	4 (20)
Frequency of injection last month (%)					
Not last month	7 (4)	6 (3)	11 (5)	11 (6)	8 (4)
Less than weekly	15 (8)	22 (10)	29 (13)	27 (14)	27 (15)
Weekly not daily	49 (25)	43 (19)	48 (22)	46 (24)	36 (19)
Daily or more	124 (63)	150 (68)	131 (60)	106 (55)	112 (60)
Not reported	1 (1)	1 (<1)	0 (0)	2 (1)	3 (2)

Table 9.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2008	2009	2010	2011	2012
Last drug injected (%)	N=196	N=222	N=219	N=192	N=186
Cocaine	0 (0)	2 (1)	0 (0)	1 (<1)	1 (<1)
Heroin	62 (32)	74 (33)	66 (30)	48 (25)	48 (26)
Methadone	5 (3)	12 (5)	13 (6)	12 (6)	6 (3)
Methamphetamine	54 (28)	43 (19)	58 (26)	65 (34)	59 (32)
Performance/Image-enhancing drugs	0 (0)	1 (<1)	1 (<1)	0 (0)	1 (<1)
Pharmaceutical opioids	42 (21)	37 (17)	31 (14)	34 (18)	28 (15)
Suboxone®	--	4 (2)	10 (5)	11 (6)	9 (5)
Subutex®/Buprenorphine	18 (9)	16 (7)	8 (4)	8 (4)	11 (6)
More than one	10 (5)	11 (5)	22 (10)	12 (6)	19 (10)
Other drug	0 (0)	18 (8)	14 (6)	0 (0)	1 (<1)
Not reported	5 (3)	8 (4)	6 (3)	1 (<1)	3 (2)
N° Injected last month	N=188	N=215	N=208	N=179	N=175
Places injected last month (%)*					
Any public	103 (55)	105 (49)	88 (42)	75 (42)	61 (35)
All private	83 (44)	110 (51)	97 (47)	91 (51)	105 (60)
Not reported	2 (1)	0 (0)	23 (11)	13 (7)	9 (5)
Use of new sterile needles & syringes last month (%)					
All injections	119 (63)	148 (69)	131 (63)	126 (70)	118 (67)
Most of the time	56 (30)	56 (26)	47 (23)	33 (18)	34 (19)
Half of the time	5 (3)	4 (2)	5 (2)	2 (1)	5 (3)
Some of the time	3 (2)	3 (1)	2 (1)	6 (3)	6 (3)
Not last month	3 (2)	1 (<1)	0 (0)	0 (0)	1 (<1)
Not reported	2 (1)	3 (1)	23 (11)	12 (7)	11 (6)
Re-used another's used needle & syringe last month (%)					
None	150 (80)	168 (78)	151 (73)	131 (73)	128 (73)
Once	11 (6)	13 (6)	8 (4)	7 (4)	15 (9)
Twice	10 (5)	12 (6)	13 (6)	9 (5)	7 (4)
3-5 times	8 (4)	12 (6)	4 (2)	9 (5)	9 (5)
>5 times	8 (4)	6 (3)	4 (2)	9 (5)	6 (3)
Not reported	1 (1)	4 (2)	28 (13)	14 (8)	10 (6)
Number of people needle & syringe was re-used after last month (%)					
None	150 (80)	168 (78)	151 (73)	131 (73)	128 (73)
One	16 (9)	23 (11)	16 (8)	20 (11)	14 (8)
Two	2 (1)	5 (2)	4 (2)	1 (<1)	3 (2)
Three to five	1 (1)	1 (<1)	1 (<1)	2 (1)	1 (<1)
More than five	0 (0)	1 (<1)	1 (<1)	3 (2)	5 (3)
Don't know	8 (4)	6 (3)	5 (2)	4 (2)	5 (3)
Not reported	11 (6)	11 (5)	30 (14)	18 (10)	19 (11)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	16 (9)	18 (8)	21 (10)	19 (11)	10 (6)
Casual sex partner	3 (2)	0 (0)	2 (1)	2 (1)	1 (<1)
Close friend	8 (4)	13 (6)	11 (5)	8 (4)	13 (7)
Acquaintance	3 (2)	5 (2)	6 (3)	5 (3)	7 (4)
Other	2 (1)	5 (2)	3 (1)	5 (3)	3 (2)
Equipment used after someone else last month (%)*					
Spoon	37 (23)	48 (24)	36 (17)	42 (23)	39 (22)
Water	29 (18)	37 (19)	28 (13)	15 (8)	30 (17)
Filter	20 (12)	35 (18)	23 (11)	17 (10)	27 (15)
Drug mix	20 (12)	20 (10)	19 (9)	11 (6)	18 (10)
None**	100 (61)	131 (66)	126 (61)	107 (60)	107 (61)
Injected by someone after that person injected themselves or others last month (%)					
No	150 (80)	172 (80)	160 (77)	140 (78)	135 (77)
Yes	30 (16)	39 (18)	23 (11)	140 (78)	26 (15)
Not reported	8 (4)	4 (2)	25 (12)	12 (7)	14 (8)
Present when someone injected for the first time in the last 12 months (%)**					
No	--	--	--	--	139 (79)
Yes	--	--	--	--	23 (13)
Not reported	--	--	--	--	13 (7)

* More than one option could be selected ** New question in 2012

Table 9.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2008	2009	2010	2011	2012
N° surveyed	N=196	N=222	N=219	N=192	N=186
Sex with a regular partner last month (%)					
No	81 (41)	103 (46)	99 (45)	86 (45)	105 (56)
Yes	113 (58)	113 (51)	109 (50)	93 (48)	74 (40)
Not reported	2 (1)	6 (3)	11 (5)	13 (7)	7 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=113	N=113	N=109	N=93	N=74
Never	80 (71)	89 (79)	77 (71)	70 (75)	56 (76)
Sometimes	12 (11)	12 (11)	12 (11)	10 (11)	8 (11)
Every time	14 (12)	5 (4)	12 (11)	10 (11)	6 (8)
Not reported	7 (6)	7 (6)	8 (7)	3 (3)	4 (5)
Sex with other partner/s last month (%)					
No	164 (84)	180 (81)	187 (85)	163 (85)	147 (79)
Yes	29 (15)	32 (14)	22 (10)	24 (13)	28 (15)
Not reported	3 (2)	10(5)	10 (5)	5 (3)	11 (6)
Condom used with other partner/s last month (%)					
N° surveyed	N=29	N=32	N=22	N=24	N=28
Never	6 (21)	12 (38)	8 (36)	11 (46)	14 (50)
Sometimes	14 (48)	9 (28)	6 (27)	5 (21)	8 (29)
Every time	7 (24)	11 (34)	8 (36)	7 (29)	5 (18)
Not reported	2 (7)	0 (0)	0 (0)	1 (4)	1 (4)
Sex work last month (%)					
No	177 (90)	203 (91)	200 (91)	173 (90)	169 (91)
Yes	11 (6)	11 (5)	6 (3)	10 (5)	11 (6)
Not reported	8 (4)	8 (4)	13 (6)	9 (5)	6 (3)
Condom used at last sex work last month (%)					
Yes	9 (82)	8 (73)	5 (83)	8 (80)	8 (80)

Table 9.1.4 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2008	2009	2010	2011	2012
N° surveyed	N=196	N=222	N=219	N=192	N=186
Previous HIV test (%)					
Yes, last year	99 (51)	111 (50)	113 (52)	104 (54)	81 (44)
> 1 year ago	75 (38)	78 (35)	60 (27)	63 (33)	67 (36)
Never tested	14 (7)	26 (12)	33 (15)	19 (10)	28 (15)
Not reported	8 (4)	7 (3)	13 (6)	6 (3)	10 (5)
Previous HCV test (%)					
Yes, last year	108 (55)	128 (58)	124 (57)	115 (60)	96 (52)
> 1 year ago	65 (33)	71 (32)	63 (29)	58 (30)	69 (37)
Never tested	15 (8)	15 (7)	13 (6)	8 (4)	10 (5)
Not reported	8 (4)	8 (4)	19 (9)	11 (6)	11 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=90	N=92	N=120	N=106	N=93
Interferon/Interferon+Ribavirin	9 (10)	13 (14)	19 (16)	21 (20)	12 (8)
Other	4 (4)	1 (1)	2 (2)	3 (3)	2 (2)
No treatment	75 (83)	72 (78)	92 (77)	77 (73)	77 (83)
Not reported	2 (2)	6 (7)	7 (6)	5 (5)	2 (2)
Current treatment for HCV					
N°	N=5	N=5	N=5	N=8	N=4
Interferon/Interferon+Ribavirin	3	5	4	6	2
Other	2	0	1	2	2

Table 9.1.5 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2008	2009	2010	2011	2012
N° surveyed	N=196	N=222	N=219	N=192	N=186
Any treatment/therapy for drug use (%)					
No	54 (28)	57 (26)	50 (23)	43 (22)	49 (26)
Yes	139 (71)	158 (71)	165 (75)	147 (77)	133 (72)
Not reported	3 (2)	7 (3)	4 (2)	2 (1)	4 (2)
History of methadone maintenance treatment (%)					
Currently	39 (20)	53 (24)	53 (25)	41 (21)	35 (19)
Previously	55 (28)	52 (23)	56 (26)	59 (31)	49 (26)
Never	99 (51)	112 (50)	97 (44)	84 (44)	101 (54)
Not reported	3 (2)	5 (2)	11 (5)	8 (4)	1 (<1)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	21 (11)	27 (12)	21 (10)	19 (10)	21 (11)
Previously	59 (30)	43 (19)	44 (20)	39 (20)	39 (21)
Never	111 (57)	149 (67)	152 (69)	124 (65)	125 (67)
Not reported	5 (3)	3 (1)	2 (1)	10 (5)	1 (<1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	18 (9)	25 (11)	25 (11)	32 (17)	23 (12)
Previously	24 (12)	28 (13)	30 (14)	25 (13)	23 (12)
Never	149 (76)	164 (74)	160 (73)	129 (67)	136 (73)
Not reported	5 (3)	5 (2)	4 (2)	6 (3)	4 (2)

Table 9.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2008	2009	2010	2011	2012
N° Injected last month	N=188	N=215	N=208	N=179	N=175
Needle Syringe Program	159 (85)	102 (47)	175 (84)	154 (86)	134 (77)
Chemist/Pharmacy	96 (51)	72 (33)	55 (26)	44 (25)	60 (34)
Personal sources	--	46 (21)	32 (15)	24 (13)	24 (14)
Dispensing/Vending Machine	--	0 (0)	1 (1)	4 (2)	3 (2)
Other sources	--	5 (2)	4 (2)	3 (2)	0 (0)

* More than one option could be selected

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2008	106	2 (1.9)	62	0 (0.0)	168	2 (1.2)
2009	126	1 (0.8)	85	1 (1.2)	212	2 (0.9)
2010	121	0 (0.0)	92	1 (1.1)	213	1 (0.5)
2011	112	1 (0.9)	77	3 (3.9)	190	4 (2.1)
2012	120	0 (0.0)	63	3 (4.8)	184	3 (1.6)
X ² trend p value		0.141		0.028		0.411

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008	101	59 (58)	59	32 (54)	160	91 (57)
2009	125	60 (48)	85	42 (49)	211	102 (48)
2010	119	65 (55)	92	54 (59)	211	119 (56)
2011	110	69 (63)	73	34 (47)	184	104 (57)
2012	120	71 (59)	64	31 (48)	185	103 (56)
X ² trend p value		0.227		0.482		0.521

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heterosexual	91	53 (58)	39	19 (49)	130	72 (55)
Bisexual	4	2 (50)	14	10 (71)	18	12 (67)
Homosexual	3	1 (33)	4	2 (50)	7	3 (43)
p value		0.707		0.332		0.509
2009						
Heterosexual	109	52 (48)	68	32 (47)	177	84 (47)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	4	2 (50)	6	2 (17)	10	4 (40)
p value		0.851		0.143		0.162
2010						
Heterosexual	110	62 (56)	65	40 (62)	175	102 (58)
Bisexual	3	1 (33)	11	5 (45)	14	6 (43)
Homosexual	0	0 (0)	8	3 (38)	8	3 (38)
p value		0.583		0.316		0.316
2011						
Heterosexual	98	64 (65)	55	27 (49)	153	91 (59)
Bisexual	4	0 (0)	11	5 (45)	16	6 (38)
Homosexual	3	1 (33)	6	2 (33)	9	3 (33)
p value		0.006		0.845		0.090
2012						
Heterosexual	106	64 (60)	43	24 (56)	149	88 (59)
Bisexual	6	2 (33)	10	3 (30)	17	6 (35)
Homosexual	0	0 (0)	4	2 (50)	4	2 (50)
p value		0.226		0.329		0.151

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
< 25 years	5	1 (20)	5	0 (0)	10	1 (10)
25 – 34	39	21 (54)	25	15 (60)	64	36 (56)
35+ years	56	36 (64)	29	17 (59)	85	53 (62)
p value		0.126		0.039		0.007
2009						
< 25 years	8	2 (25)	6	0 (0)	14	2 (14)
25 – 34	36	17 (47)	33	18 (55)	70	35 (50)
35+ years	81	41 (51)	46	24 (52)	127	65 (51)
p value		0.382		0.042		0.030
2010						
< 25 years	2	0 (0)	6	3 (50)	8	3 (38)
25 – 34	31	16 (52)	30	14 (47)	61	30 (49)
35+ years	86	49 (57)	56	37 (66)	142	86 (61)
p value		0.296		0.197		0.174
2011						
< 25 years	6	1 (17)	2	1 (50)	8	2 (25)
25 – 34	25	13 (52)	24	8 (33)	49	21 (43)
35+ years	78	54 (69)	47	25 (53)	126	80 (63)
p value		0.017		0.254		0.007
2012						
< 25 years	3	1 (33)	1	0 (0)	4	1 (25)
25 – 34	29	18 (62)	19	7 (37)	48	25 (52)
35+ years	88	52 (59)	43	23 (53)	132	76 (58)
p value		0.685		0.278		0.408

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
<3 years	0	0 (0)	2	1 (50)	2	1 (50)
3 to 10 years	23	8 (35)	17	5 (29)	40	13 (33)
11 + years	74	48 (65)	40	26 (65)	114	74 (65)
p value		0.011		0.047		0.002
2009						
<3 years	4	0 (0)	5	1 (20)	9	1 (11)
3 to 10 years	20	6 (30)	22	7 (32)	42	13 (31)
11 + years	95	52 (55)	58	34 (59)	154	86 (56)
p value		0.018		0.040		0.001
2010						
<3 years	6	0 (0)	4	2 (50)	10	2 (20)
3 to 10 years	13	4 (31)	21	11 (52)	34	15 (44)
11 + years	98	60 (61)	66	40 (61)	164	100 (61)
p value		0.001		0.733		0.014
2011						
<3 years	2	0 (0)	4	3 (75)	6	3 (50)
3 to 10 years	19	6 (32)	15	7 (47)	34	13 (38)
11 + years	83	57 (69)	54	24 (44)	138	82 (59)
p value		0.002		0.588		0.073
2012						
<3 years	2	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	16	9 (56)	10	4 (40)	26	13 (50)
11 + years	98	59 (60)	50	24 (48)	149	84 (56)
p value		0.640		0.867		0.674

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Heroin	1	1 (100)	49	34 (69)	52	37 (71)
Methamphetamine	1	0 (0)	40	13 (33)	42	13 (31)
Other	0	0 (0)	62	38 (61)	63	39 (62)
p value		0.157		0.001		<0.001
2009						
Heroin	1	1 (100)	70	38 (54)	71	39 (55)
Methamphetamine	3	0 (0)	36	7 (19)	41	7 (17)
Other	5	0 (0)	87	52 (60)	93	52 (56)
p value		0.011		<0.001		<0.001
2010						
Heroin	3	1 (33)	61	42 (69)	66	45 (68)
Methamphetamine	2	0 (0)	53	17 (32)	55	17 (31)
Other	5	1 (20)	79	53 (67)	84	54 (64)
p value		1.000		<0.001		<0.001
2011						
Heroin	2	2 (100)	42	26 (62)	46	30 (65)
Methamphetamine	2	0 (0)	57	23 (40)	61	25 (41)
Other	2	1 (50)	72	46 (64)	76	49 (64)
p value		0.600		0.018		0.010
2012						
Heroin	0	0 (0)	48	32 (67)	48	32 (67)
Methamphetamine	3	2 (67)	54	16 (30)	58	18 (31)
Other	1	1 (100)	47	47 (66)	76	51 (67)
p value		1.000		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Less than daily	1	0 (0)	50	27 (54)	52	27 (52)
Daily or more	1	1 (100)	100	59 (59)	104	63 (61)
Not last month	0	0 (0)	4	1 (25)	4	1 (25)
p value						
2009						
Less than daily	5	0 (0)	56	23 (41)	62	23 (37)
Daily or more	3	1 (33)	138	76 (55)	144	79 (55)
Not last month	1	0 (0)	2	0 (0)	4	0 (0)
p value						
2010						
Less than daily	4	1 (25)	80	46 (58)	84	47 (56)
Daily or more	5	1 (20)	110	67 (61)	117	70 (60)
Not last month	1	0 (0)	8	2 (25)	10	2 (20)
p value		1.000		0.147		0.051
2011						
Less than daily	2	1 (50)	68	36 (53)	70	37 (53)
Daily or more	4	2 (50)	94	55 (59)	102	61 (60)
Not last month	0	0 (0)	8	3 (38)	10	5 (50)
p value		1.000		0.453		0.639
2012						
Less than daily	2	1 (50)	60	30 (50)	63	32 (51)
Daily or more	2	2 (100)	106	64 (60)	111	68 (61)
Not last month	0	0 (0)	6	1 (17)	8	1 (13)
p value		1.000		0.074		0.018

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No receptive sharing	2	1 (50)	121	70 (58)	127	74 (58)
Receptive sharing	0	0 (0)	28	16 (57)	28	16 (57)
p value		---		1.000		1.000
2009						
No receptive sharing	7	1 (14)	150	73 (49)	160	75 (47)
Receptive sharing	1	0 (0)	40	24 (60)	42	25 (60)
p value		1.000		0.218		0.167
2010						
No receptive sharing	9	2 (22)	136	78 (57)	147	82 (56)
Receptive sharing	0	0 (0)	28	18 (64)	28	18 (64)
p value		--		0.535		0.533
2011						
No receptive sharing	5	2 (40)	118	68 (58)	125	72 (58)
Receptive sharing	1	1 (100)	30	13 (43)	33	16 (48)
p value		1.000		0.218		0.431
2012						
No receptive sharing	4	3 (75)	121	64 (53)	127	69 (54)
Receptive sharing	0	0 (0)	36	24 (67)	37	24 (65)
p value		--		0.144		0.255

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 9.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No imprisonment	2	1 (50)	133	74 (56)	139	78 (56)
Imprisonment	0	0 (0)	18	12 (67)	18	12 (67)
p value		---		0.453		0.456
2009						
No imprisonment	9	1 (11)	172	82 (48)	185	85 (46)
Imprisonment	0	0 (0)	19	15 (79)	20	15 (75)
p value		---		0.014		0.018
2010						
No imprisonment	10	2 (20)	143	77 (54)	156	81 (52)
Imprisonment	0	0 (0)	15	11 (73)	15	11 (73)
p value		--		0.179		0.174
2011						
No imprisonment	3	2 (67)	146	79 (54)	154	86 (56)
Imprisonment	2	0 (0)	13	10 (77)	16	11 (69)
p value		0.400		0.148		0.429
2012						
No imprisonment	4	3 (75)	150	78 (52)	158	83 (53)
Imprisonment	0	0 (0)	19	16 (84)	20	16 (80)
p value		--		0.012		0.020

* Total includes people who did not report duration of drug injection

Table 9.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
No sex work	2	1 (50)	140	79 (56)	146	83 (57)
Sex work	0	0 (0)	9	4 (44)	9	4 (44)
p value		---		0.510		0.507
2009						
No sex work	9	1 (11)	178	90 (51)	193	93 (48)
Sex work	0	0 (0)	10	5 (50)	10	5 (50)
p value		---		1.000		1.000
2010						
No sex work	9	2 (22)	182	106 (58)	194	110 (57)
Sex work	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		1.000		1.000
2011						
No sex work	6	3 (50)	156	84 (54)	166	91 (55)
Sex work	0	0 (0)	8	4 (50)	9	5 (56)
p value		--		1.000		1.000
2012						
No sex work	4	3 (75)	159	89 (56)	168	95 (57)
Sex work	0	0 (0)	10	7 (70)	11	7 (64)
p value		--		0.517		0.760

* Total includes people who did not report duration of drug injection

Table 9.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Non Indigenous	93	54 (58)	53	31 (58)	146	85 (58)
Indigenous	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.313		0.309		0.079
2009						
Non Indigenous	122	57 (47)	78	39 (50)	201	96 (48)
Indigenous	1	1 (100)	7	3 (43)	8	4 (50)
p value		0.472		1.000		1.000
2010						
Non Indigenous	113	61 (54)	80	46 (58)	193	107 (55)
Indigenous	3	1 (33)	7	6 (86)	10	7 (70)
p value		0.597		0.234		0.518
2011						
Non Indigenous	101	64 (63)	68	33 (49)	170	98 (58)
Indigenous	7	4 (57)	5	1 (20)	12	5 (42)
p value		0.708		0.363		0.369
2012						
Non Indigenous	109	63 (58)	55	27 (49)	165	91 (55)
Indigenous	8	5 (63)	8	3 (38)	16	8 (50)
p value		1.000		0.710		0.795

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
English speaking	95	55 (58)	58	32 (55)	153	87 (57)
Non-English speaking	6	4 (67)	1	0 (0)	7	4 (57)
p value		1.000		0.458		1.000
2009						
English speaking	120	55 (46)	85	42 (49)	205	97 (47)
Non-English speaking	4	4 (100)	0	0 (0)	5	4 (80)
p value		0.049		---		0.198
2010						
English speaking	111	58 (52)	89	51 (57)	200	109 (55)
Non-English speaking	6	5 (83)	1	1 (100)	7	6 (86)
p value		0.215		1.000		0.135
2011						
English speaking	105	65 (62)	72	34 (47)	178	100 (56)
Non-English speaking	5	4 (80)	1	0 (0)	6	4 (67)
p value		0.649		1.000		0.699
2012						
English speaking	113	69 (61)	61	28 (46)	175	98 (56)
Non-English speaking	7	2 (29)	2	2 (100)	9	4 (44)
p value		0.120		0.223		0.515

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2008						
Australia	77	44 (57)	43	24 (56)	120	68 (57)
Other Oceania	6	1 (17)	7	2 (29)	13	3 (23)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	8	6 (75)	5	4 (80)	13	10 (77)
Other	7	5 (71)	4	2 (50)	11	7 (64)
p value		0.139		0.374		0.042
2009						
Australia	102	46 (45)	67	34 (51)	169	80 (47)
Other Oceania	3	1 (33)	5	3 (60)	8	4 (50)
Asia	4	3 (75)	0	0 (0)	5	3 (60)
UK & Ireland	9	7 (78)	9	2 (22)	18	9 (50)
Other	4	2 (50)	3	2 (67)	7	4 (57)
p value				0.364		0.972
2010						
Australia	95	52 (55)	74	43 (58)	169	95 (56)
Other Oceania	7	1 (14)	6	2 (33)	13	2 (23)
Asia	2	2 (100)	1	1 (100)	3	3 (100)
UK & Ireland	9	6 (67)	7	5 (71)	16	11 (69)
Other	4	2 (50)	2	1 (50)	6	3 (50)
p value		0.148		0.594		0.057
2011						
Australia	90	55 (61)	51	23 (45)	142	79 (56)
Other Oceania	4	3 (75)	7	5 (71)	11	8 (73)
Asia	2	2 (100)	1	1 (100)	3	3 (100)
UK & Ireland	11	7 (64)	8	4 (50)	19	11 (58)
Other	3	2 (67)	6	1 (17)	9	3 (33)
p value		0.945				0.287
2012						
Australia	99	60 (61)	50	22 (44)	150	83 (55)
Other Oceania	5	4 (80)	7	5 (71)	12	9 (75)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	10	5 (50)	3	2 (67)	13	7 (54)
Other	5	2 (40)	3	1 (33)	8	3 (38)
p value		0.543		0.516		0.453

* Total includes people whose gender was not reported or reported as transgender

Participating NSP services

<i>Year</i>		'08	'09	'10	'11	'12
Number of NSP sites		51	51	52	52	52
Australian Capital Territory		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales		20	20	21	20	20
Albury	Albury Community Health Centre	✓	✓	✓	✓	✓
Ballina/Byron	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services	✓	✓	✓	✓	✓
Canterbury	Resource and Education Program for IDUs	✓	✓	✓		
Central Coast	Gosford, Long Jetty and Woy Woy Harm Reduction	✓	✓	✓	✓	✓
Liverpool	Health ConneXions	✓	✓	✓	✓	✓
Kings Cross	Clinic 180 (formerly K2)	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Kogarah/Sutherland	Central Access Service	✓	✓	✓	✓	✓
Mt Druitt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Murwillumbah/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Nepean	South Court Primary Care NSP	✓	✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Illawarra	First Step Program, SEIAHS (Port Kembla and Nowra)	✓	✓	✓	✓	✓
Redfern	Resource and Education Program for IDU	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Wagga Wagga Community Health Centre			✓	✓	✓
Northern Territory		3	3	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Queensland		8	8	8	8	8
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP	✓	✓	✓	✓	✓

<i>Year</i>		'08	'09	'10	'11	'12
Number of NSP sites		51	51	52	52	52
<i>South Australia</i>		7	7	7	7	7
Adelaide	Nunkuwarrin Yunti Community Health Centre	✓	✓	✓	✓	✓
Angle Park	SAVIVE - Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Keswick	SAVIVE, Clean Needle Program	✓	✓	✓	✓	✓
Noarlunga	Noarlunga Primary Health	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Salisbury	SAVIVE, Shopfront Youth Health Service	✓	✓	✓	✓	✓
<i>Tasmania</i>		4	4	4	4	4
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service	✓	✓	✓	✓	✓
Launceston	Salvation Army Launceston	✓	✓	✓	✓	✓
<i>Victoria</i>		6	6	5	6	6
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Collingwood	InnerSpace NSP	✓	✓	✓	✓	✓
Footscray	Health Works				✓	✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
Northcote	Northcote NSP Services	✓	✓			
St Kilda	Health Information Exchange	✓	✓	✓	✓	✓
<i>Western Australia</i>		2	2	3	3	3
South West Coast	Western Australia Substance Users Association (WASUA)			✓	✓	✓
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data presented in this report were analysed using Stata, Version 12 (Stata Corporation, College Station TX). Changes in HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trend. Associations between demographic and behavioural variables and HIV and HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years. In 2012, one new core question was added to the questionnaire and this will be included in future surveys ("In the last 12 months, have you been present when someone injected for the first time?").

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

List of Tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (%) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey
Table 1.1.3	Number (%) of respondents by sexual behaviour in the month prior to survey and year of survey
Table 1.1.4	Number (%) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year
Table 1.1.5	Number (%) of respondents by treatment for drug use and survey year
Table 1.1.6	Number (%) of respondents by source of needle and syringe acquisition in the last month

2. HIV prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by duration of drug injection, gender and survey year
Table 1.2.5	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.6	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. Hepatitis C prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by duration of drug injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by last drug injected, duration of drug injection and survey year
Table 1.3.6	HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year
Table 1.3.7	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year
Table 1.3.9	HCV antibody prevalence by sex work last month, duration of drug injection and survey year
Table 1.3.10	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.11	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.12	HCV antibody prevalence by region/country of birth, gender and survey year

